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Abstract 
 Antibiotic susceptibility testing represents a key first step for determining therapeutic 
regimens to treat bacterial infections.  Current technologies are slow and cumbersome, require 
large sample volumes for analysis, have poor detection sensitivity and limited combinatorial 
capabilities.  These factors often preclude the timely administration of correct antibiotics, which 
complicates the clinical management of infections and exacerbates the escalating problem of 
antibiotic resistance development in pathogens.  My work has focused on developing 
microfluidic platforms for rapid antimicrobial susceptibility testing with a future potential in 
point-of-care diagnostics.  I have employed the platform to quantify the effects of commonly 
used antibiotics on E. coli cells at various concentrations (0.5-500 μg/mL) of each antibiotic as 
well as combinations thereof, on cellular proliferation and morphology as a proof-of-concept.  I 
demonstrated that combinations of three or more antibiotics are not necessarily better suited to 
eradicating pathogens in comparison to antibiotic pairs, which is a significant result for 
prescribing therapeutic regimens based on antibiotic cocktails.  Then, I addressed the effects of 
initial cell density (ranging from 108 -1010 cells/mL) on the efficiency of antibiotic action.   
Finally, I extended the platform to test more clinically relevant pathogens such as P. aeruginosa 
and K. pneumoniae in monomicrobial and polymicrobial cultures.  I demonstrated that bacteria 
behave significantly differently when co-cultured and individual susceptibility to antibiotics such 
as amikacin and tobramycin increases in co-cultures. I illustrate the advantages of using 
microfluidics over conventional methods for AST for precise determination of antibiotic dosing 
regimen, which encompass a significant potential to address the issue of antibiotic resistance.  
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Chapter 1 
Introduction 
1.1 Antibiotic resistance 
Incorrect use of antibiotics over several decades has led to widespread emergence of 
antibiotic resistance in clinical pathogens, which poses a rising critical global health issue [1].   
Recent years have shown increasing resistance to even one of the most powerful carbapenem 
antibiotics [1].  For instance, in 2003, Klebsiella infections were infrequent and often went 
unnoticed; however, by 2007 approximately 21% Klebsiella infections appeared with 
carbapenem-resistance in the state of New York and 5% all over the USA [2].  Similarly, 
methicillin-resistant Staphylococcus aureus (MRSA) accounts for 60% of the S. aureus 
population, and possesses resistance to multiple antibiotics including quinolones, macrolides, 
and sulfonamides [3].  Also, since majority of the antibiotics (~ 80%) in the USA are given to 
chicken, pigs, turkey, and cattle primarily as a preventive measure against illness, trace amounts 
of antibiotics often end up in milk and food products used for human consumption [4].  
Typically, a sub-lethal antibiotic dose gives rise to antibiotic resistance.  When a bacterium is 
exposed to an incorrect antibiotic dose, it gradually develops resistance against that drug even 
when administered at higher concentrations in the future.  Hence, trace amounts of antibiotics 
found in food products has further exacerbated the issue of antibiotic resistance and has 
prompted several critical reviews of current agricultural practices [4-6].  
One of the key reasons for rising antibiotic resistance is the prescription of incorrect 
antibiotics and the failure to detect resistance early when treating infections [7].  Current practice 
for treating infections entails antibiotic susceptibility testing (AST), or determination of 
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antibiotic susceptibility profiles against various pathogens in infections [8].  Although 
conventional methods for AST are widely and successfully used for treatment of bacterial 
infections, several issues exist with these methods.  Hence, in the absence of a precise antibiotic 
susceptibility profile of bacteria resulting from the long assay time and low sensitivity of the 
conventional methods, physicians often utilize empirical approaches with broad spectrum 
antibiotics that gives rise to the indiscreet use of antibiotics and is known to intensify the issue of 
antibiotic resistance [9,10].  Development of alternative techniques for generating precise 
antibiotic susceptibility profiles is indispensable for mitigating antibiotic resistance and for 
providing better clinical care.  In this thesis, I discuss approaches to address this issue by 
utilizing microfluidic platforms.  Specifically, I will discuss microfluidic platforms currently 
being developed for addressing the issue of conventional methods for AST and then I will 
discuss the application of microfluidics platforms for performing pharmacodynamics/ 
pharmacokinetics modeling later on in the thesis, which provides superior metrics for 
determining antibiotic dosing regimen. 
1.2. Antibiotic susceptibility testing 
1.2.1 Conventional methods 
Broth dilution and disk diffusion are two widely used methods for AST.  The latter 
method is the “gold standard” at the clinics and provides qualitative information by categorizing 
each strain into resistant or sensitive categories without providing any quantitative information 
about actual concentration of antibiotics that would be effective against infections [11].  In the 
broth dilution method, which utilizes 96-well plates, minimum inhibitory concentration (MIC) is 
the most commonly used parameter to describe the efficacy of the antibiotics against the 
pathogens.  In both the methods, the bacteria is first isolated from the patient samples (24 – 48 h) 
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followed by pre-culturing of isolated bacteria to enrich cell density to detectable levels (24 – 
48 h).  Then, the cells are incubated with antibiotics in 96-well plates or petri dishes (24 - 48 h) 
and finally the bacterial growth is determined using absorption spectroscopy or by visual 
assessment. 
Several limitations exist with the current techniques for AST.  First, these techniques 
involve multiple time-consuming steps (3-7 days) [12] leading to long assay times (as long as a 
few days).  Second, these techniques typically require significant quantities (10 - 30 mL) of 
patient samples such as blood, sputum, or urine for analysis [13], which preclude high-
throughput or multiplexed screening for different antibiotic concentrations/ combinations.  Third, 
the limited sensitivity of current techniques for AST makes them unsuitable for detecting the 
presence of “persister” microbes.  Although persister cells represent only a small fraction (≈ 10-5) 
of microbial cells, they tend to evade antibiotic-mediated killing by switching to a metabolically 
dormant or “persistent” state [14,15].  Persister cells constitute a significant threat due to their 
ability to re-initiate infection upon discontinuation of antibiotic therapy [16].  Fourth, 
inconsistencies in results obtained from different AST techniques further complicate diagnosis 
and treatment [17-22].  Fifth, all the conventional techniques for AST have been standardized for 
monomicrobial cultures only, while several infections are polymicrobial in nature (e.g., urinary 
tract infections (UTIs), chronic wounds, cystic fibrosis, and nosocomial bacteremia) caused by 
more than one microbe [23-25].  The interaction between different microbial species is known to 
influence the efficacy of the antibiotic treatment [26,27], yet antibiotic dosing regimen is often 
extrapolated from the monomicrobial AST results from conventional techniques further 
exacerbating the issue of antibiotic resistance.  
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1.2.2 Microfluidic approaches 
Microfluidics is an attractive technology that can address the issues of the conventional 
methods for AST.  Microfluidic chips/reactors/platforms comprise a simple to complex network 
of channels, chambers, valves, pumps etc. and enable precise spatio-temporal control over flow 
of reagents.  As a result, microfluidics has been explored for a wide range of applications, from 
chemical synthesis to fundamental biological studies [28-46].  With respect to performing AST, 
microfluidics offers several advantages compared to conventional techniques including assay 
with low sample volumes (~ 1-10 µL), enhanced detection sensitivity (~ 1 cell), faster analysis 
(2-4 h), improved portability, and the ability to perform species-specific AST in polymicrobial 
infections.   
Due to the aforementioned advantages, numerous microfluidic platforms have been 
developed for antimicrobial susceptibility testing [47-52].  Several of these platforms have 
focused on improving sensing capabilities to detect changes in metabolic activities of bacteria.  
For example, electrochemical sensors have been utilized to determine susceptibility by 
measuring small changes in growth of cells in monomicrobial cultures [48].  A surface-plasmon 
resonance-based biosensor platform [47] was used to categorize strains as susceptible or resistant 
by detecting variations in optical properties of bacteria when treated with antibiotics [47].  
Another interesting approach for AST utilized an asynchronous magnetic bead rotation biosensor 
to monitor single cells or cell populations after treatment with antibiotics [53].  Filter chip and 
optical detection biosensing system have also been developed to provide susceptibility results in 
one hour [52].   
These microfluidic-based biosensor technologies enable sensitive and rapid assays; 
however, most of these platforms lack multiplexing capabilities.  Integrated microfluidics on the 
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other hand is an attractive technology for the multiplexed implementation of biological assays 
with rapid turnaround times and minimal sample consumption [54].  Integrated microfluidics 
enables convenient manipulation of small reagent volumes (nL) within small chambers (µm) 
enabling the testing of multiple conditions with small volumes in rapidly in a convenient format.  
Several promising integrated microfluidic platforms for AST have been reported [55-61].  For 
example, droplet-based microfluidics has been utilized to compartmentalize bacterial cells, 
nutrients, antibiotics, and fluorescent viability indicators in water-in-oil emulsions [55,57].  A 
microfluidic platform was developed to confine bacterial cells in square micro-wells connected 
to a central flow channel that continuously delivers nutrients and antibiotics to cells [59] and a 
microfluidic agarose channel system was reported for rapid AST by tracking single cell growth 
[62].  Weibel and colleagues have developed a portable microfluidic chip for AST with the 
objective of making the device point-of-care [58].  Here, the key advantage of the portable chip 
is the automatic loading of bacterial cells into microfluidic chambers preloaded with antibiotics 
using a ‘degas driven flow’.   
These existing approaches for microfluidic-based antibiotic susceptibility testing offer 
promising routes towards the development of a rapid and portable screening tool.  However, 
many of these methods suffer from one or more of the following limitations: (1) complicated 
platform fabrication and/or operation procedures [61], (2) poor portability due to the requirement 
for syringe pumps, pneumatic actuators, and other ancillary equipment [57,61,62], and (3) 
unstable droplet formation [63].  In addition, almost all the microfluidic approaches have been 
developed for monomicrobial cultures, although several infections are polymicrobial in nature. 
To address these limitations of existing microfluidic approaches, our group has developed 
a microfluidic platform featuring a spatially addressable 4x6-array of wells to simultaneously 
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monitor the effects of multiple antibiotics at different concentrations, as well as their 
combinations, on bacterial cells for AST.  This technology integrates ease-of-fabrication and use 
with enhanced combinatorial capabilities, and further provides improved portability and usability 
by circumventing the requirement for expensive syringe pumps and pneumatic actuators by 
implementing normally closed valves.  In addition, the platform is amenable to automated 
analysis by using time-lapse fluorescence microscopy (TLFM).  I employed the microfluidic 
platform to interrogate the antibiotic sensitivity profile of Escherichia coli to four commonly 
used bactericidal and bacteriostatic antibiotics.  Furthermore, I explored synergistic and 
antagonistic effects of different antibiotic cocktails, as well as the effects of E. coli cell densities 
on the efficiency of antibiotic action.  Overall, this platform capitalizes on several key 
advantages of integrated microfluidics technology including miniaturization of assays, expedited 
analysis, multiplexing, and improved detection sensitivity along with ease-of-use and portability.  
I further extended the proof-of-concept AST technology from monomicrobial cultures to 
polymicrobial cultures comprising K. pneumoniae and P. aeruginosa, and E. coli to determine 
species-specific bacterial susceptibility.  I then used the experimental data from these studies to 
examine the potential of the microfluidic platform for performing 
pharmacodynamics/pharmacokinetic modeling, which is expected to provide a more accurate 
prediction of in vivo antibiotic action for a more precise determination of antibiotic dosing 
regimen.   
1.3 Thesis objectives 
 The overall objective of my research was to develop high throughput microfluidic 
platforms for antibiotic susceptibility testing (AST) for precise prediction of antibiotic dosing 
regimen to treat bacterial infections.  Empirical approaches to prescribe antibiotics accounts for 
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as much as 50% incorrect prescription, and these practices have led to an increase in global 
health issue of antibiotic resistance.  Conventional techniques for AST are time consuming, 
require large sample volumes, low throughput, and have low sensitivities.  Hence, Integrated 
microfluidic platforms are an attractive way to address the limitations of conventional 
techniques.  
 My research can be divided into three broad phases.  In phase 1, I optimized components 
used in microfluidic devices for biological screening applications.  In phase 2, I validated the 
optimized microfluidic platform for biological studies and performed antibiotic susceptibility 
testing on monomicrobial and polymicrobial cultures. Phase 2 encompasses bulk of my research 
and in phase 3, I utilized the experimental results to perform proof-of-principle 
pharmacodynamics/pharmacokinetic studies to predict in vivo results for accurate prescription of 
antibiotic dosing regimen.  
 Specifically, chapter 2 discusses optimization of normally closed valves with respect to 
their designs, parameters, and operational considerations for their incorporation into high-
throughput biological screening applications with the purpose of reliable sample routing.  
Chapter 3 discusses a proof-of-concept microfluidic platform for performing antibiotic 
susceptibility testing on monomicrobial cultures of  E. coli cells.  First, I first validated the 
platform by deriving growth profiles of E. coli.  Second, I performed antibiotic susceptibility 
testing against E. coli cells using single antibiotics followed by antibiotic pairs and combinations 
of three and four to study the effects of combination therapy utilized in the clinics for treating 
infections.  Third, I discussed the implications of cell density on the efficacy of antibiotics using 
microfluidic platforms.  Finally, I extended the AST platform to be utilized for more clinically 
relevant pathogens such as P. aeruginosa.  In chapter 4, I utilized the clinically relevant 
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pathogens such as K. pneumoniae and P. aeruginosa to perform polymicrobial AST with the aim 
of determining susceptibility of bacteria in polymicrobial infections.  Chapter 5 introduces the 
concept of pharmacodynamic/pharmacokinetic modeling that utilizes time-kill curves generated 
in chapters 3 and 4, to predict the in vivo antibiotic action over 24 hours.  The screening 
experiments for AST were performed using genetically modified bacteria (not applicable at the 
clinical level).  Hence, with the objective to further extend the platform for testing “real 
bacteria”, I discussed a range of options with optical dyes (chapter 6).  Finally, chapter 7 
briefly describes the summary of my research and its future outlook.  
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 Chapter 2 
Normally closed valves 1 
2.1 Introduction 
Miniaturization of various microfluidic components and their integration into dense networks 
is crucial to enable massively parallel operations on a single device.  Fine control is required for 
a variety of applications where small volumes of fluids (picoliters to nanoliters) are manipulated 
and mixed [1-4].  Microvalves that route flow are probably one of the most important 
components in these microfluidic devices.  Although significant progress has been made in 
improving the performance of valves with respect to their response time, leakage, dead volume, 
power consumption, sensitivity to particulate contamination, and chemical compatibility, further 
improvements are needed [5, 6]. 
A new type of valve that incorporates most or all the above ideal characteristics is highly 
desired.  For instance, elastomeric pneumatic microvalves [7] have been successfully used in 
many applications that require multi-step and high throughput operations on a single device [1, 
4].  A significant advantage of these pneumatic microvalves is that the fabrication of the valves 
is compatible with standard soft lithographic techniques, allowing easy integration of these 
valves into complex microfluidic devices. 
Pneumatic microvalves can be broadly classified into two types: normally open (NO) and 
normally closed (NC) [2], similar to fail-close and fail-open valve architecture at larger scale 
                                                                 
1 Part of the work has been published: Ritika Mohan, Benjamin R. Schudel, Amit V. Desai, Joshua D. Yearsley, 
Christopher A. Apblett, and Paul J.A. Kenis, “Design Considerations for Elastomeric Normally Closed Valves”, 
Sensors and Actuators B, 160, 2011, 1216-1223.  
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systems [8].  Although NO valves are widely used in many microfluidic applications [9, 10], 
devices employing these NO valves have limited portability in applications that require 
continuous closed state for operation, as these valves need bulky ancillaries (pumps, nitrogen gas 
cylinders, pneumatic peripherals) for actuation.  For example, in my investigations of on-chip 
protein-antibody interactions [11] or virus detection [12], the valves need to be open only for a 
short period of time when the solutions are being mixed.  Use of NO valves in these applications 
would have hampered portability between the mixing station and detection ancillaries such as a 
microscope [11, 12].  NC valves not only address the above limitation of restricted portability, 
but also retain the ease of fabrication and integration into microfluidic devices.  Moreover, NO 
microvalves typically require actuation pressures of 6 to 30 psi [13, 14], whereas NC valves can 
be actuated with lower pressures, in the range of 1 to 12 psi, as demonstrated here and by Grover 
et al. [15]. 
NC valves made out of silicon and glass have been used in several applications, such as 
portable fuel cell systems using piezoelectric valves [16] and bidirectional gas regulators for 
micro-gas chromatography systems [17].  The focus of this chapter will be on NC valves made 
out of elastomeric materials, such as polydimethylsiloxane (PDMS), a commonly used material 
in microfluidics.  Valves made out of elastomeric materials are typically easier to fabricate and 
actuate at lower pressures.  Elastomeric NC valves have been used previously in different 
microfluidic applications, including cell sorting [18], on-chip electrophoresis [1], combinatorial 
protein-antibody interaction screening [8], virus detection [12] and on-chip chemical synthesis 
[19, 20].  Some of these NC valves have been characterized for pumping of fluids for a range of 
flow rates (0-400 nL/s) and operating pressures (0-30 kPa) [21].  None of these studies, however, 
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have specifically focused on design rules to optimize the performance of NC valves, in particular 
with respect to minimizing their actuation pressures and optimizing their reliability. 
Formulation of a set of design rules for these microvalves is important because the actuation 
of these microvalves involves complex interplay between (i) mechanical deformation of the 
membrane and (ii) adhesion forces between hard and soft materials, which cannot be quantified 
easily due to the hysteresis that appears when polymeric substrates contact a stiffer surface.  In 
addition, design rules are needed for devices with dense networks of channels because pressure 
losses across the device may cause failure of the valves that are furthest away from the actuation 
pressure source.  Hence, design rules are needed that will aid in minimizing actuation pressures 
for these cases.  Furthermore, the design rules will enable fabrication of valves with dimensions 
that can be easily achieved with standard soft lithography. 
2.2 Experimental  
2.2.1 Soft lithography 
I fabricated microfluidic devices with NC valves using standard procedures for PDMS-based 
multi- layer soft lithography [7].  The fabricated two-layer devices consisted of (a) a control layer 
composed of microchannels that act as pneumatic lines for applying negative pressure and (b) a 
fluid layer composed of microchannels.  RTV 615 poly(dimethylsiloxane) (PDMS) was obtained 
from General Electric Company (Waterford, NY).  Negative photoresists, SU-8 250 and SU-8 
25, were obtained from MicroChem Corporation (Newton, MA).  (Tridecafluoro-1,1,2,2-
tetrahydrooctyl) trichlorosilane was obtained from Gelest, Inc. (Morrisville, PA).  The thickness 
of the photoresist and PDMS layers were measured using Dektak 3030.  Negative patterns of the 
features of the fluid layer and the control layer were patterned on silicon using 20-25 μm thick 
negative photoresist.  Then, a silane monolayer was evaporated onto the silicon masters to 
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prevent the covalent adhesion of PDMS to the silicon substrates.  Next, a thin layer of 15:1 
PDMS (weight ratio of polymer to cross-linker) was spun on the fluid layer master, 5:1 PDMS 
was poured on to the control layer master to a thickness of 2 mm, and the two layers were 
partially cured at 65 °C for approximately 30 minutes.  The thickness of the valve membrane in 
the fluid layer was controlled by the spin speed ranging from 1000 to 2000 rpm, yielding 20-60 
µm layer thicknesses.  After partial curing, the control layer mold was removed from the master, 
holes were punched for the inlets and outlets of the control layer using a 20 gauge needle (B-D 
Precision Slide), and the control layer mold was aligned manually with the fluid layer under an 
optical microscope (Leica MZ6).  The aligned layers were further cured at 65 °C for 
approximately 12 hours to yield the final assembled device.  The device was then peeled off the 
fluid layer master, and holes were punched into the fluid layer using a 20 gauge needle.  For 
experiments studying the reversibly sealed nature of the PDMS devices, the device was placed 
onto a clean glass substrate by simply bringing the PDMS assembled mold and the glass into 
contact.  I chose a glass substrate, as glass is the most commonly used substrate in microfluidic 
devices when the channels are fabricated out of PDMS [22, 23].  Since the objective of the 
research presented here was to study the influence of valve geometry on actuation pressures, I 
did not modify the material properties of PDMS. 
2.2.2 Selective irreversible bonding of PDMS device to glass 
In some of the experiments, the PDMS device was irreversibly bonded to glass.  In this case, 
the surface of the assembled device that had the microfluidic features and the glass substrate 
were treated with atmospheric plasma consisting of oxygen and helium (1:75 volumetric ratio) 
using a plasma pen (Surfx technologies, AtomfloTM plasma) at 80 W for 2 to 4 seconds.  After 
the plasma treatment, all NC valves were actuated so that the valve stops do not touch the glass 
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substrate during bonding, and the PDMS device and the glass were brought into contact.  The 
valves were left actuated for approximately 6-8 hours, after which the PDMS device was 
irreversibly bonded to glass only in the channel areas. 
2.2.3 Actuation of NC valves in microfluidic devices 
Negative pressure was applied to the NC valves using a pump (Gast DOA-P704-AA Vacuum 
Pump 1/8 HP 115 VAC), and the actuation pressures of the microvalves were measured using a 
pressure controller (Cole Parmer, model 68027-78); the schematic illustration of the set-up is 
shown in Fig. 2.1.  The valve actuation was performed under an optical microscope (Leica 
M205) to confirm opening of the valve.  Note that the valve is open and will allow fluid flow, 
when the valve stop is lifted off from the substrate.  However, this partial opening of the valve 
cannot be ascertained by visualizing the device from the top (Fig. 2.2c).  Hence, I define the 
open state of the valve based on formation of contact lines.  Two sets of contact lines appear 
upon actuation, one due to gradual delamination of the valve stop and side walls of the fluid 
channel, and one due to adhesion of the valve membrane to the roof of the control channel.  
Specifically, the valve is defined as ‘completely’ open when at least one of the two contact lines 
(typically circular or oval in shape) links the two opposite edges of the valve stop (Fig. 2.2c).  I 
thus define ‘actuation pressure’ as the pressure required to completely open the valve, based on 
the definition of ‘completely’ open valve.  After testing 8 different devices, I observed that the 
actuation pressures for all the valves were in the range of 1 – 6 psi.  The standard deviation for 
actuation pressures for valves with identical geometries (same dimensions) on different devices 
was ±0.15 psi, which I represent as 0.3 psi error bars.  This implies that the device-to-device 
variability resulted in a 0.3 psi variation in actuation pressures.  Each valve on the same device 
was tested in triplicate, and I observed that the actuation pressures for that same valve were 
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within 0.01 psi.  Note that all the valves were tested without any flow in the fluid channels, and 
the actuation pressures refer to static values. 
 
Figure 2.1.  Schematic illustration of the setup for actuating NC valves.  For clarity, only one 
valve is shown.  
 
Figure 2.2. (a) Cross-sectional and (b) perspective schematic views of a normally closed 
straight microvalve in closed and open state. (c) Optical micrographs (top view) of a valve in the 
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closed and open state. (i) indicates the region of the fluid channel that is lifted off the glass 
substrate, while (ii) indicates the region of the valve that touches the roof of the control channel. 
2.3 Results and Discussion 
2.3.1 Design of the valve 
To actuate (i.e., open) a NC valve, the membrane that is connected with the valve stop needs 
to get deflected upwards under the influence of an applied pressure that is lower than ambient 
(Fig. 2.2).  The key factors that determine the actuation pressure are (a) the mechanical 
properties of the membrane, and (b) the adhesion forces between the valve stop and the surface it 
rests against.  In turn, these factors depend on a variety of parameters, including the thickness of 
the membrane, the bulk and surface properties of materials used, and the dimensions of the 
control and fluid channels. 
Fig. 2.2(a) shows cross-sectional views of a NC valve in the closed and open state.  The 
microvalve consists of a control layer with a channel height (hc) of 25 – 50 μm and a fluid layer 
with a channel height (hf) of 25 – 50 μm.  The main operational part of the valve consists of a 
membrane with a thickness (t) of 15 – 60 μm, and a valve stop with a width of 50 μm to block 
the flow.  Fig. 2.2(b) shows a perspective view of the NC valve. 
Fig. 2.2(c) shows optical micrographs of a NC valve in the closed and open state.  In this 
figure, the circular or oval-shaped contact area (i) indicates the region of the fluid channel that is 
lifted off the glass substrate, while (ii) indicates the region of the valve membrane that touches 
the roof of the control channel.  To study the effect of asymmetry on valve performance, I varied 
two parameters: (1) the shape of the valve stop: straight, diagonal, or v-shaped, and (2) the 
position of the valve stop within the control chamber, as quantified by the ratio L1:L2 ranging 
from 1:1 to 1:5 (Fig. 2.2(c)).  The rationale behind introducing asymmetry is the creation of a 
weak point along the contact line of the adhering substrates, so these surfaces can detach from 
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each other more easily upon application of a smaller pressure difference.  The width of the fluid 
channel (w) was also varied from 50 to 350 μm, which is expected to influence the adhesive 
contact area between the valve stop and the glass substrate, and consequently the actuation 
pressures.  In addition to these operational, often advantageous characteristics, this valve design 
can be easily fabricated using standard multi- layer soft lithography [24]. 
2.3.2 Optimization of valve parameters 
Membrane thickness 
Membrane thickness influences membrane stiffness, which in turn influences membrane 
deformation and consequently the actuation pressures.  I studied thickness dependence for 
straight valves only, and the fluid channel width was maintained constant at 175 μm.  I observed 
that the actuation pressures change only marginally (2.4 – 2.6 psi) for valves with different 
membrane thicknesses, ranging from 16 to 60 μm.  Apparently, other parameters also determine 
the actuation pressure, in particular adhesion forces (see below).  I also observed that the 
actuation pressures decrease with decrease of the membrane thickness without any glass 
substrate (Fig. 2.3).  This trend is expected because it is known that the pressure required to 
deflect membranes increases with increased thickness [25].  Based on the above observations, I 
conclude that the actuation pressure is primarily governed by the adhesion between the 
contacting surfaces and not by the membrane stiffness.  Since the actuation pressures are not 
significantly influenced by membrane thicknesses (for the range of values tested here), thicker 
membranes are preferable, since thinner membranes are susceptible to collapse during 
fabrication [26] and are usually unreliable during operation (inconsistent actuation pressures).  
Hence, for all the experiments, I used a membrane thickness of an intermediate value, 
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approximately 36 μm, which yielded reliable valve operation, i.e., variations in actuation 
pressures for the same valve were within 0.01 psi for different trials.    
 
 
Figure 2.3.  Effect of thickness of the membrane (t) on actuation pressures, when tested without 
any substrate.  For comparison, I also include pressure values with a glass substrate.  
Thicknesses of 16, 36, and 60 μm were tested.  Each data point represents the average from 
experiments on 8 identical valves.  Each valve was tested three times. 
Fluid channel width 
Since adhesion forces were postulated to affect the actuation pressures, fluid channels widths 
were varied.  For all three valve shapes, I observed that the actuation pressures decreased with 
increasing fluid channel width (Fig. 2.4).  However, the actuation pressures measured for devices 
without any substrate do not show dependence on width.  Hence, the width-dependence of the 
actuation pressures is primarily due to the adhesion between the valve and the glass substrate.  
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To explain this width-dependence, scaling laws were derived for the actuation pressure based on 
the peeling of soft rectangular strips from hard substrates (supplementary section[24]).  For 
straight valves, the actuation pressure (ΔP) scales as 
wL
P 11
0
+∝∆ ,  (1) 
where w is width of the fluid channel, 2L0 = L1 + L2 (refer to Fig. 2.2(c) for definition of L1 and 
L2).  Note that L0 was maintained constant for all the experiments.  The width-dependence of 
actuation pressures can also be explained by considering the area of valve contact with glass, 
which increases with decreasing width.  In this case, it can be shown that the actuation pressure 
scales as (supplementary section [24]) 
cL
wP −∝∆ 1 ,  (2) 
where Lc is the width of the square chamber in the control layer (Fig. 2.2(c)).  I speculate that 
Eq. (1) (based on peeling) captures the actuation phenomena more accurately compared to 
Eq. (2) (based on area of contact).  In other words, peeling is the more dominant mode of 
actuation, and hence, I observe a non-linear decrease in actuation pressures with decreasing 
channel width.  In case of v-shaped and diagonal valves, the corner feature determines the 
actuation pressure, and hence, Eq. (1) may not be applicable, since the equation is derived on the 
basis of peeling of a rectangular strip.  However, the width-dependence of actuation pressures for 
these valves can still be explained using Eq. (2). 
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Figure 2.4.  Actuation pressure for different microvalve shapes (straight, v-shaped, and 
diagonal) as a function of the width of the fluid channel.  Each data point represents the average 
value from three experiments using the same valve.  The errors represented in the plot originate 
from device-to-device variability, which were a maximum of 0.3 psi for identical valves on 8 
different devices.  
Shape of the valve stop 
As discussed above, asymmetry may reduce actuation pressures because it introduces a weak 
point in the adhesion between the valve stop and the substrate.  One of the ways I introduced 
asymmetry was by modifying the shape of the valve stop.  Fig. 2.4 shows the experimentally 
determined actuation pressures as a function of fluid channel width for three different shapes of 
the valve stop: straight, diagonal and v-shaped.  I observed that the actuation pressures were 
lower for v-shaped valves compared to those for straight valves (Fig. 2.4).  To explain this shape 
dependence, I describe the actuation of the valve as peeling of a soft adhesive strip (PDMS 
valve) off a hard substrate (glass).  The peeling of the strip (e.g., a scotch tape on a hard 
substrate) is typically easier from a corner as opposed to peeling from the edge, and hence, the 
actuation pressures are expected to be lower for v-shaped valves with a corner feature than for 
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straight valves.  The lower actuation pressures required for v-shaped valves can be explained 
semi-quantitatively by considering the relation between the force required to peel (peeling force) 
and the width of the feature being peeled.  Within a first order of approximation, the peeling 
force is proportional to the width [27, 28].  In case of a v-shaped valve, the corner feature results 
in a very small local width, on the order of the radius of curvature of the corner (~10 μm), while 
for a straight valve, the peeling width is the whole channel width (~100 μm).  Due to the 
differences in peeling widths, the actuation pressures for v-shape valves are lower than those for 
straight ones.   
Interestingly, I also observed that the actuation pressures for diagonal valves are higher than 
those for straight ones, in spite of the presence of a corner feature.  This observation mainly 
results from the fact that for the diagonal valves the corner feature is located away from the 
central axis.  The opening of the valve is initiated along the central axis (Fig. 2.2(c)), since the 
valve is least constrained to deflect upwards at the center of the fluid channel.  This deflection 
profile for the valve can be understood in terms of deflection of a fixed-fixed beam [29] (cross-
section BB/ in Fig. 2.2(a)).  Since valve opening occurs along the central axis of the channel, 
actuation pressures will be lower only if the peeling forces are small at the center of the valve.  In 
case of diagonal valves, the peeling forces are minimized at the valve edges, and not at the 
center, thus leading to higher actuation pressures.  In contrast, the v-shaped valves have the 
corner feature along the central axis, and hence actuate at lower pressures.  Based on the above 
discussion, I conclude that the peeling forces should be minimized in the region where the valve 
opening is initiated to result in lower actuation pressures.  A more rigorous explanation for the 
shape-dependence of actuation pressure based on stress concentration and crack initiation can be 
found in the supplementary information published [24]. 
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Placement of the valve stop 
Another way I lowered symmetry in the valve geometry was by varying the position of the 
valve stop (Fig. 2.2) within the control line chamber, which I quantified using the ratio L1:L2 
(Fig. 2.2(c)).  In the case of straight valves, I observed that the actuation pressures were similar 
for L1:L2 ratios of 1:1 and 2:1, and decreased for 5:1 ratio (Fig. 2.5).  I attribute this decrease in 
actuation pressure to the fact that in the latter case one of the membrane lengths is significantly 
larger than the other.  A larger membrane length (L1 here) will lead to lower stiffness of the 
corresponding membrane (upper membrane in Fig. 2.2(c)).  As a result, the membrane deflects at 
a much lower applied pressure and the membrane touches the ceiling of the control channel.  
Then, upon the application of additional pressure the outer contact line rapidly propagates, since 
additional deformation of the membrane, and hence extension of the inner contact line is 
hindered by contact of the membrane with the ceiling.  I speculate that this rapid propagation of 
the outer contact line linking the two opposite edges of the valve stop leads to lower actuation 
pressures for straight valves with L1:L2 ratios of 5:1. 
Interestingly, in case of v-shaped valves, I observed a reverse trend, where the actuation 
pressures increased when the L1: L2 ratio was varied as 1:1, 2:1 and 5:1 (Fig. 2.5).  I speculate 
that as the L1: L2 ratio increases in v-shaped valves the axial distance of the shorter side (L2) is 
much shorter than in the case of straight valves, due to the presence of the corner feature in v-
shaped valves.  As a result, the pressure required to deflect the membrane along the central axis 
increases significantly due to the shorter length.  Hence, the increase in length of the larger side 
(L1) is more than offset by the reduction in length of the shorter side.  This effect is more 
pronounced in v-shaped valves compared to straight valves, since the opening of v-shaped valves 
is predominantly along the central axis due to the sharp corner feature.  Consequently, I observed 
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an increase in actuation pressures with increasing asymmetry in v-shaped valves, due to drastic 
reduction in the membrane dimension along the central axis and the explanation is published in 
the supplementary section of the manuscript [24]. 
 
Figure 2.5. Effect of asymmetry on actuation pressures for straight and v-shaped valves.  
Asymmetry ratios tested were 1:1, 2:1, and 5:1.  
Effect of channel height on hysteresis in valve actuation 
Hysteresis becomes important during dynamic, repeated actuation of the valve, since the 
different pressures required to open and close the valve may lead to temporal delays in operation.  
Hence, minimizing hysteresis is important for precise control of microfluidic metering and flow 
control [7].  In NC valves, hysteresis primarily results from the valve membrane adhering to the 
roof of the control channel in the open state, which is illustrated by formation of a circular or 
oval shaped contact line in Fig. 2.6.  The hysteresis of adhesion and detachment of the 
membrane from the roof, typical during adhesive contact between two elastic surfaces, causes 
hysteresis in the actuation pressures of these valves.   
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Figure 2.6.  Semi-quantitative hysteresis plot of actuation pressures for NC valves.  Two 
different heights for the control channel were tested, 20 and 50 μm.  The fluid channel width in 
all the optical micrographs was 175 μm.  The valve is considered open when the oval contact 
line touches the roof of the control channel and the shorter axis of the oval is approximately the 
size of the fluid channel width (see Fig. 1(c) for open valve).  The colors of the optical 
micrographs have been artificially modified to differentiate the two types of valves.  Lines 
connecting the data points are added to guide the eye. 
In Fig. 2.6, I plot the degree by which the valve opens as a function of actuation pressures, 
where I define the valve as open when the oval contact line touches the roof of the control 
channel and the shorter axis of the oval is approximately the size of the fluid channel width; Fig. 
2.2(c) shows an open valve.  To estimate the fraction of valve opening, the length of the shorter 
axis of the oval contact line is compared to that of an open valve.  The actuation pressures were 
higher for the taller control channels, since the valve had to deflect a larger distance upward to 
touch the roof of the control channel.  However, I observed lower hysteresis for the taller control 
channel, i.e. the ratio of the area enclosed within the curve to the actuation pressure is lower for 
the taller control channel.  I attribute the lower hysteresis to the fact that a taller control channel 
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allows for more relief of the membrane deformation when the pressure is decreased, since the 
membrane is stretched more in a taller control channel.  This additional relief results in easier 
detachment of the valve membrane from the roof, which leads to lower influence of the adhesion 
forces between the membrane and the roof when pressure is decreased.  Note that the higher 
actuation pressure for the device with a taller control channel is mainly due to my definition of 
an open valve.  In reality, devices with taller control channels are preferable since the valve can 
deflect over larger distances, and hence allow more fluid to pass through the channel in the open 
state. 
2.3.3 Operational considerations 
Valve performance in a dense network 
In microfluidic devices with dense networks, the actuation pressures increase across a 
network of serially connected valves, due to leakage or pressure losses associated with increasing 
channel length.  As a model for dense microfluidic network, I tested the performance of NC 
valves by actuating 44 identical valves in series and compared the valve performance to those in 
a device with only 3 valves in series.  Additionally, to demonstrate the advantage of valves 
operating at lower actuation pressures in dense networks, I compared valve performance in 
devices with v-shaped (lower actuation pressures) and straight valves.  The fluid channel width 
was 175 μm and the L1:L2 ratio was 1:1.  In devices with straight valves, 9 out of the 44 valves 
did not actuate (maximum pressure applied was 12 psi), however, in devices with v-shaped 
valves, all of the 44 valves actuated in the range of 2 to 5 psi.  As expected, all the 3 valves in the 
simpler microfluidic device actuated for both valve shapes.  The above experiments demonstrate 
that optimization of valve geometry to reduce actuation pressures and to ensure reliable actuation 
is crucial for the design of integrated microfluidic networks that contain NC valves. 
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Valve actuation over elongated periods for reversibly and irreversibly bonded devices 
Leakage due to weak device-to-substrate bonding presents additional challenges in 
microfluidics, especially during fluid manipulation.  In case of NC valves, the leakage issue 
becomes even more important due to the requirement of selective bonding, where strong bonding 
is needed for the channels, while the valves remain non-bonded.  Although, Yang et al. [20] and 
Irimia et al. [18] were able to achieve selective irreversible bonding, their technique required 
additional fabrication steps, such as patterning of a metallic or polymeric layer at the valve stop.  
Here, I developed a simpler alternative to selectively bond microfluidic devices with NC valves.  
Oxygen plasma treatment of glass and PDMS as an irreversible bonding technique has been 
characterized in previous work before bonding is known to lead to strong irreversible bonding 
[30].  I utilized this technique to irreversibly bond the PDMS device to glass substrate.  To 
prevent the valves from permanently sealing to glass, I exposed the PDMS and glass surfaces to 
oxygen plasma and then actuated the valves before bringing the PDMS and glass substrate into 
contact, so that the valves do not contact the glass.  I left the valves actuated for 6 – 8 hours, 
which was sufficiently long for the PDMS surface to lose its hydrophobicity and consequently, 
the tendency to irreversibly bond to glass [31].  As a result, the device is irreversibly bonded to 
the glass substrate, except in the areas where the valve stop contacts the glass. 
Since the adhesion forces between glass and PDMS are known to increase with time [32] and 
hence expected to influence the valve operation, I measured the actuation pressures of reversibly 
and irreversibly bonded devices with glass substrate over a period of 4 weeks.  For these 
experiments, I used v-shaped valves, L1: L2 ratio of 1:1, and a channel width of 175 μm.  In case 
of reversibly bonded devices, I observed that the actuation pressures increased with time (4 
weeks), if the PDMS device and the glass substrate are maintained in contact, while in case of 
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irreversibly bonded devices, the actuation pressures remained nearly constant over time; a 
qualitative plot indicating the effect of device-substrate contact time on actuation pressure is 
shown in Fig. 2.7.  The increase in actuation pressures for reversibly bonded devices can be 
attributed to time-dependent plastic deformation (creep) of PDMS over micro and nanoscopic 
features on the glass substrate.  This creep-assisted deformation was observed in one study, 
where PDMS was shown to plastically deform and encapsulates nanoparticles gradually over 
time [33].  This encapsulation over time will lead to an increase in contact area of the PDMS 
valve with the glass substrate and hence stronger adhesion, thus resulting in increasing actuation 
pressures with time.  In case of irreversibly bonded devices, however, the actuation pressures 
remained almost constant over time (Fig. 2.7).  This behavior is due to the fact that the plasma 
treatment used for irreversible bonding hardens the PDMS surface by formation of a thin oxide 
layer (~100 nm, small compared to the thickness of the valve membrane) [31], which retards the 
ability of PDMS to plastically deform.  
 
Figure 2.7.  Qualitative plot showing the effect of device-substrate contact time on actuation 
pressures for reversibly and irreversibly bonded devices.  The dashed vertical line indicates that 
reversibly bonded device could not be actuated. 
I also observed that the actuation pressures at the beginning for irreversibly bonded devices 
are approximately 1 psi higher compared to those for reversibly bonded device (Fig. 2.7).  The 
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plasma exposure during irreversible bonding decreases the surface roughness of both the PDMS 
and the glass, which in turn increases the contact area.  The increased contact area leads to 
stronger adhesion, and consequently, higher actuation pressures.  However, in the case of 
reversibly bonded devices, after the PDMS device was peeled off and brought into contact again 
with the glass substrate, the actuation pressures returned to its original values.  I speculate that 
the peeling of the PDMS breaks the adhesive bonds with the glass surface and new bonds are 
formed when the PDMS is brought into contact again.   
2.4 Conclusions 
Design rules for integrating normally closed microvalves in microfluidic devices 
Based on the above experimental results and discussion, I formulate the following set of 
design rules to integrate NC valves into microfluidic devices:  
1. Valve shape: V-shaped valves are better than straight valves or diagonal valves in terms of 
actuation pressures and reliability, because they not only actuate at lower pressures than 
straight for the same fluid channel width, but v-shaped valves also actuate more consistently 
and their actuation pressure vary less from device to device. 
2. Fluid channel width:  Actuation pressures do not significantly change (only 2 – 3 psi) for a 
wide range of fluid channel widths (Fig. 2.4), 50 - 400 μm.  Hence, the NC valves reported in 
this chapter can be used in microfluidic devices with different channel widths. 
3. Membrane thickness:  For membrane thicknesses in the range of 15 – 60 μm, the actuation 
pressures did not vary significantly (only 1 – 3 psi).  However, thicker membranes are 
preferable, since valves with thicker membranes actuate more reliably, and valves with 
thinner membranes are more challenging to fabricate. 
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4. Position of valve stop:  For straight valves, inducing asymmetry by changing the position of 
the valve stop reduces actuation pressures, but fabrication limitations might constrain the 
extent of asymmetry.  For instance, in the devices, I could not lower the symmetry in the 
position of the valve stop beyond a L1:L2 ratio of 5:1.  For v-shaped valves, moving the valve 
stop does not have a beneficial effect.  
5. Hysteresis in valve actuation:  For taller control channels (50 μm), the hysteresis of valve 
actuation was lower compared to that for shallower channels (25 μm), and hence, taller 
control channels are preferable, especially for dynamic actuation.  Moreover, taller channels 
allow for more fluid displacement.  
6. Bonding: Selective irreversible bonding will minimize liquid leakage in devices.  However, 
in applications where the PDMS device needs to be peeled off (e.g., when cleaning of the 
channels is not possible in an assembled device) or the glass substrate cannot be exposed to 
plasma treatment (e.g., glass surface has been functionalized with oxygen-sensitive chemical 
groups), then reversible bonding is preferable. 
All the experiments were performed with a glass substrate.  Since PDMS also adheres well to 
other materials typically used for microfluidic devices (e.g., PMMA, COC, PC, and PDMS itself), 
the design rules derived here will also apply to those cases.   
The above analyses and the derived design rules were based on the assumption that 
adhesion forces between the device and substrate are much larger than the forces required to 
deflect the membrane.  The above assumption is valid for most microfluidic applications because 
(1) the adhesion forces between device and substrate are high enough to prevent leakage, and (2) 
the valves are made of soft materials (lower Young’s modulus), such as PDMS, to ensure low 
actuation pressures, and hence the membrane deflection forces will be low.  One could encounter 
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a situation in which the forces needed to deflect the membrane become important, for example 
when adhesion forces have been reduced due to fouling.  As a result, the design rules involving 
factors that contribute significantly to valve stiffness will change.  Specifically, the actuation 
pressures will increase with decreasing fluid channel width and increasing membrane thickness.  
However, the actuation pressures will not be significantly influenced by the shape of the valve 
stop and the asymmetry in the position of the valve stop.  To investigate how the design rules 
change when membrane deflection forces dominate, I studied valve actuation in the absence of 
the bottom glass substrate (thus eliminating the influence of adhesion) using finite element 
analysis.  The results of these studies and an explanation of how the lack of adhesion forces 
affects the design rules is provided in Section 7 of the supplementary information of the 
published manuscript [24]. 
  
  
34 
 
2.5 References 
1. Blazej, R.G., P. Kumaresan, and R.A. Mathies, Microfabricated bioprocessor for integrated 
nanoliter-scale Sanger DNA sequencing. Proceedings of the National Academy of Sciences 
of the United States of America, 2006. 103(19): p. 7240-7245. 
2. Lee, C.-C., et al., Multistep Synthesis of a Radiolabeled Imaging Probe Using Integrated 
Microfluidics. Science, 2005. 310(5755): p. 1793-1796. 
3. Pal, R., et al., An integrated microfluidic device for influenza and other genetic analyses. Lab 
on a Chip, 2005. 5(10): p. 1024-1032. 
4. Rohde, C.B., et al., Microfluidic system for on-chip high-throughput whole-animal sorting 
and screening at subcellular resolution. Proceedings of the National Academy of Sciences of 
the United States of America, 2007. 104(35): p. 13891-13895. 
5. Kovacs, G.T.A., Micromachined Transducers Sourcebook. 1998, New York: McGraw-Hill. 
6. Oh, K., W.  and C.H. Ahn, A review of microvalves. Journal of Micromechanics and 
Microengineering, 2006. 16(5): p. R13. 
7. Unger, M.A., et al., Monolithic Microfabricated Valves and Pumps by Multilayer Soft 
Lithography. Science, 2000. 288(5463): p. 113-116. 
8. Skousen, P.L., Valve Handbook. 1997, New York: McGraw-Hill Professional Publishing. 
9. Go, J.S. and S. Shoji, A disposable, dead volume-free and leak-free in-plane PDMS 
microvalve. Sensors and Actuators A: Physical, 2004. 114(2-3): p. 438-444. 
10. Lee, S., W. Jeong, and D.J. Beebe, Microfluidic valve with cored glass microneedle for 
microinjection. Lab on a Chip, 2003. 3(3): p. 164-167. 
11. Schudel, B.R., et al., Microfluidic chip for combinatorial mixing and screening of assays. 
Lab on a Chip, 2009. 9(12): p. 1676-1680. 
12. Schudel, B.R., et al., Multiplexed detection of nucleic acids in a combinatorial screening 
chip. Lab on a Chip, 2011. 11(11): p. 1916-1923. 
13. Kartalov, E.P., et al., Experimentally validated quantitative linear model for the device 
physics of elastomeric microfluidic valves. Journal of Applied Physics, 2007. 101(6). 
14. Studer, V., et al., Scaling properties of a low-actuation pressure microfluidic valve. Journal 
of Applied Physics, 2004. 95(1): p. 393-398. 
15. Grover, W.H., et al., Development and multiplexed control of latching pneumatic valves 
using microfluidic logical structures. Lab on a Chip, 2006. 6(5): p. 623-631. 
16. Zhao, H., et al., Structure and characterization of a planar normally closed bulk-
micromachined piezoelectric valve for fuel cell applications. Sensors and Actuators A: 
Physical, 2005. 120(1): p. 134-141. 
17. Bae, B., et al., A Bidirectional Electrostatic Microvalve With Microsecond Switching 
Performance. Microelectromechanical Systems, Journal of, 2007. 16(6): p. 1461-1471. 
18. Irimia, D. and M. Toner, Cell handling using microstructured membranes. Lab on a Chip, 
2006. 6(3): p. 345-352. 
19. Hosokawa, K. and R. Maeda, A pneumatically-actuated three-way microvalve fabricated 
with polydimethylsiloxane using the membrane transfer technique. Journal of 
Micromechanics and Microengineering, 2000. 10(3): p. 415-420. 
20. Yang, Y.-N., S.-K. Hsiung, and G.-B. Lee, A pneumatic micropump incorporated with a 
normally closed valve capable of generating a high pumping rate and a high back pressure. 
Microfluidics and Nanofluidics, 2009. 6(6): p. 823-833. 
35 
 
21. Grover, W.H., et al., Monolithic membrane valves and diaphragm pumps for practical large-
scale integration into glass microfluidic devices. Sensors and Actuators B: Chemical, 2003. 
89(3): p. 315-323. 
22. Fiorini, G.S. and D.T. Chiu, Disposable microfluidic devices: fabrication, function, and 
application. BioTechniques, 2005. 38(3): p. 429–446. 
23. Kuo, J.S. and D.T. Chiu, Disposable microfluidic substrates: Transitioning from the research 
laboratory into the clinic. Lab on a Chip, 2011. 11(16): p. 2656-2665. 
24. Mohan, R., et al., Design considerations for elastomeric normally closed microfluidic valves. 
Sensors and Actuators, B: Chemical, 2011. 160(1): p. 1216-1223. 
25. Timoshenko, S. and S. Woinowsky-Krieger, Theory of Plates and Shells. 2nd ed. 
Engineering Societies Monographs. 1959, New York: McGraw-Hill Book Company. 
26. Mastrangelo, C.H. and C.H. Hsu, Mechanical stability and adhesion of microstructures under 
capillary forces - Part II: Experiments. Journal of Microelectromechanical Systems, 1993. 
2(1): p. 44-55. 
27. Gent, A.N. and G.R. Hamed, Peel Mechanics. The Journal of Adhesion, 1975. 7(2): p. 91 - 
95. 
28. Kendall, K., Thin-film peeling-the elastic term. Journal of Physics D: Applied Physics, 1975. 
8(13): p. 1449. 
29. Timoshenko, S., Strength of Materials. 3rd ed. ed. 1983: Krieger Publishing Company. 
30. Xia, Y. and G.M. Whitesides, Soft Lithography. Angewandte Chemie International Edition, 
1998. 37(5): p. 550-575. 
31. Hillborg, H., et al., Crosslinked polydimethylsiloxane exposed to oxygen plasma studied by 
neutron reflectometry and other surface specific techniques. Polymer, 2000. 41(18): p. 6851-
6863. 
32. Willis, P.A., et al., Monolithic photolithographically patterned FluorocurTM PFPE 
membrane valves and pumps for in situ planetary exploration. Lab on a Chip, 2008. 8(7): p. 
1024-1026. 
33. Demejo, L.P., et al., Time Dependent Adhesion Induced Phenomena: The Flow of a 
Compliant Silicone-Polyester Copolymer Substrate Over Rigid Micrometer Size Gold and 
Polystyrene Particles. The Journal of Adhesion, 1995. 48(1): p. 47 - 56. 
  
36 
 
 
 Chapter 3 
Antibiotic susceptibility screening (proof-of-concept) 2 
3.1 Introduction 
In recent years, antibiotic resistance traits among microbial pathogens have escalated at 
alarming rates, which has spurred the development of technologies for rapid and accurate 
detection of antibiotic susceptibility profiles of pathogens[1].  Established techniques for 
antibiotic susceptibility testing (AST), such as broth dilution and disc diffusion (Fig. 3.1), 
involve multiple time-consuming steps[2, 3] including: (1) isolation of pathogens from patient 
samples (24 - 48 hrs.), (2) pre-culturing of isolated bacteria to enrich cell density to detectable 
levels (24 - 48 hrs.), (3) incubation of cells with antibiotics in 96-well plates or petri dishes (24 - 
48 hrs.), and (4) determination of bacterial growth using absorption spectroscopy or by visual 
assessment. Broth dilution and disc diffusion assays typically require significant quantities (10 - 
30 mL) of patient samples such as blood, sputum, or urine for analysis [4].  In addition, the 
limited sensitivity of macroscale techniques for AST makes them unsuitable for detecting the 
presence of “persister” microbes.  Although persister cells represent only a small fraction (≈ 10-5) 
of microbial cells, they tend to evade antibiotic mediated killing by switching to a metabolically 
dormant or “persistent” state [5, 6].  Persister cells constitute a significant threat due to their 
ability to re-initiate infection upon discontinuation of antibiotic therapy [7].   Finally, 
inconsistencies in results obtained from different AST techniques further complicate diagnosis 
and treatment [8-13].  Hence, in the absence of precise information about the antibiogram of 
                                                                 
2 Part of the work has been published: Ritika Mohan*, Arnab Mukherjee*,Emre E.  Sevgen, Chotitath 
Sanpitakseree, Jaebum Lee, Charles M. Schroeder, and Paul J.A. Kenis, “A multiplexed microfluidic platform for 
rapid antibiotic susceptibility testing”, Biosensors & Bioelectronics, 49, 2013, 118-125.  
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particular pathogen, physicians often resort to empirical therapies that utilize broad-spectrum 
antibiotics.  Indiscreet use of antibiotics in this manner is known to intensify the problem of 
antibiotic resistance [14, 15]. 
 
Figure 3.1.  Conventional methods for antibiotic susceptibility testing (A) micro-broth dilution 
method and (B) Disk diffusion method, also known as the “gold standard” method  
To address the aforementioned issues, platforms with improved sensitivity and fast analysis 
time have been developed for antimicrobial susceptibility testing [16-21].  For example, sensors 
have been utilized to determine susceptibility by measuring small changes in growth of cells 
[18].  Chiang et al., have developed a surface plasmon  resonance-based biosensor platform to 
categorize strains as susceptible or resistant by detecting variations in optical properties of 
bacteria when treated with antibiotics [17].  Another interesting approach for antibiotic 
susceptibility testing utilizes an asynchronous magnetic bead rotation biosensor to monitor single 
cells or cell populations after treatment with antibiotics [22].  In addition, filter chip and optical 
detection biosensing system have been developed that can provide susceptibility results in one 
hour [21].  These microfluidic-based technologies are sensitive and rapid, however, most of these 
platforms lack multiplexing capabilities [17, 21, 22].  Hence, integrated microfluidics represents 
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an attractive technology for the multiplexed implementation of biological assays with rapid 
turnaround times and minimal sample consumption [23].  Several successful microfluidic 
platforms for AST have been reported [24-30] (Fig. 3.2).  For example, droplet-based 
microfluidics has been utilized to compartmentalize bacterial cells, nutrients, antibiotics, and 
fluorescent viability indicators in water-in-oil emulsions [24, 26].  Sun et al. have reported on the 
development of a microfluidic platform for the confinement of bacterial cells in square 
microwells connected to a central flow channel that continuously delivers nutrients and 
antibiotics to cells [28].  Choi et al. have reported a microfluidic agarose channel system for 
rapid antibiotic susceptibility testing by tracking single cell growth [31].   Weibel and colleagues 
have developed a portable microfluidic chip for AST for point-of-care use [27].   The key 
advantage of the portable chip is the automatic loading of bacterial cells into microfluidic 
chambers that had been preloaded with dehydrated antibiotics using a ‘degas driven flow’.   
 
Figure 3.2. Antibiotic susceptibility testing methods. (A) Optical image of the device used for 
long-term bacterial colony monitoring and antibiotic testing in high throughput manner[28].  (B) 
Microfluidic biosensor for detection of MRSA[16] (C)Schematic of microfluidic channels 
geometry used in a device for determining antibiotic susceptibility testing for S. aureus[32].  (D) 
A self-loading device to determine minimum inhibitory concentrations of antibiotics[27].  
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The existing approaches for microfluidic-based antibiotic susceptibility testing offer 
promising routes toward the development of a rapid and portable screening tool.  However, many 
of these methods suffer from one or more of the following limitations: (1) complicated platform 
fabrication and/or operation procedures [30], (2) poor portability due to the requirement for 
syringe pumps, pneumatic actuators, and other ancillary equipment [26, 30, 31], and (3) unstable 
droplet formation [33].  In this chapter, I report on the design and fabrication of a microfluidic 
platform with biosensing capabilities featuring a spatially addressable 4x6-array of wells to 
simultaneously monitor the effects of multiple antibiotics at different concentrations, as well as 
their combinations, on bacterial cells for AST.  This technology integrates ease-of-fabrication 
and use with enhanced combinatorial capabilities, and further provides improved portability and 
usability by circumventing the requirement for expensive syringe pumps and pneumatic 
actuators by implementing normally closed valves.  In addition, the platform is amenable to 
automated analysis by using time-lapse fluorescence microscopy (TLFM).  I employed the 
microfluidic platform to interrogate the antibiotic sensitivity profile of Escherichia coli to four 
commonly used bactericidal and bacteriostatic antibiotics.  Furthermore, I explored synergistic 
and antagonistic effects of different antibiotic cocktails, as well as the effects of E. coli cell 
densities on dictating the efficiency of antibiotic action.  Overall, this platform capitalizes on 
several key advantages of biosensor based integrated microfluidics technology including 
miniaturization of assays, expedited analysis, multiplexing, and improved detection sensitivity 
along with ease-of-use and portability.   
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3.2 Experimental 
3.2.1 Fabrication and experimental setup 
The microfluidic chip for AST was fabricated using standard soft lithographic techniques 
[34] (Fig. 3.3).  Briefly, molds for casting the fluidic and control layers were made by patterning 
negative photoresist on silicon wafers using photolithography.  A thin layer of 20:1 PDMS 
(weight ratio of polymer to cross-linker) was spin coated on to the fluidic layer master and 5:1 
PDMS was poured on to the control layer master.  The two layers were partially cured at 65 °C 
for 30 minutes.  Next, the control layer was carefully peeled off the silanized silicon master, and 
three holes for actuation of the mixing and sample loading valves were punched using a 20-
gauge needle.  The control layer was manually aligned with the fluidic layer under an optical 
microscope (Leica MZ6), and the aligned layers were cured overnight (~ 12 hrs.) at 65 °C to 
yield a monolithic device.  Finally, the assembled device was peeled off the fluid layer master, 
inlet ports were punched using a 20-gauge needle, and the assembly was placed on a glass 
coverslip to create a reversible seal.   
 
Figure 3.3. Fabrication of the chip using standard two layer soft lithography 
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3.2.2 Bacterial strains, growth media, and antibiotic solutions 
Wild type E. coli MG1655 (ATCC 47076) was genetically engineered to constitutively 
express green fluorescent protein (GFP), thereby enabling detection and enumeration of cells 
using fluorescence microscopy.  Specifically, E. coli MG1655 cells were transformed with a low 
copy plasmid expressing a bright GFP variant from a constitutive promoter derived from 
bacteriophage lambda [35].  Details of plasmid construction are provided as supporting 
information (Table 3.1).  I verified that the recombinant GFP-expressing E. coli cells were 
phenotypically similar to wild type cells with respect to growth rates.  E. coli cells were routinely 
cultivated in Lennox broth (10 g/L tryptone, 5 g/L yeast extract, and 5 g/L NaCl) supplemented 
with kanamycin at a concentration of 30 µg/mL in order to maintain the GFP-expressing 
plasmid.  Kanamycin was omitted for on-chip cultures with no noticeable effect on cellular 
fluorescence.  Antibiotic stock solutions of 10 mg/mL tetracycline hydrochloride and 10 mg/mL 
chloramphenicol were prepared in 70% ethanol.  Stock solutions of 30 mg/mL kanamycin, 100 
mg/mL ampicillin, and 1 mg/mL cefalexin hydrate were prepared in sterile deionized water.  All 
stock solutions were filtered using a 0.45 µm syringe filter (Millex- HV filter unit, Millipore) 
prior to use.  Antibiotic dilutions were made directly into Lennox broth.   
Construction of GFP-Expressing Plasmid Construct 
The GFP-expressing plasmid is based on a previously reported pUA139 promoter probe plasmid 
[36] that expresses GFP under the control of an upstream promoter.  The plasmid was engineered 
to include a 3-frame stop codon and a strong synthetic ribosome binding site between the GFP 
gene and the upstream promoter.   
42 
 
Table 3.1.  Oligonucleotide sequences employed to construct GFP-expressing plasmid 
Seq. 
No. Oligonucleotide Sequence Reference 
1 phage λ-tetO promoter sense strand 
TCCCTATCAGTGATAGA
GATTGACATCCCTATCA
GTGATAGAGATACTGA
GCAC 
[35] 
2 phage λ-tetO promoter antisense strand 
GTGCTCAGTATCTCTAT
CACTGATAGGGATGTCA
ATCTCTATCACTGATAG
GGA 
[35] 
3 Synthetic ribosome binding site ATTAAAGAGGAGAAA 
BioBricks Parts 
Registry (MIT) 
4 rrnB2 transcriptional terminator 
AGAAGGCCATCCTGAC
GGATGGCCTTTT 
BioBricks Parts 
Registry (MIT) 
 
The promoter was ligated in the plasmid construct using BamHI and XhoI restriction enzymes 
and T4 DNA ligase.  In addition, a transcriptional terminator was included upstream of the 
promoter sequence to arrest divergent transcription from the promoter. Sequences for the 
promoter oligonucleotides, synthetic ribosome binding site, and transcriptional terminator are 
provided in Table 3.1.  Cloning was accomplished using standard molecular biology techniques 
[37]. 
3.2.3 On-chip antibiotic susceptibility testing 
Microfluidic chips were sterilized by autoclaving prior to each experiment.  Nonspecific 
interactions between the chip surface and cells or antibiotics were minimized by passivating the 
walls of the fluid layer and the glass coverslip with sterile bovine serum albumin (BSA) at a 
concentration of 10 mg/mL for 15 minutes before each experiment.  In a typical experiment (Fig.  
3.4), the microfluidic chip-cover slip assembly is placed in contact with an aluminum-heating 
block heated to 35 °C using a temperature controller (Bionomic System BC-110).  Antibiotic and 
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cell solutions (≈1 µL volume for each) are placed on their respective inlet ports and introduced 
into the wells by actuating the filling valves using a vacuum pump (3 psig; GastDOA-P704-AA 
VacuumPump 1/8 HP 115 VAC).  Enhanced mixing of adjacent sets of antibiotic and cell 
solutions is initiated by actuating the mixing valves for 15 minutes.  To minimize solvent loss 
due to evaporation during long-term experiments, reservoirs filled with bacterial growth medium 
(Lennox broth) or sterile water were placed around the device, and the assembly was sealed at 
the top by affixing a glass slide (Fig.  3.4).  On-chip measurements were performed by TLFM 
using an inverted fluorescence microscope (Leica, DMI4000) equipped with a 1600 x 1200 pixel 
CCD camera (QImaging, Retiga-2000R), a 480/40 nm excitation filter, 527/30 nm emission 
filter, a motorized stage to raster the imaging field-of-view, and automated focus control 
implemented with a Z-motor (Ludl Electronic Products).  Images were acquired every 10 
minutes over a period of 10 hours using a 10x objective (Plan Achromat, NA = 0.25).  The 
shallow fluid channels (15 µm) ensured that all cells were within the depth of focus throughout 
the experiment.  During data acquisition, the exposure time was set to 200 ms and the fluorescent 
light source was shuttered between successive exposures to minimize photobleaching.  Stage 
rastering, focus control, image acquisition, and capture were implemented using ImagePro Plus 
software (Media Cybernetics).   
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Figure 3.4. Experimental setup for on-chip AST:  (A) The microfluidic device-coverslip assembly 
is placed in contact with an aluminum block whose temperature is maintained at 35 °C. 
Evaporation is minimized by positioning reservoirs filled with sterile growth medium at the four 
corners of the heating block and sealing the assembly with a glass slide at the top.  (B) Cells 
and antibiotics are readily loaded using a micropipette followed by vacuum actuation of the 
normally closed valves. 
3.2.4 Image processing and data analysis 
Images were analyzed using ImageJ version 1.46a [38].  Specifically, 8-bit grayscale images 
were converted to binary images by manual thresholding to capture all cells within a range of 
fluorescence intensities, which is defined on the low end by a minimum signal-to-noise ratio and 
determined on the high end by the inability to visualize cells.  The number of cells in each 
chamber was also estimated by counting the local fluorescence intensity maxima, and this 
algorithm provided consistent results within this range of manual thresholding.  In order to 
highlight long-term trends in cell proliferation (or death), I implemented a moving average filter 
to smooth the time series data.  I quantified antibiotic efficacy in terms of the fraction of the 
initial cell population that survives antibiotic treatment after 10 hours, which is estimated as: 
  (3.1) 
𝐹𝐹𝐹𝐹𝑎𝑎𝑎𝑎 ,𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐 = 𝑁𝑁10𝑁𝑁0  
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where FLab, conc  denotes the fraction of live cells at t = 10 hrs., subscripts ab and conc refer to the 
antibiotic and its concentration in units of µg/mL, No is the total number of cells in a microfluidic 
chamber at t = 0, and N10 is the total number of cells in the same chamber at t = 10 hrs.  Synergy 
and antagonism between pairs of antibiotics are calculated using a criterion variable A: 
  (3.2) 
where FLab1+ab2 denotes the fraction of live cells at t = 10 hours post-treatment with a pair of 
antibiotics (ab1+ab2), and FLab1 and FLab2  denote the fraction of live cells at t = 10 hours post-
treatment with each antibiotic individually at the same concentration as in the combination (in a 
different experiment).  Using this convention, an antibiotic combination is defined as being 
synergistic if A < 1 and antagonistic if A > 1.  
For experiments in which three antibiotics are used, the quantity A is determined by: 
 𝐴𝐴 =  𝐹𝐿𝑎𝑏1+𝑎𝑏2+𝑎𝑏3
𝑚𝑖𝑛( 𝐹𝐿𝑎𝑏1 , 𝐹𝐿𝑎𝑏2 ,𝐹𝐿𝑎𝑏3 ,𝐹𝐿𝑎𝑏1+𝑎𝑏2 , 𝐹𝐿𝑎𝑏2+𝑎𝑏3 , 𝐹𝐿𝑎𝑏3+𝑎𝑏1) (3.3) 
For experiments in which four antibiotics are used, the quantity A is determined by: 
 𝐴𝐴 =  𝐹𝐿𝑎𝑏1+𝑎𝑏2+𝑎𝑏3+𝑎𝑏4
min ( 𝐹𝐿𝑠𝑖𝑛𝑔𝑙𝑠 , 𝐹𝐿𝑝𝑎𝑖𝑟𝑠 ,𝐹𝐿𝑡𝑟𝑝𝑙𝑠 ) (3.4) 
where FLab1+ab2+ab3 and FLab1+ab2+ab3+ab4 denotes the fraction of live cells at t = 10 hours after 
being treated with the antibiotic combination. FLsngls represents these values for each single 
antibiotic comprising the combination, FLpairs denotes these values for pairs of antibiotics 
included in the combination and FLtrpls stands for combinations of three antibiotics.  Using this 
convention, an antibiotic combination is defined as being synergistic if A < 1 and antagonistic if 
A > 1. 
𝐴𝐴 =  𝐹𝐹𝐹𝐹𝑎𝑎𝑎𝑎1+𝑎𝑎𝑎𝑎2
𝑚𝑚𝑚𝑚𝑐𝑐(𝐹𝐹𝐹𝐹𝑎𝑎𝑎𝑎1,𝐹𝐹𝐹𝐹𝑎𝑎𝑎𝑎2,) 
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3.2.5 Off-chip (macro-scale) antibiotic susceptibility testing 
To benchmark our microfluidic platform against macroscale methods for antibiotic 
screening, we performed antibiotic susceptibility testing on E. coli using 96-well plates.  E. coli 
cell cultures were prepared as described above and added to the wells of a 127.8 mm x 85.5 mm 
flat-bottom 96-well plate (Nunclon).  Antibiotics were added to each well at the desired 
concentrations, and the plates were incubated at 35 oC with linear shaking (linear mode, 3.5 mm 
amplitude) in a microplate reader (TECAN Infinite M200 PRO).  Cell growth or death was 
monitored by recording optical density at a wavelength of 600 nm in each well every 15 minutes 
over a period of 15 hours.  In bulk-level experiments, evaporation was minimized by using 
covered plates. 
Estimation of Antibiotic Minimal Inhibitory Concentration 
Minimal inhibitory concentration (MIC) is defined as the lowest concentration of an antibiotic 
that inhibits cell growth as determined by visual inspection.  I estimated the MIC of each 
antibiotic against E. coli MG1655 using the broth dilution method as described in the manual of 
Clinical Laboratory Standards [39].  The results are listed in Table 3.2.  Specifically, E. coli cell 
cultures were prepared as described above and added to the wells of a 96-well plate (Nunclon) 
and mixed with an equal volume of antibiotic at the desired concentration.  Twelve serial 
dilutions were prepared for each antibiotic to span a concentration range from 0.1-500 µg/mL.  
Plates were incubated with shaking (linear mode, 3.5 mm amplitude) at 35 °C in a microplate 
reader (TECAN Infinite M200 PRO) and the optical density at 600 nm of each well was recorded 
every 15 minutes over a period of 15 hours.  Evaporation was minimized through the use of 
covered plates.  The MIC was defined as the lowest concentration of antibiotic that completely 
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inhibited cell growth as determined by absorbance readings as well as visual inspection.  The 
antibiotic solutions were diluted using Lennox broth. 
Table 3.2.  Minimum Inhibitory Concentration (MIC) of antibiotics against E. coli MG1655 
Seq. No. Antibiotic MIC (µg/mL) 
1 Ampicillin 8 
2 Cefalexin 12 
3 Chloramphenicol 8 
4 Tetracycline 2 
 
3.3 Results and Discussion 
3.3.1 Validation of the platform for biological studies 
The microfluidic platform used in this study (Fig. 3.5) consists of a two-layer poly (dimethyl-
siloxane) chip comprising: (1) a control layer for actuating the mixing and filling valves, and (2) 
a fluidic layer that houses the flow channels and a 4x6-array of wells.  Each well consists of two 
half wells that house the cells and antibiotic solutions, respectively.  Each half well is 400 μm 
wide, 15 μm tall and 500 μm long.  In this way, the 4x6 array design facilitates the treatment of 
one microbial cell sample with six distinct antibiotic solutions, thereby enabling the execution of 
up to six unique screens per chip along with four replicates for each screen (Fig. 3.5).  Antibiotic 
solutions and cell samples are readily loaded and mixed by actuating the respective filling and 
mixing valves using a vacuum pump.  The incorporation of normally closed valves improves 
platform portability by obviating the need for continuous actuation using positive pressure [40-
43].  To validate the feasibility of the microfluidic platform for biological studies, I determined 
the doubling times of E. coli cultured on-chip and in 96-well plates using two different kinds of 
media: nutrient-rich Lennox medium and minimal glucose-based M9 medium.  I verified that the 
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on-chip growth profiles of E. coli cells were in close agreement with the growth profiles 
observed in the 96-well plate based experiments (Fig.  3.6).  Specifically, the on-chip doubling 
times of E. coli were approximately 35 minutes and 70 minutes in Lennox broth and M9 
medium, respectively.  The corresponding doubling times in the same media when using 96-well 
plates were 30 minutes and 73 minutes, respectively.  The general scheme of the sensing system 
is shown in Fig.  3.7.   
 
Figure 3.5. Optical micrographs of the microfluidic platform for on-chip AST:  (A) The device 
features a 4x6 array of 3 nL volume wells, which are loaded with colored dyes for display 
purposes.  (B) Antibiotics at various concentrations and/or different antibiotic combinations are 
loaded in each well through fluid lines A-F (represented by green, red, blue, magenta, indigo 
and colorless solutions).  E. coli cells are loaded in the wells adjacent to the antibiotics through 
fluid lines G-L (represented by yellow solutions).  (C) Normally-closed pneumatic valve set 1 is 
used to control the antibiotic and cell loading in the wells.  (D) Actuation of mixing valve set 2 is 
used to mix the antibiotics and cells in adjacent chambers by enhanced diffusion, represented 
by a change in colors (blue/yellow to green) in the optical micrographs. 
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Figure 3.6. Comparison of growth profiles of E. coli cultured in Lennox broth and M9 medium 
using (A) the microfluidic chip and (B) in conventional 96-well plates.  Growth on-chip is 
quantified by periodically counting cells in each well of the microfluidic device, which is then 
normalized to the initial cell number loaded in the well. Growth in 96-well plates is quantified by 
periodically measuring absorbance at 600 nm, which is normalized to the initial absorbance.  All 
measurements are conducted at 35 °C.  Each data point represents the mean of at least three 
experiments.  Errors bars represent the standard error of the mean (SEM) and are shown for 
every fifth data point for visual clarity. 
 
Figure 3.7. General scheme of the sensing system using the 4x6 multiplexed microfluidic 
platform. 
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3.3.2 Effects of individual antibiotics on E. coli cells  
 
Figure 3.8.  Effects of individual antibiotics on E. coli growth using an on-chip assay.  Time 
traces represent the effects of bactericidal antibiotics: (A) ampicillin and (B) cefalexin and 
bacteriostatic antibiotics: (C) tetracycline and (D) chloramphenicol on cell growth.  Cell growth 
and death were monitored by counting cells in each well, every 10 minutes, over a period of 10 
hours.  Cell numbers are normalized to the initial (t = 0) value.  Each data point represents the 
mean of measurements from three experiments.  Error bars represent the standard error of the 
mean (SEM) and are depicted for every fifth data point for visual clarity. 
 
I employed the microfluidic screening chip to investigate the effects of four widely 
prescribed antibiotics on E. coli expressing GFP.  The use of GFP as a genetically encodable 
indicator of cell viability has been previously reported [44].  Transformation of bacteria to 
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express GFP is a standard procedure routinely used in microbiology or for applications in 
monitoring cell growth over an extended period of time.  Antibiotics were selected to comprise 
bactericidal (ampicillin, cefalexin) and bacteriostatic (tetracycline, chloramphenicol) classes.  I 
treated early log-phase cultures of E. coli with varying concentrations of each antibiotic on-chip 
and quantified cell numbers using TLFM over a period of 10 hours (Fig. 3.8).  Representative 
optical images showing action of an antibiotic on bacteria over a period of 10 hours are shown in 
Fig. 3.9.  Although cell numbers are quantified over a period of 10 hours, antibiotic 
susceptibility information is discernible within 2-4 hours (Fig.  3.10).  I estimated antibiotic 
efficiency in terms of the fraction of the initial cell population in a chamber that survives 
antibiotic treatment at the end of an experiment (FLab, conc) as defined by Eq. (1).  FLab, conc values 
are tabulated in Table 3.3.  In case of unperturbed cell growth (no antibiotics added), FL 
typically has a value close to 166, which corresponds to 6-8 population doubling events over a 
period of 10 hours.  Bactericidal (cell killing) antibiotic action is expected to result in a value of 
FLab,conc < 1, whereas bacteriostatic (growth arresting) antibiotic action will lead to FLab, conc ≈ 1.  
In this way, FLab,conc serves as a robust measure of antibiotic potency.   
Table 3.3.  Efficacy of individual antibiotics quantified in terms of FL values  
Conc (µg/mL) FLamp FLcef FLchl FLtet 
500 0.16 ± 0.05   0.06 ± 0.00 0.37 ± 0.01 0.33 ± 0.01 
50 0.12 ± 0.01 0.58 ± 0.06 0.66 ± 0.02 1.00 ± 0.08 
5 0.55 ± 0.04  33.16 ± 3.82 1.24 ± 0.08 1.21 ± 0.04 
0.5 15.44 ± 1.41 23.45 ± 3.93 29.19 ± 5.99 32.86 ± 2.57 
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Figure 3.9. Killing of E. coli over a period of 10 hours when treated with 500 µg/mL of ampicillin.  
 
 
Figure 3.10.  FL values of single antibiotics on E. coli cells, assessed at t = 4 hrs.  
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I observed that all four antibiotics failed to inhibit cell growth when employed at low 
concentrations (0.5 µg/mL), although the final cell densities (at t = 10 hrs.) are considerably 
lower than in the case where cells are not treated with antibiotics (FLamp,0.5  ≈ 15.4, FLcef,0.5  ≈ 
23.5, FLchl,0.5  ≈ 29.2, and FLtet,0.5  ≈ 32.9).  At a 10-fold higher concentration (5 µg/mL), 
ampicillin results in a substantial amount of cell death by lysis (FLamp,5  ≈ 0.55), whereas 
tetracycline and chloramphenicol almost completely abrogate cell division without causing 
significant lysis (FLtet,5  ≈ 1.21, and FLchl,5  ≈ 1.24).  These results are consistent with the 
bactericidal and bacteriostatic mode of action of the respective antibiotics.  Interestingly, cell 
proliferation is observed in the case of cefalexin (FLcef,5  ≈ 33.2).  At the highest concentration 
(500 µg/mL), I observed significant cell death for all antibiotics (FLamp,500  ≈  0.16 and FLcef,500  ≈ 
0.06; FLtet,500  ≈ 0.33 and FLchl,500  ≈ 0.37).   
Cell growth data obtained using the on-chip microfluidic assay are generally in good 
agreement with those obtained in the 96-well plate assays, albeit with a few notable differences 
(Figure  3.11).  In particular, 96-well plate based assays revealed robust cell growth upon 
treatment with cefalexin at 50 µg/mL, whereas complete growth arrest was observed using the 
on-chip assay for the same antibiotic concentration (FLcef,50  ≈  0.58).  This difference can be 
explained by the different ways in which cell density is determined using the microfluidic on-
chip assay versus the bulk-level 96-well plate assay.  At a concentration of 50 µg/mL, cefalexin 
causes massive cell filamentation because it inhibits cell wall synthesis in E. coli.  Indeed, in on-
chip experiments, I observed a nearly 20-fold increase in cell length within 4 hours of cefalexin 
treatment (Figure 3.12).  Cell elongation contributes to increased absorbance at 600 nm; 
however, in bulk assays that rely on optical absorbance to quantify cell growth, cell filamentation 
is perceived as an increase in cell density.  In an analogous fashion, in the early stages (t ≈ 1.5 
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hrs.) of ampicillin treatment (5 µg/mL) and cefalexin treatment (50 and 500 µg/mL), cell 
filamentation is misconstrued as rapid growth by the bulk absorbance based assay performed in 
the 96-well plates (See Fig.  3.12 and Fig. 3.13).  In this way, the microfluidic-based assay relies 
on single cell measurements to determine the efficacy of treatment, which intrinsically results in 
a more accurate measure of antibiotic potency. 
 
Figure 3.11. Effects of single antibiotics on E. coli growth investigated using 96-well plate 
assays.  E. coli cells were treated with different concentrations of bactericidal antibiotics: (A) 
ampicillin and (B) cefalexin, and bacteriostatic antibiotics: (C) tetracycline and (D) 
chloramphenicol. All values are normalized to the absorbance at the initial (t = 0) time point.   
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Figure 3.12. Elongation of E. coli cells upon treatment with (A) cefalexin and (B) ampicillin (t = 4 
hrs.). 
 
Figure 3.13. Elongation of E. coli cells upon treatment with cefalexin during early stage 
misconstrued as growth in 96-well plate 
A second important difference between bulk-level AST and microfluidic-based AST is the 
possibility of antibiotic precipitation at high concentrations, which can obscure absorbance 
measurements in bulk-level analysis.  We observed this phenomenon in the case of tetracycline.  
Based on 96-well plate measurements, the highest concentration of tetracycline (500 µg/mL) 
fails to inhibit cell growth initially (up to t  ≈ 1.5 hrs.), whereas the same concentration results in 
cell lysis using the on-chip assay (FLtet,500 ≈ 0.33).  Moreover, inhibition of cell growth by 
tetracycline appears to be more effective at lower concentrations of the antibiotic (5 and 50 
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µg/mL).  I attribute this discrepancy to the rapid precipitation of tetracycline in aqueous solution 
at concentrations exceeding 500 µg/mL [45].  Precipitation of tetracycline from solution in the 
bulk-level assays results in an erroneous ~3-fold increase in optical absorbance at 600 nm 
(Abs600, 0.5 mg/L tet  =  0.25 versus Abs600, blank = 0.08).  In addition, it is well known that 
hydrophobic small molecules can be absorbed by PDMS.  Therefore, I performed a series of 
control experiments to ensure that the on-chip antibiotic concentrations in the microfluidic 
platform were not significantly perturbed during the course of the experiments (Table 3.4).  I 
quantified antibiotic concentrations before and after on-chip incubation for 10 hours using liquid 
chromatography-mass spectrometry (LC-MS) discussed in more details in the next section.  
Based on mass spectrometry, ampicillin, cefalexin, and chloramphenicol showed no significant 
absorption by PDMS.  However, I observed some degree of absorption in case of tetracycline at 
the endpoint of prolonged 10-hour incubation in PDMS devices.  Nevertheless, the on-chip AST 
results followed the same general trends compared to bulk-level growth experiments, including 
growth inhibition at low concentrations of tetracycline (5 µg/mL), which is consistent with 96-
well plate measurements (Fig. 3.8 and Fig. 3.11). 
Table 3.4. Fraction of antibiotic lost after 10 hours of incubation in the PDMS chip 
Conc (µg/mL) Amp Cef Chl Tet 
1000 0.11 0.03 0.16 0.34 
100 0 0.12 0.20 0.57 
 
Study of Antibiotic Absorption by PDMS 
PDMS is biocompatible, optically transparent, and inexpensive, which makes it an attractive 
material for biological assays [23].  However, hydrophobic small molecules such as drugs are 
often readily lost by absorption by the PDMS bulk material and/or adsorption on the PDMS 
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surface, which has the potential to interfere with quantitative biological assays [46].  To ensure 
that the on-chip antibiotic concentrations in the microfluidic platform were not significantly 
perturbed, I quantified the antibiotic concentrations before and after on-chip incubation for 10 
hours using liquid chromatography-mass spectrometry (LC-MS).  I used two different 
concentrations of each antibiotic: 1000 µg/mL and 100 µg/mL.  The respective antibiotic 
solutions were added to the microfluidic chip and incubated at 35 °C for 10 hours.  The chip 
design was modified slightly to include open-ended channels to enable collection of antibiotic 
samples after incubation. The experiment was set up in exactly the same manner as a typical on-
chip experiment with cells, except that the cells were omitted.  Based on the results (Table 3.4), I 
conclude that ampicillin, cefalexin, and chloramphenicol concentrations are minimally affected 
during incubation in a PDMS-based chip, even at high concentrations of the antibiotics.  In 
addition, even though tetracycline is absorbed to some extent, the on-chip results follow the trend 
as expected including at low concentrations of 5 µg/mL, in which the cell growth is inhibited 
consistently on-chip and in 96-well plate experiments.  I conjecture that tetracycline is absorbed 
by PDMS owing to its hydrophobic properties [47].  
Estimation of Antibiotic Minimal Inhibitory Concentration (MIC)  
Minimal inhibitory concentration (MIC) is defined as the lowest concentration of an antibiotic 
that inhibits cell growth as determined by visual inspection.  I estimated the MIC of each 
antibiotic against E. coli MG1655 using the broth dilution method as described in the manual of 
Clinical Laboratory Standards [39].  The results are listed in Table 3.2.  Specifically, E. coli cell 
cultures were prepared as described above and added to the wells of a 96-well plate (Nunclon) 
and mixed with an equal volume of antibiotic at the desired concentration.  Twelve serial 
dilutions were prepared for each antibiotic to span a concentration range from 0.1-500 µg/mL.  
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Plates were incubated with shaking (linear mode, 3.5 mm amplitude) at 35 °C in a microplate 
reader (TECAN Infinite M200 PRO) and the optical density at 600 nm of each well was recorded 
every 15 minutes over a period of 15 hours.  Evaporation was minimized through the use of 
covered plates.  The MIC was defined as the lowest concentration of antibiotic that completely 
inhibited cell growth as determined by absorbance readings as well as visual inspection.  
Antibiotic stocks were prepared as described in Materials and Methods.  The antibiotic solutions 
were diluted using Lennox broth. 
3.3.3 Effect of antibiotics in pairs  
 
Figure 3.14. Synergistic and antagonistic effects of antibiotic combinations on E. coli. Time 
traces represent the effects of (A) pairs of antibiotics and (B) combinations of 3 and 4 antibiotics 
on E. coli cell growth.  All values are normalized to the initial (t = 0) cell number.  Each data 
point represents the mean of at least three experiments.  Errors bars represent the standard 
error of the mean (SEM) and are depicted for every fifth data point for visual clarity. 
The development of novel antimicrobials has lagged in pace relative to the rapid emergence 
of microbial drug resistance against several existing antibiotics [48].  In the absence of new 
potent pharmaceuticals, multidrug resistant pathogens are frequently treated with combinations 
of two or more antibiotics.  Combination therapy offers a potential way to mitigate the 
emergence of drug resistance traits because microbial pathogens are less likely to simultaneously 
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develop mutations that render them resistant to multiple antibiotics [49, 50].  However, 
interactions between multiple antibiotics may exhibit either synergistic or antagonistic behavior, 
wherein the combination shows improved or decreased efficiency compared to each antibiotic 
applied individually.  To evaluate the effects of antibiotic combinations on E. coli cell growth, 
we treated cells with the aforementioned antibiotics administered in pairs at a concentration of 5 
µg/mL per antibiotic (Fig. 3.14).  In this way, I selected an antibiotic concentration that is lower 
than the antibiotic MIC  that we determined using 96-well plates (Table 3.2).  Discernible 
changes in cell numbers were obtained within 4 hours of antibiotic treatment (Fig.  3.15).  I 
quantify synergistic or antagonistic behavior of a pair of antibiotics based on its ability to 
eradicate bacterial cells relative to the action of each antibiotic applied individually.  For each 
antibiotic pair, I calculate the value of a criterion variable A as defined above in Eq. (2).  
Synergistic combinations of antibiotics successfully eradicate E. coli cells more effectively than 
any individual antibiotic (A < 1).  In contrast, a combination is deemed antagonistic if it 
eliminates fewer cells relative to the most potent single antibiotic used in the combination (A > 
1).   
Figure 3.15.  FL values of antibiotics combinations on E. coli cells, assessed using microfluidic 
chip at t = 4 hrs.  (A) FL values for antibiotics tested in pairs where 1: Amp + Cef, 2: Amp + Chl, 
3: Amp + Tet, 4: Cef + Chl, 5: Cef + Tet, 6: Chl + Tet.  (B) FL values for antibiotics tested in 
combinations of three and four where 1: Amp + Cef + Chl, 2: Amp + Cef + Tet, 3: Amp + Chl + 
Tet, 4: Cef + Chl + Tet, 5: Amp + Cef + Chl + Tet  
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Table 3.5 lists the FL and A values that I determined for each antibiotic pair after performing 
the corresponding on-chip experiment.  This data indicates that the ampicillin-cefalexin pair 
exhibited the best antibacterial activity (FLamp+cef  ≈ 0.06).  In contrast, neither ampicillin nor 
cefalexin exhibit appreciable cell killing activity when used individually at 5 µg/mL.  The results 
indicate that a high degree of synergy occurs when the two antibiotics are used in combination (A 
= 0.11).  Indeed, synergism between beta-lactam antibiotics, like ampicillin and cefalexin, 
constitutes the clinical basis for their widespread paired application in treating recalcitrant 
infections [51, 52].   
Table 3.5. Synergistic/antagonistic interactions of antibiotic combinations 
Combinations FL A Interaction 
Amp + Cef 
Amp + Chl 
Amp + Tet 
Cef + Chl 
Cef + Tet 
Chl + Tet 
0.06 ± 0.01 
0.31 ± 0.04 
0.46 ± 0.03 
6.34 ± 0.41 
8.85 ± 0.44 
7.94 ± 0.45 
0.11 
0.52 
0.77 
5.12 
7.29 
6.54 
synergistic 
synergistic 
synergistic 
antagonistic 
antagonistic 
antagonistic 
Amp + Cef + Chl 
Amp + Cef + Tet 
Amp + Chl + Tet 
Cef + Chl + Tet 
Amp + Cef + Chl + Tet 
0.24 ± 0.04 
0.29 ± 0.12 
0.22 ± 0.01 
10.0 ± 2.63 
0.38 ± 0.16 
3.44 
4.17 
0.70 
8.23 
5.61 
antagonistic 
antagonistic 
synergistic 
antagonistic 
antagonistic 
In contrast, combinations of the bacteriostatic antibiotics, the chloramphenicol-tetracycline 
pair resulted in antagonistic behavior.  Slow cell growth was observed in this case (FLtet+chl ≈ 7.9, 
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FLtet, 5 ≈ 1.21 and FLchl,5 ≈ 1.24).  Tetracycline and chloramphenicol exert their bacteriostatic 
effects by inhibiting protein synthesis through their interactions with the bacterial ribosome.  As 
both antibiotics aim for very similar target sites in the ribosome, antagonism may result from 
mutual exclusion of the antibiotics from their preferred target sites in cells [53].   
 
Figure 3.16 Effects of antibiotic combinations on E. coli cells, assessed using 96-well plates. 
Synergistic and antagonistic interactions were explored for (A) pairs of antibiotics and (B) 
combinations of three and four antibiotics. Antibiotics were used at a concentration of 5 µg/mL.  
All values are normalized to the initial absorbance (t = 0).  Each data point represents the mean 
of at least three experiments.  Errors bars represent the standard error of the mean (SEM) and 
are depicted for every fifth data point for visual clarity. 
Paired combinations of ampicillin with tetracycline or chloramphenicol proved to be 
moderately synergistic  (FLamp+tet ≈ 0.46, FLamp+chl ≈ 0.31) [54].  However, cephalexin resulted in 
significant antagonism with regards to cell proliferation when combined with tetracycline or 
chloramphenicol and observed up to 10 hours (FLcef+chl ≈ 6.34, FLcef+tet ≈ 8.85).  Antagonism of 
growth inhibitory effects of the bacteriostatic antibiotics by cefalexin can be attributed to 
cefalexin’s activity on the bacterial cell wall.  Consistent with the mode of action of 
cephalosporin antibiotics, cefalexin interferes with cell wall peptidoglycan synthesis and 
compromises the integrity of the bacterial cell wall [55].  Enhanced cell wall permeability may 
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hinder intracellular retention of chloramphenicol and tetracycline to concentrations sufficient for 
antibacterial activity [53].  Although ampicillin exerts an analogous effect on the bacterial cell 
wall, antagonism is likely to be less apparent due to the greater potency of ampicillin relative to 
cefalexin (Table 3.2).  Specifically, as mentioned above, 5 µg/mL ampicillin is sufficient to 
prevent cell growth, whereas higher concentrations of cefalexin need to be used to accomplish 
the same effect.  Interestingly, E. coli cells respond to the cefalexin-chloramphenicol pair in a 
biphasic manner; herein, an initial phase of cell elongation and rapid lysis (up to t = 5 hrs.) is 
followed by a period of steady growth.  Finally, the microfluidic-based on-chip results agree well 
with those obtained from 96-well plate assays with similar differences as described in the 
previous section (Fig.  3.16).  In particular, cell elongation in the case of antibiotic pairs 
involving ampicillin or cefalexin is misconstrued as rapid initial growth by the absorbance-based 
bulk assay. 
3.3.4 Effect of antibiotics in combinations of three and four 
Moving beyond simple pairs of antibiotics, I also tested combinations of three and four 
antibiotics together to assess whether higher order antibiotic combinations could significantly 
enhance the antibacterial activity compared to antibiotic pairs (Fig. 3.14).  Synergistic or 
antagonistic interactions between combinations of three or four antibiotics are defined based on 
the ability of the combination to inhibit cell proliferation relative to the effect of each antibiotic 
in isolation, as well as to that of sub-groups of antibiotics (pairs and triplets) included in the 
higher order combination.  I calculated the criterion variable A using Eq. (3) in a manner 
analogous to antibiotic pairs (Table 3.5).  Interestingly, all tested combinations of three or four 
antibiotics performed worse than the ampicillin-cefalexin pair (FLamp+cef+chl  ≈ 0.24 , FLamp+cef+tet  
≈ 0.29, FLamp+chl+tet  ≈ 0.22, FLcef+chl+tet  ≈ 10, FLamp+cef+chl+tet  ≈ 0.38 ).  This key observation 
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suggests that a high degree of antagonism results when combinations of beta lactam antibiotics 
(ampicillin, cefalexin) are supplemented with one or more bacteriostatic antibiotics 
(chloramphenicol, tetracycline), with the exception of ampicillin-chloramphenicol-tetracycline, 
which was the only higher order combination that exhibits synergistic effects (A = 0.70).  Beta 
lactam antibiotics rely on active cell division with concomitant synthesis of the bacterial cell wall 
to exert their effects [56].  Bacteriostatic antibiotics have been known to antagonize the effects of 
beta lactam antibiotics through their inhibition of protein synthesis and consequent stalling of 
cell wall synthesis [57].  Consistent with my earlier observations, combinations of cefalexin, 
chloramphenicol, and tetracycline proved to be highly antagonistic (FLcef+chl+tet ≈ 10.0).  Finally, 
most of the combinations of three and four antibiotics caused substantial cell elongation, which 
was anomalously interpreted as cell growth by 96-well plate assays (Fig.  3.16).  
3.3.5 Effect of cell density on killing efficacy of antibiotics 
The efficiency of an antibiotic in eradicating pathogen populations is critically dependent on 
the density of the infecting cells (pathogen load) at the site of infection [58].  Dense bacterial 
populations often successfully counter antibacterial activities of several potent antibiotics 
through the initiation of complex genotypic responses based on quorum sensing [59, 60].  
Bacterial cells colonizing infection sites can rapidly reach very high densities, because these cells 
are confined in the constrained space of the host organism.  In this work, the microfluidic 
chambers (dimensions 500 μm x 400 μm x 15 μm and volume = 3 nL) provide a suitable mimic 
for the microconfinement effects experienced by colonizing pathogens in vivo [61].  Therefore, I 
assessed the effects of initial cell density on the killing efficacy of otherwise lethal doses of 
antibiotics.  For this purpose, I chose the most potent antibiotic combination: the ampicillin-
cefalexin pair (FLamp+cef ≈ 0.06 at an initial pathogen load of 108 cells/mL).  I varied cell 
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densities over two orders of magnitude (109 - 1010 cells/mL).  Use of high cell densities 
precludes direct enumeration of cell numbers due to spatial crowding.  In these cases, cell growth 
was quantified by measuring the integrated fluorescence intensity over time in each 
microchamber.  As depicted in Fig. 3.17, the ampicillin-cefalexin combination proved to be 
ineffective at cell concentrations of 109 cells/mL and 1010 cells/mL.  I obtained similar results 
using another potent antibiotic cocktail comprising ampicillin, cefalexin, and chloramphenicol 
(FLamp+cef+chl  ≈ 0.23).  The rapid loss of antibiotic efficiency with 10-100 fold variations in 
population levels emphasizes the acute need to rapidly establish antibiograms of pathogens 
before infecting populations escalate to untreatable levels.  This further highlights the utility of 
the microfluidic approach used here, which provides practical information within 4 hours.  In 
contract, alternative methods based on current technologies require much longer time (at least 8 
hours, more typically 24-72 hours [62] to provide the same observation.  
 
Figure 3.17 Effects of initial E. coli cell density on antibiotic efficacy.  Population effects of E. 
coli cells were investigated for (A) a combination of ampicillin and cefalexin and (B) combination 
of ampicillin, cefalexin, and chloramphenicol.  Cell growth was quantified by calculating the 
integrated fluorescence intensity in a microchamber as the dense crowding hindered counting of 
single cells.  Errors bars represent the standard error of the mean (SEM) and are depicted for 
every fifth data point for visual clarity. 
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3.4 Conclusions 
In summary, I have developed a multiplexed microfluidic platform comprised of arrays of 
small volume chambers (3 nL) that enables monitoring the effects of several antibiotics and their 
combinations on E. coli cells.  Conventional methods for antibiotic susceptibility testing (e.g., 
broth dilution and disc diffusion) are time consuming and tedious, generally requiring large 
sample and reagent volumes.  From this perspective, the microfluidic platform provides 
substantial improvements over existing methods with regard to timescale of analysis and sample 
volumes.  In particular, the platform possesses key several advantages such as low sample and 
reagent volume requirements (< 6 µL), enhanced detection sensitivity (~ 1 cell), rapid turnaround 
times (2-4 hours), improved portability, and enhanced combinatorial capabilities compared to 
several alternative microfluidic techniques.  Even though I quantified antibacterial effects on 
cells over a total time period of 10 hours, changes in cell numbers are already discernible within 
2 to 4 hours.  In this way, the platform substantially accelerates antibiotic susceptibility testing 
compared to broth dilution and disk diffusion by circumventing the need for pre-culturing cells 
to detectable levels, which often takes > 24 hrs.  Moreover, the method further enables direct 
observation and enumeration of cellular phenotypes (growth, morphology).  As such, the 
microfluidic method reported here provides precise quantification of cell numbers, in contrast to 
bulk methods that rely on population averaged metrics (e.g., optical absorbance) as an indirect 
proxy for cell number.  In addition, the use of normally closed valves in the platform facilitates 
portability and easy loading of samples and reagents.   
On-chip experiments involving combinations of different antibiotics highlight the importance 
of thorough evaluation of the effectiveness of each combination before use in the clinic.  In 
several instances, antibiotic combinations perform poorly.  These results also showcase the 
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utility of the platform for studies like these, as well as for rapid diagnosis and management of 
infections.  The microfluidic platform described in this chapter relies on genetically modified 
bacteria for analysis; however, this issue can be circumvented by utilizing fluorescence based or 
optical dyes.  In addition, the methodology reported here relies on the use of fluorescent 
microscopy, a nearly ubiquitous method that is routinely utilized in medical fields including 
microbiology, immunology, and pathology testing labs.  One can envision using AST chips such 
as those reported here for further development of point-of-care diagnostic platforms for bacterial 
infections.   
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Chapter 4 
Antibiotic susceptibility testing of polymicrobial cultures3 
4.1 Introduction 
Microbes seldom exist in isolation[1, 2],  hence several infections such as urinary tract 
infections (UTIs), chronic wounds, cystic fibrosis, and nosocomial bacteremia are polymicrobial 
in nature, that is they involve more than one microbial agent[3-5].  These infections, in the 
literature also referred to as mixed, complex, synergistic, or co-infections, are known for their 
higher mortality rate than their monomicrobial constituents[3].  In spite of the larger debilitating 
effects, these polymicrobial infections are not well studied [3, 6-8].  Furthermore, since microbes 
involved in polymicrobial infections are more recalcitrant to several antibiotics compared to the 
same microbes in monomicrobial cultures, polymicrobial infections frequently require a stronger 
antibiotic dosing regimen[4].  Billions of dollars are spent each year in USA to treat these 
infections; however the majority of the treatments are solely based on monomicrobial 
susceptibility information [9-11], in spite of the fact that monomicrobial antibiotic susceptibility 
information often does not necessarily apply to polymicrobial cultures[12-15]. This incorrectly 
assumed correlation can lead to inaccurate antibiotic dosing regimen further exacerbating the 
global health issue of increasing antibiotic resistance[16].  Due to the severity of these 
polymicrobial infections and the rising antibiotic resistance, understanding the mechanisms and 
quantifying the antibiotic susceptibility of the microbes involved in these infections is 
imperative.   
                                                                 
3 Part of this work has been submitted for publication: Ritika Mohan, Chotitath Sanpitakseree, Amit V. Desai, Emre 
S. Sevgen, Charles M. Schroeder, and Paul J.A. Kenis, “A microfluidic approach for antibiotic susceptibility testing of 
polymicrobial infections”, submitted.  
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Conventional antibiotic susceptibility testing (AST) procedures such as disk diffusion and 
broth dilution are standardized only for monomicrobial cultures[17].  While these methods 
provide useful insights about the bacterial susceptibility in isolate cultures, they possess several 
limitations in obtaining analogous information in mixed cultures, including (1) the inability to 
acquire individual species-specific antibiotic susceptibility information, and (2) the inability to 
investigate the inter-species interaction, which influences the efficacy of antibiotics.  In addition, 
AST of polymicrobial cultures becomes more tedious than conventional monomicrobial AST, 
because the number of plates needed increases with the number of bacterial strains in the 
sample[18]. Also, the conventional methods require (1) large sample volumes (10-30 mL) and 
long incubation times (>24 h) for pre-culturing the bacteria to detectable levels, leading to 
cumbersome analysis, and (2) the determination of bacterial growth changes by visual inspection 
or absorbance-based spectroscopy.  Both these factors lead to imprecise results[19, 20]. 
Only few studies have utilized conventional AST techniques for polymicrobial cultures.  
For instance, a study involving P. aeruginosa, B. cenocepacia, and E. coli demonstrated an 
increase in the antibiotic resistance of the population compared to their monomicrobial cultures 
and this observation was attributed to the transfer of resistance from a sub-bacterial 
population[21].  Although this study demonstrated the application of conventional methods of 
monomicrobial susceptibility to polymicrobial cultures, these methods are still plagued by their 
limitations, i.e., long time for analysis and low sensitivity, and the inability to determine species-
specific susceptibility.  Culture-independent techniques, such as the quantitative terminal 
restriction fragment length polymorphism (qT-RFLP) approach that enumerates genome copies 
through 16S rRNA gene (proxy for bacterial cell number), have been utilized to obtain species 
specific information [17, 18, 22].  However, this method is tedious due to the complicated 
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sample preparation and data analysis procedures, and consists of the inherent problems 
associated with PCR-based methods such as preparation of precise primers and occasional 
appearance of false peaks [23].   
The few studies that have focused on the effects of bacterial interaction on AST [24-26] 
have attributed observed changes in antibiotic susceptibility primarily to the production of 
enzymes such as beta-lactamases, which protect co-existing bacteria[24].  Developing a better 
understanding of bacterial interactions is crucial for two reasons: (1) investigation of how 
changes to bacterial susceptibility lead to critical cases of infections, and (2) the possibility of 
discovering novel molecules that are induced only in the presence of different species [11, 27-
30], as these novel molecules may in turn modulate the physiology of other microbes affecting 
bacterial pathogenesis [30].  Current techniques (e.g., broth dilution) are end-point assays and are 
unable to quantify bacterial interaction, hence, the development of new techniques for 
quantifying the effects of antibiotics due to bacterial interaction in polymicrobial infections is 
indispensable.     
The use of integrated microfluidics represents an attractive technology for a range of bio-
based applications [31-33] and has the potential to address some of the aforementioned issues 
associated with the currently used AST methods.  Specifically, integrated microfluidics can 
satisfy key requirements for polymicrobial AST, for example quantification of bacterial 
interaction and determination of species-specific susceptibility by distinguishing and accurately 
enumerating different species in a time-resolved fashion.  Microfluidic platforms also enable the 
investigation of bacterial interaction without the need to pre-culture cells to a detectable level, 
which drastically reduces the assay time.  Different microbial species can be easily identified and 
visualized individually.  Other advantages include the low sample and reagent volume 
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requirements, the high degree of spatial control over reagents, and the option to automate 
operations for high-throughput studies.  Some of these advantages inherent to microfluidics have 
been exploited previously to study a variety of phenomena in bacterial populations such as the 
influence of physical (shear stresses) and chemical cues (toxins) on cell viability, motility, 
functionality, and proliferation[11, 34-37].  In other work, microfluidics has also been utilized to 
study the co-culture of cells or cell-cell interactions in 2D and 3D environments for a wide range 
of applications, including tissue engineering and biomimetic niches[38-40], as well as bacterial 
interaction in biofilms[41].  However, only few studies have focused on the effect of bacterial 
interactions on AST [42, 43].  Some studies, such as those that utilized microfluidic “lobster 
traps”, microcavities permeable to small molecules, to study antibiotic resistance in low-cell-
number/high-density bacterial population[44], have commented on the utility of this approach to 
study polymicrobial interactions in the future, but such studies have not appeared to my 
knowledge.  Several other microfluidic approaches have been explored for monomicrobial AST 
[45-51], but none for polymicrobial AST, but these often suffer from issues such as limited 
portability[47, 50, 52], or complicate platform fabrication and/or operation [50, 53]. 
In this work, I address the limitations of the conventional AST techniques and current 
microfluidic approaches by developing a multiplexed microfluidic platform for studying 
bacterial interaction and species-specific polymicrobial AST.  The platform enables 
measurement of minimum inhibitory concentrations with sample volumes as low as ~ 2.4 nL in 
less than 4 hours.  More importantly, the high sensitivity not only enables accurate quantitation 
of susceptibility values but also provides species-specific information.  I demonstrate the 
application of this platform to study the interaction between E. coli, P. aeruginosa, and K. 
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pneumomoniae, in the absence and presence of commonly used antibiotics for MIC 
determination.   
 
4.2 Experimental 
4.2.1 Bacterial strains, media and antibiotics 
Bacterial strains of E. coli, P. aeruginosa and K. pneumoniae were routinely cultivated in 
Lennox broth (10 g/L tryptone, 5 g/L yeast extract, and 5 g/L NaCl) and supplemented with 
respective antibiotics as shown in Table 4.1 to maintain the GFP/ RFP plasmid.  Wild type E. 
coli MG1655 cells were transformed with pAM06[54] to constitutively express GFP under 
control of the PL promoter from phage lambda.  K. pneumoniae strain 342 carrying plasmid 
pRK2073[55] constitutively expressing GFP was generously provided to us by Prof. Eric Triplett 
at the University of Florida, and P. aeruginosa expressing red fluorescent protein (RFP) with the 
tdtomato gene under the transcriptional control of the nptll promoter on pBBR1-based plasmid 
pMQ132[56]  was generously provided to us by Prof. Robert Shanks at the University of 
Pittsburgh.  Incorporation of GFP and RFP markers enabled easy detection and enumeration of 
bacterial cells using time lapse fluorescence microscopy.  Prior to all monomicrobial and 
polymicrobial experiments, frozen stocks were revived overnight on LB agar plates 
supplemented with the appropriate antibiotic.  Single colonies from plates were then used to 
inoculate in 5 mL LB broth and the culture was incubated overnight at 37 °C with aeration (200 
rpm).  
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Table 4.1.  Antibiotic supplements in growth media for overnight pathogen culture 
Pathogen Supplemented Antibiotic 
pQE80L-PLGFP/E. coli 30 μg mL-1 kanamycin 
pRK2073-GFP/K. pneumoniae 30 μg mL-1 kanamycin 
pMQ132-Pnptlltdtomato/P. aeruginosa 40 μg mL-1 gentamicin 
Wild-type E. coli No antibiotic 
 For polymicrobial culture preparation (Fig. 4.1), 50 μL of the two monomicrobial 
cultures (cell types 1 and 2 in Fig. 4.1) were inoculated into separate tubes containing 5 mL of 
LB without supplemental antibiotic and were incubated for three hours.  The incubated cultures 
were then concentrated 10X by centrifugation (3200 g for 10 min) to remove all traces of 
antibiotics.  A range of cell type 1 and type 2 concentrations were then prepared by diluting in 
LB as shown in Fig. 4.1.  The diluted cultures of the two types were then mixed to obtain a range 
of polymicrobial combinations.  In the preparation of polymicrobial cultures, it was ensured that 
the observations of the competition experiments were solely due to the interaction between 
bacterial cells and not due to the antibiotics by removing antibiotics by centrifugation and by 
utilizing LB without antibiotics for the dilution steps.  I did not observe a change in cellular 
fluorescence after cells were sub-cultured in LB without antibiotics in my experiments.  
All antibiotic stocks were filtered using a 0.45 µm syringe filter (Millex-HV filter unit, 
Millipore) prior to use.  Antibiotic stock solutions of 10 mg/mL gentamicin sulfate salt, 10 
mg/mL tobramycin, 30 mg/mL kanamycin sulfate and 10 mg/mL amikacin were prepared in 
sterile deionized water.  The antibiotics gentamicin sulfate and tobramycin were purchased from 
Sigma-Aldrich, kanamycin sulfate was purchased from Invitrogen, and amikacin was purchased 
from Fisher Scientific.   
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Figure 4.1.  Preparation of mixed cultures of E. coli, P. aeruginosa, and K. pneumoniae in pairs 
4.2.2 Pyocyanin extraction assay 
The extraction procedure for pyocyanin was followed as previously described by Essar 
(Fig. 4.2).[57]  Briefly, pyocyanin was extracted from 4 mL of overnight culture using 3 mL of 
chloroform.  The chloroform layer (blue) was separated and extracted with 1 mL of 0.2 M HCl 
yielding an acidic layer (red).  Absorbance of this acidic layer was measured at 520 nm (OD520) 
and the concentration of pyocyanin was determined by comparison to calibration curves. 
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Figure 4.2. Extraction of pyocyanin by procedure outlined by Essar [57]  
4.2.3 Antibiotic susceptibility testing off-chip 
To compare the MIC obtained on-chip to conventional methods, I performed AST against 
E. coli, K. pneumoniae, and P. aeruginosa using 96-micro-well plates with each well 360 µL in 
volume (broth dilution method) or the conventional two-fold dilution protocol.  The 
monomicrobial cell cultures were prepared as described previously [58] and polymicrobial 
cultures were prepared as shown in Fig. 4.1.  Bacterial solution (100 µL) and antibiotics (100 
µL) were added to the wells of a 127.8 mm x 85.5 mm flat-bottom 96-well plate (Nunclon), and 
the plates were incubated overnight at 37 °C.  The MICs were determined by visual inspection of 
the bacterial density in each well, where the minimum concentration of antibiotic that prevented 
cell growth was determined to be the MIC.  Since the antibiotic concentrations were prepared by 
the two-fold dilution protocol, the precision of the method is considered to be plus or minus one 
two-fold concentration [59].  I report a range of MIC values in several cases since occasionally a 
particular antibiotic concentration would allow for only slight growth of the cells, while the next 
higher concentration would cause cell death.   
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4.2.4 Antibiotic susceptibility testing on-chip  
 All microfluidic devices were sterilized by autoclaving prior to each experiment and the 
chips were treated with 10 mg/mL bovine serum albumin (BSA) for 15 minutes to prevent 
nonspecific interactions between chip surface and cells or antibiotics.  The experimental set up 
and operation of the microfluidic platform is an adaptation of previously described protocols[58]. 
 All fluorescent images were analyzed (Fig. 4.3) and post processed using ImageJ version 
1.47c.  The number of cells in each chamber was determined using local fluorescence intensity 
maxima as previously described[58].  Briefly, the function ‘Enhance Contrast’ was used to 
improve the visual perception of the bacterial cells.  Then, an ImageJ function ‘Find Maxima’ 
was used to determine the number of cells by counting the local fluorescence intensity maxima.  
Finally, I plotted time-kill curves of the bacteria for different antibiotics (cell number vs. time).  
To better highlight long-term trends in cell growth (or death), I implemented a two-point moving 
average filter which smoothens the time kill curves.  The concentration range of an antibiotic that 
leads to a negligible change in cell numbers over 10 h was considered to be the MIC range of the 
antibiotic for the pathogen.  Similar to bulk scale experiments, if a concentration of an antibiotic 
caused a slight increase in cell numbers before inhibition of cell growth and the next higher 
concentration led to obvious cell death, I reported a range of MIC values (Table 4.2). 
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Figure 4.3 A general schematic showing data analysis procedure for AST in polymicrobial cultures using 
multiplexed microfluidic platform 
 
4.3 Results and Discussion 
4.3.1 Design of the microfluidic platform 
I developed a two-layer PDMS microfluidic platform for a high-throughput AST (Fig. 
4.4).  The platform comprises (1) a control layer for actuating the mixing and filling valves, and 
(2) a fluidic layer that houses the flow channels and 48 wells (4.8 nL each).  Each well comprises 
two half-wells that are 400 μm by 400 μm and visualization of the entire well is possible using a 
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20X objective.  Visualization of all bacterial cells in the z direction is ensured with 15 μm tall 
flow channels, which is approximately equal to the depth of focus of the microscope.  For 
polymicrobial susceptibility testing, each half-well holds bacterial cells of one or more bacterial 
species and the adjacent half-well holds the antibiotic solutions, so that a set of 12 unique 
conditions can be tested in quadruplicates (48 experiments) on a single microfluidic platform.  In 
case of bacterial interaction studies, each half-well holds a unique combination of bacterial 
species in terms of number and/ or type, so that 24 unique conditions can be tested in 
quadruplicates (96 experiments) on a single platform.  Each half-well is isolated from the 
remaining wells by normally-closed valves, which enhance the portability of the platform by 
circumventing the need for continuous actuation during the experiment.  The current platform 
design is an improvement over my prior platform[58], with respect to the position of the 
quadruplicate half-wells such that these wells are equidistant from their respective inlets.  This 
configuration ensures uniform distribution of cell numbers in each of the quadruplicate half-
wells due to the equal hydraulic resistance between the inlet and each of the half-well (Fig. 4.4).  
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Figure 4.4.  Optical micrographs of the high throughput microfluidic platform for quantifying on-
chip polymicrobial interactions as well as the susceptibility of bacteria to antibiotics in 
polymicrobial cultures:  (A) 48 well-array chip in which each well is comprised of two 2.4 nL half-
wells, here filled with dyed aqueous solutions.  (B) Close up 48-well array able to screen 24 
unique conditions in quadruplicates.  For example: 12 unique antibiotic concentrations and/or 
different antibiotic combinations can be loaded in each well through fluid lines (green solutions) 
and 12 unique polymicrobial bacterial cell solutions can be loaded in the adjacent wells (red 
solutions).  (C) Antibiotic and bacterial cell chambers are isolated by mixing valves.  (D) Same 
set of wells after opening of the mixing valves, which results in uniform diffusional mixing of the 
antibiotics and cells in adjacent chambers, here represented by the dark red solution. 
I validated the multiplexed microfluidic platform by comparing the MIC of tobramycin 
and amikacin (Table 4.2) obtained on-chip to a conventional AST method (micro-broth 
dilution), against E. coli, a model bacterium, as well as against P. aeruginosa and K. 
pneumoniae, which are more clinically-relevant pathogens.  The latter two bacteria along with 
Enterococcus faecium, Staphylococcus aureus, Acinetobacter baumanii, and Enterobacter 
species belong to the ESKAPE category, widely known to “escape” the bactericidal action of 
antibiotics and are clinically significant since they are known to possess inherit resistance to 
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several antibiotics[49].  The MIC values obtained using micro-broth dilution (bulk) and on-chip 
experiments were found to be in close agreement.  Occasional discrepancies between bulk and 
on-chip outcomes can be attributed to the inherent differences in the analysis procedures.  For 
on-chip experiments, the MIC is determined by counting the changes in cell numbers over time, 
whereas in bulk experiments the MIC is determined by visually detecting changes in bacterial 
growth (micro-broth dilution method).  The key advantages of the microfluidic approach are: the 
rapid determination of MIC (2 - 4 h) with low sample volumes (< 3 nL), real time monitoring of 
growth dynamics, high sensitivity (single cell), high-throughput (compared to the current “gold 
standard” technique for AST, i.e., disk diffusion), amenability to automation, and ease of 
operation along with enhanced portability.  In this work, I utilize this high-throughput 
microfluidic platform to quantify bacterial interaction over time in the presence and absence of 
antibiotics.  
Table 4.2.  Minimum Inhibitory Concentration (MIC) of monomicrobial cultures  
 Amikacin [µg mL-1] Tobramycin [µg mL-1] 
 Bulk On-chip Bulk On-chip 
E. coli 8 4 8 4 
K. pneumoniae 8 8-16 4-8 4-8 
P. aeruginosa 2-4 4 2 2 
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4.3.2 Interaction dynamics of E. coli and P. aeruginosa (absence of antibiotics) 
 
Figure 4.5.  On-chip real-time monitoring of cell numbers of P. aeruginosa  (P) and E. coli (E) in 
the absence of antibiotics for different initial conditions (absolute and relative initial cell numbers 
of each).  Cell growth and death for (A) P. aeruginosa and (B) E. coli were monitored by 
counting cells in each well, every 30 minutes, over a period of 16 h.  Each data point represents 
the mean of the measurements from three experiments, and error bars represent the standard 
error of the mean and are depicted for every third data point for clarity.  
Since P. aeruginosa and E. coli are ubiquitous, they at times occur simultaneously in 
polymicrobial infections[60].  I employed the microfluidic platform to monitor changes in cell 
numbers using time-lapse fluorescence microscopy (TLFM) in mixed cultures of P. aeruginosa 
and E. coli expressing RFP and GFP, respectively.  The use of GFP and RFP as genetically 
encodable indicators of cell viability has been reported previously[61, 62].  I prepared co-
cultures of P. aeruginosa and E. coli prior to introducing them in the microfluidic platform (Fig. 
4.1).  The co-cultures were prepared such that the initial cell numbers for P. aeruginosa and E. 
coli varied across a wide range (10 to 900) for studying diverse cases of bacterial interaction that 
can occur in mixed infections.  The pre-mixed cells were introduced in the microfluidic platform 
and then TLFM was used to visualize and quantify the cell numbers of the different bacterial 
species over a period of 16 h (Fig. 4.5 and Fig. 4.6).   
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Figure 4.6. Optical micrographs of individual microfluidic wells visualizing changes in cell 
numbers of P. aeruginosa (expressing red fluorescent protein, rfp) and E. coli (expressing green 
fluorescent protein, gfp) in the absence of antibiotics for different initial conditions:  initial cell 
numbers of P. aeruginosa and E. coli of respectively (a) 50 and 60, (b) 90 and 190, and (c) 220 
and 60.  (d) and (e): Control experiments, cell growth of monomicrobial solutions of E. coli and 
P. aeruginosa, respectively.   
 
I observed that at higher initial cell numbers of P. aeruginosa compared to E. coli (220 
and 60), E. coli is completely eradicated within 8 hours (Fig. 4.5B).  When P. aeruginosa’s cell 
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numbers are higher than E. coli, P. aeruginosa is hypothesized to produce high concentrations of 
toxic metabolites such as pyocyanin, which are known to have antimicrobial properties against 
E. coli[63].  I tested this hypothesis by mixing supernatant of an overnight P. aeruginosa culture 
with E. coli, and observed drastic reduction in growth of E. coli suggesting toxicity of 
metabolites generated by P. aeruginosa against cell cultures of E. coli (data not shown).  
However, in a co-culture of P. aeruginosa and E. coli when mixed in 1:1 at high (~800) or low 
(~10) initial cell numbers, I observe an initial growth of E. coli followed by growth arrest in 7-8 
hours.  Similarly, at higher initial cell numbers (~ 190 and 850) of E. coli compared to those of 
P. aeruginosa (~90 and 30), the cell growth of E. coli levels of at about 6300 after 6 to 8 hours.  I 
attribute these observations to the production of indole by E. coli[60].  Indole enables E. coli to 
grow in mixed planktonic populations that includes P. aeruginosa by inhibiting pyocyanin 
production and consequently disrupting quorum sensing in P. aeruginosa[60].  In gram negative 
bacteria, cell-to-cell communication based on density is referred to as quorum sensing, and 
occurs through the release of fatty-acid-based molecules known as autoinducers (AIs) to 
coordinate gene expression within a population[64].  At high cell numbers of E. coli relative to 
P. aeruginosa, I speculate that sufficiently high accumulation of indole aids in survival and 
growth of E. coli in presence of P. aeruginosa.   
Interestingly, when starting with ~50 P. aeruginosa cells and a similar number of E. coli 
cells (ratio 1:1), E. coli first grows for 6 hours (to ~2700 cells), followed by growth arrest for 4 
hours and then cell death such that the E. coli cell number after 16 hours is ~1000 cells.  Here, I 
speculate that the killing of E. coli occurs after 10 hours due to higher cell number of P. 
aeruginosa (~6500) compared to E. coli (~2500), which leads to E. coli lysis due to 
accumulation of sufficiently high amounts of toxic metabolites such as pyocyanin.  However, the 
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production of indole by E. coli counters the effects of pyocyanin[60],  so the E. coli population 
does not get completely eradicated.  In the other two cases (90 P, 190 E & 30 P, 850 E) where 
the initial cell number of P. aeruginosa was lower than that of E. coli, E. coli expectedly does 
not lyse.  The increased viability is probably due to sufficient production of indole by E. coli and 
suppression of pyocyanin production by P. aeruginosa, both of which leads to E. coli’s survival 
and growth arrest in about 6 h.  I also observed that the doubling time of P. aeruginosa increases 
from ~50 minutes in monomicrobial cultures to ~109 minutes in presence of high initial cell 
numbers of E. coli (~850) relative to the number of P. aeruginosa cells (~30).  This observation 
is in agreement with recent literature that describes growth inhibition of P. aeruginosa in 
presence of metabolites such as indole produced by E. coli[60]. The results demonstrate that the 
growth dynamics in co-culture of E. coli and P. aeruginosa depend on their interaction which in 
turn is dependent on the absolute initial number of cells and the ratio of the initial cell numbers. 
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4.3.3 Interaction dynamics of P. aeruginosa and K. pneumoniae (absence of 
antibiotics) 
 
Figure 4.7 Optical micrographs of individual microfluidic wells visualizing changes in cell 
numbers of P. aeruginosa (expressing red fluorescent protein, rfp) and K. pneumoniae  
(expressing green fluorescent protein, gfp) in the absence of antibiotics for different initial 
conditions:  initial cell numbers of P. aeruginosa and K. pneumoniae of respectively (a) 480 and 
370, (b) 170 and 150, and (c) 490 and 130.  (d) and (e): Control experiments, cell growth of 
monomicrobial solutions of E. coli and K. pneumoniae, respectively.     
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Study of the dynamics of interaction between P. aeruginosa and K. pneumoniae is of key interest 
because several urinary tract infections (UTIs) are known to be polymicrobial communities 
involving P. aeruginosa and K. pneumoniae [65] and this co-culture also exists on the perinea of 
males with spinal cord injuries [66].  Similar to the co-culture studies of P. aeruginosa and E. 
coli, I employed the microfluidic platform to monitor changes in cell numbers using time lapse 
fluorescence microscopy (TLFM) in mixed cultures of P. aeruginosa and K. pneumoniae 
expressing RFP and GFP, respectively (Fig. 4.7 and Fig. 4.8).  Cultures of mixed bacterial cells 
were prepared similar to that of P. aeruginosa and E. coli co-cultures (Fig. 4.1).  In experiments 
with low initial cell numbers of P. aeruginosa (<200), I observed that the cell number of K. 
pneumoniae increased until a threshold value (~6700), independent of the ratio of the cell 
numbers, followed by growth arrest between 6-8 hours.  However, in experiments with initial 
cell numbers of P. aeruginosa >200, I observe almost complete cell lysis of K. pneumoniae after 
16 hours irrespective of the initial cell numbers of K. pneumoniae.  We hypothesize that the 
different responses of K. pneumoniae for different cell numbers are due to the interspecies 
interaction.  When a small number of bacteria release AIs, their concentration is too low to be 
detected or sensed.  However, when a critical cell mass of bacteria are present, the surrounding 
bacteria are able to sense, and in response, activate transcriptional activator (or R protein), i.e., 
quorum sensing[67].  I speculate that quorum sensing in this particular co-culture occurs when P. 
aeruginosa is at approximately 200 cells (which correspond to a concentration of ~108 cells/mL).  
This in turn leads to growth arrest after 6-8 h and eventually lysis of K. pneumoniae.  On the 
other hand, K. pneumoniae is unable to quorum-sense as effectively as P. aeruginosa and 
probably requires a lot more than 3000 cells (1.2 x 109 cells/mL) to survive in the presence of P. 
aeruginosa as shown in Fig. 4.7.  The results for co-culture of P. aeruginosa and K. demonstrate 
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that the growth dynamics is influenced by bacterial interaction which in turn is largely 
dependent on the initial cell number of P. aeruginosa, but independent of the ratio of their initial 
cell numbers.  This behavior is different from what I observed for the co-cultures of P. 
aeruginosa and E. coli.   
 
Figure 4.8.  On-chip real-time monitoring of cell numbers of P. aeruginosa  (P) and K. 
pneumoniae (K) in the absence of antibiotics for different initial conditions (absolute and relative 
initial cell numbers of each).  Cell growth and death for (A) P. aeruginosa and (B) K. 
pneumoniae were monitored by counting cells in each well, every 30 minutes, over a period of 
16 h.  Each data point represents the mean of the measurements from three experiments, and 
error bars represent the standard error of the mean and are depicted for every third data point 
for clarity.  
The co-culture studies indicate significant differences in the growth dynamics of bacteria and 
these growth dynamics are further dependent upon on bacteria’s absolute and relative initial cell 
numbers in their polymicrobial cultures.  Using microfluidics and TLFM, I are able to resolve 
growth dynamics at different time intervals ranging from growth of cells followed by growth 
stasis or cell lysis, which could be misinterpreted as solely growth by conventional methods that 
are typically end point assays.  
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4.3.4 Antibiotic tolerance in polymicrobial cultures for P. aeruginosa 
Since P. aeruginosa is one of the primary pathogens found in many polymicrobial 
infections of humans [4], I performed AST against P. aeruginosa in co-cultures with E. coli and 
with K. pneumoniae, as well as with all three pathogens present (Table 4.3).  In each experiment, 
the total initial cell number was set at ~100-300 cells, which corresponds to a cell density of ~108 
cells/mL, similar to values published in literature for antibiotic susceptibility testing[58].  In 
these polymicrobial experiments equal cell numbers of each bacterium were mixed to get to an 
initial number of cells of 100-300.  I chose to start all the experiments at roughly similar number 
of total cells to avoid inoculum effects that can lead to increases in the observed MICs of 
antibiotics against bacteria, if more are present at the onset[68].  In addition, since inoculum 
effects do not generally occur with aminoglycosides such as tobramycin and amikacin against 
Pseudomonas species, the increases in the MICs described against P. aeruginosa later in this 
section cannot be attributed to slight changes in total initial cell numbers[69].   
I used two commonly used antibiotics (tobramycin and amikacin) against polymicrobial 
infections involving P. aeruginosa and observed that the MIC of P. aeruginosa in co-cultures 
increases 4- to 16-fold compared to isolates (Table 4.3).  In addition, supra-lethal antibiotic 
concentrations (as high as 256 µg/mL) failed to cause cell death of all three bacteria in co-
culture.  Hence, although changes in MIC values for E. coli and K. pneumoniae in isolate vs. 
mixed cultures are small (they decrease by a factor of 2 in some cases), the antibiotic tolerance of 
both the bacteria in co-cultures increased as evident by the inability of high concentrations of the 
antibiotics (256-512 µg/mL) to kill the bacterial cells.  Furthermore, the observed increase in the 
antibiotic resistance of P. aeruginosa in co-cultures corroborates well with literature [30, 44]. 
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Table 4.3.  MIC of amikacin and tobramycin obtained on-chip in different mixed cultures   
 MIC of Amikacin 
[µg mL-1] 
MIC of Tobramycin 
[µg mL-1] 
Monomicrobial conditions   
E. coli 4 4 
K. pneumoniae 8-16 4-8 
P. aeruginosa 4 2 
Polymicrobial conditions 
      E. coli + P. aeruginosa 
  
E. coli 4-8 4 
P. aeruginosa 8-16 8-16 
      K. pneumoniae + P. aeruginosa   
K. pneumoniae 4-8 8 
P. aeruginosa 8-16 8-16 
     E. coli + K. pneumoniae + P. aeruginosa   
P. aeruginosa 16 16-32 
 
Three mechanisms are known to potentially cause the observed increase in antibacterial 
resistance in co-cultures:  (1) the drug is prevented from interacting with the target due to 
inactivity of antibiotic targets;  (2) efflux of the antibiotic from the bacterial cells before they 
reach their target site of attack; and (3) direct destruction or modification of the antibiotic 
molecule[70].  The antibiotic resistance mediated by the first mechanism can occur in scenarios 
such as differences in the metabolic activities of bacteria in co-cultures which in turn can lead to 
competition for the available nutrients.  Bacteria sensing limited nutrients initiates a mechanism 
known as stringent response, which leads to growth arrest and consequently inactivity of the 
antibiotic targets (e.g., binding elements such as ribosomal RNA), and thus an increased 
antibiotic tolerance[71].  
With respect to the second mechanism, interspecies communication in bacteria is known 
to change gene expression patterns, which may cause efflux of antibiotic molecules out of the 
cell, leading to increased antibiotic resistance.  Indeed efflux pump genes in P. aeruginosa are 
known to be up-regulated in co-culture[72].  
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The third mechanism, the destruction or modification of the antibiotic molecule, may be 
different in mono- vs. co-cultures due to differences in production of molecules that may modify 
the antibiotic molecule.  Induction of novel metabolites being produced as a result of bacterial 
interactions is in fact an exciting area of study as the specifics of chemistry involved have yet to 
be fully unraveled[30].  However, already known metabolites that are specific to certain 
pathogens can be monitored.  For example, in the case of P. aeruginosa, the increased 
production of pyocyanin observed in co-cultures with gram positive bacteria (such as S. aureus) 
is often associated with increased virulence[30, 73], whereas a decreased amount of pyocyanin is 
produced in the presence of bacteria such as E. coli ZK126[60].   Furthermore, in co-cultures of 
E. coli and P. aeruginosa, increased production of another metabolite, indole, aids in survival of 
E. coli[60].  
In the following sections, the objective is to test hypotheses driven by first and third 
mechanism mentioned above, with the goal to explain apparent increases in antibiotic tolerance 
that I observe in the polymicrobial experiments.  I did not test the second mechanism since it 
would require extensive gene expression studies, and the screening of specific genes involved in 
this mechanism is beyond the scope of this study.  
4.3.5 Antibiotic tolerance in nutrient deficit medium  
Bacteria in co-cultures have to compete for resources and often inherently differ in their 
metabolic rates.  Hence, after a certain period of time, the bacteria may encounter a limit in the 
amount of remaining available nutrients.  In literature, bacteria have been shown to become 
highly tolerant to antibiotics when nutrients are limited[71], which can be problematic, because 
antibiotics are effective only on actively growing cells[74].  In other words, nutrient limitation 
leads to growth arrest or slow growth, rendering the antibiotics ineffective even at supra-lethal 
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concentrations.  I observed an increase in doubling time of P. aeruginosa in mixed culture 
experiments, a clear indication of slower growth.  One of the reasons for this slower growth is 
the competition for limited resources in presence of other bacteria.  Hence, the reduced growth of 
P. aeruginosa indeed may result from limited resources, which leads to activation of stringent 
response [71].   The resulting increased antibiotic tolerance is evident from the observed increase 
in MIC values against P. aeruginosa in polymicrobial cultures evaluated on-chip, as well as from 
failure to kill the bacterial cells even at high concentrations (> 256 µg/mL).  To confirm this 
hypothesis, I compared the MIC values against P. aeruginosa observed in the polymicrobial on-
chip experiments to the MIC values against P. aeruginosa observed in monomicrobial cultures in 
nutrient-rich and nutrient-poor media (Table 4.4).  I observed increases by factors of 16 to 32 in 
the MIC of the antibiotics amikacin and tobramycin against P. aeruginosa in nutrient-poor 
medium, which validates the hypothesis of the first mechanism.  Similar results were observed 
for K. pneumoniae and E. coli in nutrient-poor medium.  Hence, activation of stringent response 
due to competition of resources in polymicrobial cultures is a possible reason for the observed 
increase in antibiotic resistance.  
Table 4.4. Minimum Inhibitory Concentration (MIC) of P. aeruginosa in poor (M-9) medium 
 Bulk MIC [µg mL-1] On chip MIC [µg mL-1] 
Amikacin 16 16 
Tobramycin 16-32 64 
 
4.3.6 Effect of pyocyanin on susceptibility of P. aeruginosa 
Next, I tested whether virulence in co-cultures due to pyocyanin production has a 
correlation with increased antibiotic resistance (mechanism three, see above).  Specifically, I 
hypothesized that an increased antibiotic tolerance of P. aeruginosa could be due to increased 
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production of pyocyanin, which is the major virulent factor produced by P. aeruginosa and acts 
as a signaling factor in quorum sensing of the pathogen to protect itself from other surrounding 
species[4].  When quantifying the concentrations of pyocyanin in monomicrobial and 
polymicrobial cultures, I observed a significant decrease in its production in case of co-cultures 
of P. aeruginosa & E. coli, P. aeruginosa & K. pneumoniae, and in a co-culture of all three 
bacteria compared to pyocyanin production in monomicrobial cultures of P. aeruginosa (Table 
4.5).  These results demonstrate that lower virulence (reduction in production of pyocyanin) does 
not imply a decrease or an increase in the antibiotic tolerance.  Since the production of 
pyocyanin is suppressed in co-cultures, it appears that change in production of pyocyanin is not 
responsible for the resulting increases in antibiotic tolerance, as the decreased production should 
have led to decreased MIC values, which is contrary to my observations.   
Table 4.5. Effect of mixed population on production of pyocyanin by P. aeruginosa 
Initial conditions [cells mL-1] 
Pyocyanin concentration [µg mL-1] P. aeruginosa E. coli K. pneumoniae 
P. aeruginosa  
35x106 - - 25.5 ± 6.0 
P. aeruginosa + E. coli  
35x106 125x106 - 3.5 ± 4.7 
35x106 60x106 - 2.3 ± 1.5 
35x106 30x106 - 3.2 ± 1.5 
P. aeruginosa + K. pneumoniae  
35x106 - 310x106 11.0 ± 4.8 
35x106 - 160x106 15.6 ± 3.6 
35x106 - 80x106 18.3 ± 4.4 
 
4.3.7 Effect of indole on the susceptibility of P. aeruginosa  
As the production of indole is known to aid in the survival and growth of E. coli in co-
cultures by inhibiting quorum sensing in P. aeruginosa [60], I explored this effect on the 
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susceptibility of P. aeruginosa.  To simulate the effect of increased indole production in co-
cultures, I determined the MIC of tobramycin and amikacin against monomicrobial cultures of P. 
aeruginosa in the presence of varying concentrations of indole (500 µm to 5 mM) (Table 4.6).  
The experiments showed that the presence of indole at physiologically relevant concentrations 
(500 µm to 1 mM) had negligible effect on the MIC values against P. aeruginosa and 
concentrations >= 5 mM of indole were toxic to both P. aeruginosa and E. coli[60].  
Furthermore, the production of pyocyanin decreased as expected based on the color of the 
overnight culture.  These observations suggest that, although indole suppresses the production of 
pyocyanin in P. aeruginosa, the presence of indole by itself is not necessarily responsible for the 
higher antibiotic tolerance observed in P. aeruginosa.   
Table 4.6. Minimum Inhibitory Concentration (MIC) of P. aeruginosa with indole concentration ranging 
from 500 µM-1 mM 
 Bulk MIC [µg mL-1] On chip MIC [µg mL-1] 
Amikacin 2-4 2-4 
Tobramycin 2 2 
 
4.4 Conclusions 
Here, I reported a multiplexed microfluidic platform for quantification of interactions 
between P. aeruginosa, E. coli, and K. pneumoniae in the presence and absence of antibiotics.  
This approach allows for the study of species-specific antibiotic susceptibility information and 
real-time monitoring of bacterial interaction, a seemingly neglected aspect in studying 
polymicrobial infections.  Furthermore, these types of experiments are challenging to perform 
using conventional techniques.  The current practice often involves extrapolating monomicrobial 
AST results to determine treatment of polymicrobial infections.  In contrast, the approach 
reported here offers the potential to prescribe an appropriate antibiotic dosing regimen in a 
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timely fashion based on polymicrobial AST results.  In addition, the technique presents an 
opportunity to study dynamic bacterial interactions for extended periods of time.  Notably, the 
existing conventional methods are standardized only for monomicrobial susceptibility and 
possess several limitations including the use of large sample volumes, time consuming steps, low 
sensitivity, and inability to provide bacterial species specific susceptibility information.   
The results demonstrate that the growth dynamics of bacteria in polymicrobial cultures 
depend on bacterial interactions, the starting cell numbers, and the ratio of starting cell numbers.  
The antibiotic tolerance of P. aeruginosa increases in mixed populations significantly, 
highlighting the need to standardize polymicrobial AST.  Since polymicrobial interactions are 
widely dependent upon the type and the number of bacteria, technologies to study these 
interactions need to be developed for better clinical treatment of polymicrobial infections.    
In summary, the microfluidic platform presented not only enables fundamental 
investigations correlations between bacterial interactions and antibiotic tolerance, but also has 
the potential to serve as a clinical diagnostic platform for determining AST in polymicrobial 
infections.  The microfluidic approach reported here relies on genetically modified bacteria to 
ensure compatibility with TLFM analysis, which is not appropriate to analyze clinical samples.  
In chapter 6, I have tried to address this drawback by using optimized optical dyes for long-term 
monitoring of wild-type bacterial growth dynamics.   
Finally, the ability of the platform to perform long-term polymicrobial cell studies in 
multiplexed fashion may also have significant potential in the field of microbiology, for example 
to study responses of mixed bacterial populations to external stresses. 
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Chapter 5 
Pharmacodynamic/Pharmacokinetics modeling using microfluidics 
5.1 Introduction 
Three goals must be met for an optimal antibiotic treatment: (1) maximized rate of 
clearance of an infection, (2) minimized toxicity and side effects, and (3) minimized likelihood 
of resistance ascending and being transmitted during the course of therapy [1].  To achieve the 
above three goals, the clinician is required to determine optimal drug or drug combination 
effective against the pathogen, optimal dose and dosing regimen (frequency of administration), 
and an optimal term of treatment.  As described in previous section, MIC is the most commonly 
used parameter in AST to describe the efficacy of an antibiotic against a specific bacterial strain 
and is often reported in a “range” format where the acceptable range can vary by two-folds.  
However, MIC is not an optimal parameter since it reflects only a range estimate of the effect of 
antibiotic on the bacteria and does not take the time course of the effect into account [2].  In fact, 
the use of MIC alone to determine antibiotic treatment regimens has led to prescription of sub-
lethal concentrations of antibiotics for several years [3], leading to increased antibiotic 
resistance. Consequently, determination of optimal antibiotic regimen based on superior metrics 
is important to address the issue of antibiotic resistance [4]. Hence, studies on 
pharmacodynamics are increasing in the hopes of establishing new breakpoints to clear bacterial 
infection effectively, thereby minimize the spread of antibiotic resistance. 
Pharmacodynamics (PD) analysis of time kill curves can be used to precisely determine 
the MIC (instead of a range) in conjunction with other PD parameters, which provides time-
dependent information on the effect of antibiotics on bacteria [3, 5-7] and an understanding of 
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the PD characteristics can provide insights into the optimal regimen for antibiotics [8].  For 
instance, for concentration-dependent antibiotics, a high once-daily dose is the best way to 
eradicate pathogens, while for concentration- independent drugs, the goal is to maximize the 
duration of antibiotic exposure above MIC at the site of infection [3].  Due to differences in the 
PD properties, antibiotics with same MIC can behave differently.  The PD parameters can further 
be used to perform pharmacokinetic (PK) modeling for predicting in vivo antibiotic dosing 
regimen.  Although, the right choice of antibiotic (determined by MIC) is important in treating 
bacterial infections, the optimum dose and dosing interval (determined by PK/PD analysis) is 
critical for achieving optimal clinical responses to prevent the emergence of resistant pathogens. 
Several models have been explored for PD analysis of antibiotics [2-7, 9-11], where the 
advantages of PD analysis to better predict clinical outcomes have been demonstrated.  In a 
typical PD analysis, first, in-vitro time-kill curves (number of bacteria as a function of time) for 
varying antibiotic concentrations are acquired.  Then, models such as the Zhi modeling methods 
are used to fit the data and determine PD parameters such as (1) the ratio of Cmax to MIC 
(Cmax:MIC), (2) the ratio of the drug’s AUC to MIC (AUC:MIC), and (3) the time the drug 
concentration exceeds the MIC (T>MIC), where Cmax is the drug’s peak concentration and AUC 
is area under the plasma concentration-time curve [7].  These parameters could then be used to 
predict the optimal antibiotic dosing regimen therapy.  
Microfluidics provides several advantages for such PD analysis.  First, microfluidics 
enables automated, rapid, generation of precise time-kill curves (cell number vs. time) without 
the need to manually collect samples every 30 minutes to estimate the change in bacterial counts, 
and the high sensitivity enables knowing precise quantitative information about cell numbers at 
different time points.  Hence, this feature also increases the temporal resolution of the technique 
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allowing us to more effectively discern the dynamics of antibiotic-bacteria interactions.  Second, 
microfluidics provides capabilities for high-throughput, multiplexed screening allowing us to test 
a large number of antibiotic concentrations and/or combinations.  This capability further enables 
acquisition of more data compared to conventional methods, which will lead to more accurate 
data-fitting and consequently more accurate prediction of PD parameters.  Third, the ability to 
perform rapid, high-throughput analysis with low sample volumes will enable determination of 
patient-specific PD parameters.  This specificity is important as significant variation exists 
between response of different individuals to the same antibiotic regimen, which precludes the 
universal application of empirical results [6].  Motivated by these advantages, researchers have 
explored the use of microfluidic platforms to better predict the in vivo effect of several drugs 
including antibiotics [12-15].  Hence, microfluidics has the potential to significantly impact the 
field of AST by enabling faster and more accurate PD analysis of the effect of antibiotics on 
bacteria. 
The antibiotic concentration in bloodstream decreases exponentially after injection due to 
the excretion mechanisms in the human body.  Hence, in cases of bacterial infection, several 
antibiotic doses over a time period are needed to keep the drug concentration above MIC to 
effectively inhibit bacterial growth.  While pharmacodynamics modeling provides precise 
effective antibiotic concentration, it cannot predict the change of antibiotic concentration over 
time in vivo resulting in a transient growth of bacteria.  Pharmacokinetics can effectively address 
the issue by describing the relationship between antibiotic concentration and bacterial 
growth/death rate as a function of time.  The values of MIC, growth rate constant, maximum 
killing rate, and Hill coefficient derived from pharmacodynamics modeling are generally 
employed to construct the pharmacokinetics model [8]. We utilized the precise parameters 
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obtained from the microfluidic platform to construct proof-of-concept pharmacokinetic models 
in monomicrobial cultures of P. aeruginosa.  The modeling concept can further be extended to 
polymicrobial susceptibility results for treating polymicrobial infections.  In this chapter, I will 
discuss the pharmacokinetics modeling procedure for amikacin and tobramycin against P. 
aeruginosa cultures. 
5.2 Materials and Methods 
Proof-of-concept PD model was developed to determine precise values of MIC.  Fig. 5.1 
describes the general flow of how an antibiotic dosing regimen can be predicted from PK/PD 
modeling. 
 
Figure 5.1 lllustration of steps leading to prediction of cell numbers in vivo using high-
throughput microfluidic platform with a prescribed antibiotic dosing regimen.  The main steps 
include (1) pre-experimental set-up such as fabrication of microfluidic platforms and sample 
(cell) preparation, (2) antibiotic susceptibility testing, entailing derivation of time-kill curves, (3) 
pharmacodynamic modeling to determine parameters in vitro, and (4) pharmacokinetic modeling 
to predict in vivo action of the antibiotics on bacterial cell numbers over time 
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5.2.1 Hills modeling 
Hill’s modeling was used to determine the precise MIC and the Hill coefficient values in 
monomicrobial and polymicrobial cultures since this type of modeling has been commonly used 
in pharmacodynamics [16].  In order to simplify the model, the antibiotics concentration is 
assumed to be constant inside microfluidic chambers over the experiment duration (no 
absorption into PDMS) [17].  Monomicrobial growth model in presence of an antibiotic can be 
described by the following equation [8]: 
     ( )t
dB G K B
dt
= − ⋅ ,      (5.1) 
where B is the cell number in a microfluidic chamber, G is the growth rate constant in 
exponential phase in absence of the antibiotic [h-1], and Kt is the bacterial killing rate in presence 
of the antibiotic at time t [h-1].  The bacterial killing rate constant, Kt, can be expressed by the 
sigmoid Emax model [18]: 
     max
50
t
t
t
K CK
C C
γ
γ γ
⋅
=
+
,      (5.2) 
where Ct [µg mL-1] is the antibiotic concentration at time t, Kmax [h-1] is the maximum bacterial 
killing rate for an antibiotic, C50 [µg mL-1] is the concentration corresponding to the time when 
the maximum bacterial killing rate is half, and γ is the Hill coefficient.   
At MIC, the net growth rate of bacteria is zero, hence, the concentration, Ct, is equal to 
MIC.  This implies that bacterial killing rate constant, Kt, is equal to the growth rate constant, G, 
at MIC which is given by the following expression: 
107 
 
    max
50
K MICG
C MIC
γ
γ γ
⋅
=
+
.      (5.3) 
Hence,  
     max50
K GC MIC
G
γ −= ⋅ .     (5.4) 
Substituting the value of C50 (Equation 5.4) in to Equation 5.3 and rearranging, we obtain the 
following equation:  
    
( )
max
max
( )ln ln ln( )t t
t
K K G C MIC
G K K
γγ
 ⋅ −
= − 
− 
    (5.5) 
Using the above expression, γ can be calculated from the slope of the equation, and the MIC 
from the intercept [-ln(MICγ)].   
The antibiotic concentration in bloodstream decreases exponentially after injection due to 
the excretion mechanisms in the human body.  Hence, in cases of bacterial infection, several 
antibiotic doses over a time period are needed to keep the drug concentration above MIC to 
effectively inhibit bacterial growth.  While pharmacodynamics modeling provides precise 
effective antibiotic concentration, it cannot predict the change of antibiotic concentration over 
time in vivo resulting in a transient growth of bacteria.  Pharmacokinetics can effectively address 
the issue by describing the relationship between antibiotic concentration and bacterial 
growth/death rate as a function of time.  The values of MIC, growth rate constant, maximum 
killing rate, and Hill coefficient derived from pharmacodynamics modeling are generally 
employed to construct the pharmacokinetics model [8]. We utilized the precise parameters 
obtained from the microfluidic platform to construct proof-of-concept pharmacokinetic models 
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in monomicrobial cultures of P. aeruginosa.  The modeling concept can further be extended to 
polymicrobial susceptibility results for treating polymicrobial infections.  Here, I discuss the 
pharmacokinetics modeling procedure for amikacin and tobramycin against P. aeruginosa 
cultures. 
5.3 Results and Discussion 
5.3.1 MIC determination from hills modeling 
The following sections will describe an example for computing Hill coefficient and MIC in (1) 
monomicrobial and (2) polymicrobial cultures. 
Monomicrobial cultures: MIC determination of E. coli against Amikacin 
 Growth curves of the bacteria in the absence of antibiotics are used to determine G using 
Equation 5.1 as described below: 
     0ln( ) ln( )B G t B= ⋅ +     (5.6) 
From Fig. 5.2, G is the slope of the straight line section of the plot and is 1.0841 h-1, 
corresponding to a doubling time of ~ 38 minutes. 
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Figure 5.2.  Ln(Cell number) or ln(B) vs. time (t) to determine G from Equation 5.6 for the 
growth curve of E. coli.   
In the presence of antibiotics, the growth rate is expected to be lower than in the absence 
of antibiotics.  Hence, the net growth rate in presence of antibiotics can be determined by 
subtracting the growth rate constant, G, from the antibiotic killing rate constant, Kt.  Hence, the 
growth rate in Equation 5.6 can be modified to give the net growth (G-Kt) as shown in 
Equation 5.7. 
     ( ) 0ln ( ) ln( )tB G K t B= − ⋅ + .    (5.7) 
Fig. 5.3 represents the time-kill curves for E. coli for different concentration of amikacin, which 
can be described using Equation 5.7.  The slope of the straight line portions of these plots will 
provide the net growth rate, G-Kt, which in turn can be computed to calculate Kt, knowing the 
value of G from growth curves.  These values of G and Kt (and hence Kmax) can be used to plot 
Equation 5.5 (Fig. 5.4), which can then be used to compute γ and MIC.  The Hill coefficient, γ, 
is determined to be 2.02 ± 0.16, and MIC is calculated as 4.2 ± 0.6 µg mL-1.  The net growth 
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rate (G-Kt) can also be plotted as a function of antibiotic concentration (Fig. 5.5) to obtain the 
Hill curve, which is a sigmoid as predicted in literature (Equation 5.2).  
 
Figure 5.3. ln(cell number) or ln(B) vs. time (t) or time-kill curves (Equation 5.7) for E. coli at 
different antibiotic concentrations of amikacin 
 
 
Figure 5.4. Determination of Hill coefficient (γ) and MIC using Equation 5.5 [8] 
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Figure 5.5. Net growth rate of E. coli as a function of amikacin concentration, i.e., the Hill 
model.   
Polymicrobial AST: MIC determination of E. coli and P. aeruginosa against Amikacin 
Similar to MIC determination in monomicrobial cultures, I calculate the species-specific 
growth rate constants for E. coli and P. aeruginosa in polymicrobial cultures (Fig. 5.6) since the 
effect of bacterial interaction on G is already accounted in the observed experimental data.  
Species-specific net growth rate for the two bacteria in the presence of antibiotics can be 
determined from slopes similar to monomicrobial cultures (Fig. 5.7-5.9).  For E. coli, the Hill 
coefficient is determined to be 1.06 ± 0.09, and MIC is determined to be 5.1 ± 1.0 µg mL-1.  For 
P. aeruginosa, the Hill coefficient is determined to be 1.32 ± 0.06, and MIC is determined to be 
7.8 ± 0.9 µg mL-1.   
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Figure 5.6. Ln(Cell number) or ln(B) vs. time (t) to determine G from Equation 5.6 for the 
growth curves of E. coli. and P. aeruginosa in co-cultures   
 
Figure 5.7.  ln(cell number) or ln(B) vs. time (t) or time-kill curves (Equation 5.7) for E. coli and 
P. aeruginosa in co-cultures at different antibiotic concentrations of amikacin 
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Figure 5.8. Determination of Hill coefficient (γ) and MIC using Equation 5.5 [8] for amikacin 
against E. coli and P. aeruginosa polymicrobial cultures 
 
Figure 5.9. Net growth rate of E. coli and P. aeruginosa as a function of Amikacin 
concentration, i.e., the Hill curves. 
 
MIC determination via conventional method, specifically microbroth dilution method, 
can provide a reliable range of MIC as discussed previously.  However, the method still lacks 
precision as the MIC is reported in a range of concentration between wells.  By utilizing Hill’s 
equation, a precise MIC was calculated (within the range of MIC reported in literature) (Table 1 
and Table 2).  Hill’s equation also provides a Hill coefficient, which describes sensitivity of the 
changes in killing rates of bacteria to the changes in antibiotic concentration.  Comparing the two 
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antibiotics with the same MIC, the antibiotic with higher Hill coefficient is considered to be 
more effective, as the killing rate will be higher at the same concentration above MIC [8].  
The MICs indicate that P. aeruginosa is more resistant to Amikacin than E. coli in P. 
aeruginosa-E. coli co-culture.  In addition, the higher Hill coefficient in P. aeruginosa also 
signifies that increasing Amikacin concentration will increase the killing rate, Kt, of P. 
aeruginosa more than increasing the killing rate of E. coli.  Finally, compared to monomicrobial 
antibiotic screening, E. coli is more resistant to amikacin, as evident from the increased MIC and 
the Hill coefficient of E. coli amikacin in co-culture is also lower than microbial culture implying 
that increasing amikacin concentration in co-culture will increase the killing rate less effectively 
than in E. coli monomicrobial culture (Table 5.1 and Table 5.2)    
Table 5.1: Determination of precise MIC and Hill coefficient using pharmacodynamics 
modeling in monomicrobial cultures 
 Amikacin Tobramycin 
MIC  γ MIC γ 
E. coli 4.2 ± 0.6 2.0 ± 0.2 4.0 ± 0.7 2.5 ± 0.2 
K. pneumoniae 10.4 ± 2.5 1.3 ± 0.1 5.8 ± 1.5 2.0 ± 0.2 
P. aeruginosa 6.4 ± 2.0  1.6 ± 0.2  3.1 ± 0.4 0.9 ± 0.1 
 
 
Table 5.2: Determination of precise MIC and Hill coefficient using pharmacodynamics 
modeling in polymicrobial cultures 
 Amikacin Tobramycin 
MIC γ MIC γ 
E. coli + P. aeruginosa     
E. coli 5.1 ± 0.9 1.1 ± 0.1 4.0 ± 0.7 0.3 ± 0.1 
P. aeruginosa 7.8 ± 0.9 1.3 ± 0.1 11.5 ± 2.9 1.2 ± 0.1 
K. pneumoniae + P. aeruginosa     
K. pneumoniae 10.2 ± 2.8 3.4 ± 0.4 10.7 ± 3.4 2.7 ± 0.2 
P. aeruginosa 8.1 ± 1.6 1.7 ± 0.1 9.4 ± 2.1 3.2 ± 0.2 
E. coli + K. pneumoniae + P. aeruginosa     
P. aeruginosa 20.5 ± 2.4 2.8 ± 0.1 14.3 ± 3.7 2.2 ± 0.2 
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5.3.2 Proof-of-concept pharmacokinetics modeling 
From pharmacodynamics modeling discussed previously and antibiotic information from 
literature [19, 20], I obtain the PD parameters for amikacin and tobramycin against P. 
aeruginosa listed in Table 5.3.  
Table 5.3. Parameters used in pharmacokinetic modeling 
 P. aeruginosa  + Amikacin P. aeruginosa + Tobramycin 
Growth rate constant, G 0.83 hour-1 0.83 hour-1 
MIC 5.91 µg mL-1 3.06 µg mL-1 
Maximum killing rate, Kmax  1.01 hour-1 0.98 hour-1 
Hill coefficient, γ 1.57 0.95 
Initial concentration, C0 25.0 µg mL-1 10.0 µg mL-1 
Dosing regimen 8.0 hour 8.0 hour 
Drug half-life, t1/2 3.01 hour 3.03 hour 
It was assumed that amikacin is usually injected every 8 hours such that the peak 
concentration in blood serum is approximately 25 µg mL-1 (roughly 4 times MIC) as 
recommended in literature since higher concentrations can be toxic to humans [21, 22], although 
the injection amount usually depends on the size of the person.  Similarly, tobramycin is injected 
every 8 hours to give a peak concentration of approximately 10 µg mL-1 (roughly 3 times MIC).  
The half-life of amikacin was determined from the predicted blood serum concentration to be 
3.01 h [23].  Similarly, the half-life of tobramycin was determined to be 3.03 hours [20].  The 
initial cell numbers in the microfluidic chambers were 200 to 300, which approximately equals 
to ~ 108 cells/mL.  The concentration of antibiotic, Ct, over time is given by [24]: 
1/2
ln(0.5)
0
t
t
t C eC ⋅= ,     (5.8) 
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where C0 is the initial antibiotic concentration [µg mL-1], t1/2 is the antibiotic half-life in human 
body [hour], and t is the time elapsed [hour].  Equation 5.8 is modified to describe Ct over time, 
where additional doses are administered after every 8 hours as shown in Fig. 5.10.  
( )
1/2
ln(0.5) 8
0
0
n t i
t
t
i
C C e
−
=
= ⋅∑ ; (t-8i) ≥ 0   (5.9) 
 
Figure 5.10. Pharmacokinetic modeling to predict the antibiotic concentrations of amikacin and 
tobramycin in the blood stream over the course of 24 hours. 
The antibiotic concentration at the 8th hour is expected to be higher than the initial 
concentration due to the residual antibiotic prior to the second dose, since the antibiotic does not 
completely get eliminated after 8 hours.  At the end of 8 hour-intervals, both the amikacin and 
tobramycin concentrations fall below the MIC.  Then, we use Equation 5.9, Equation 5.5 and 
Equation 5.7, and the value from Table 4 to predict the net growth rate over 24 hours (Fig. 
5.11).  
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Figure 5.11. Pharmacokinetic modeling to predict P. aeruginosa net growth rate in blood stream 
over the course of 24 hours. 
From Fig. 5.11, it was observe that the second and third dose of antibiotic yields lower 
net growth rate at the end of 8 hours period which is due to antibiotic accumulation.  Since the 
tobramycin dose results in higher net growth rate in the first 8 hours than amikacin, it indicates 
lower drug efficacy than amikacin (even though MIC of tobramycin is lower than amikacin).  
However, at the end of 8 hours, the net growth rate caused by both tobramycin and amikacin are 
similar (~ 0.1 h-1).  In the case of amikacin, the larger Hill coefficient (1.57) of amikacin 
correlates with a sharp increase of the net growth rate in contrast to tobramycin, which suggests 
amikacin’s higher drug potency [25].  The smaller negative net growth rate caused by 
tobramycin also implies that tobramycin is less effective in inhibiting P. aeruginosa cell growth.  
The resulting net growth rate is then used to model the changes in cell numbers over 24 hours by 
integrating Equation 5.1 to derive the following equation:   
     ( dt)0
tG t KB B e ⋅ −∫=      (5.10) 
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Figure 5.12.  Predicted cell numbers of P. aeruginosa in vivo over the course of 24 hours. 
Fig. 5.12 shows the predicted cell number for P. aeruginosa in vivo over the course of 24 
hours.  The plot demonstrates interesting differences when amikacin and tobramycin are used in 
the treatment of P. aeruginosa infections.  Amikacin causes rapid decrease in cell numbers when 
amikacin concentration is above MIC, while a rapid increase in cell number occurs at 
concentration below MIC.  Since tobramycin concentration falls below MIC faster than 
amikacin, the treatment with tobramycin allows longer time for cell growth which results in 
higher cell number at the end of 8 hour.  Hence, PK modeling suggests that amikacin suppresses 
P. aeruginosa growth more effectively than tobramycin owing to lower final cell numbers at t = 
24 h (even though MIC of tobramycin is lower than amikacin). 
5.4 Conclusions 
In this chapter, I discussed how high throughput microfluidic platforms can address the 
limitation of predicting in vivo AST results.  Specifically, I discuss the utility of microfluidic 
platforms to perform pharmacokinetic/ pharmacodynamic (PK/PD) modeling from precise time-
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kill data obtained from automated AST methods (superior than conventional AST methods) to 
determine optimal antibiotic dosing regimen for treating monomicrobial and polymicrobial 
bacterial infections.  Furthermore, PK/PD modeling yields more precise prediction of a precise 
MIC for more accurate prediction of in vivo antibiotic action as opposed a range of MIC (the 
current metric for AST).  Hence, microfluidic platforms with the capability for PK/PD modeling 
have a significant potential to provide a precise antibiotic dosing regimen, thereby minimizing 
antibiotic resistance.  
The discussed microfluidic platforms in this chapter for AST have primarily been used as 
a research tool to study the interaction of antibiotics and monomicrobial/polymicrobial bacteria.  
Further studies are required to extend the proof-of-concept PK/PD analysis to study at the 
clinical level.  The current techniques for AST have been used for decades to treat microbial 
infections, and introduction of a new technology would require collaboration between scientists 
and clinicians to specifically perform comparative studies on AST and PK/PD modeling using 
conventional techniques and microfluidic platforms.  These types of collaborations will help in 
overcoming resistance faced by the clinicians in the healthcare for the adoption of new 
technologies for prescription of antibiotic dosing regimen while utilizing lower sample volumes 
and delivering more accurate outcomes.  
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Chapter 6 
Antibiotic susceptibility testing of non-genetically modified bacteria 
6.1 Introduction 
Since genetically modified bacteria were utilized in all the experiments of AST, direct 
comparison of the results at the clinical level is challenging.  This key limitation described limits 
the applicability of the platform with real clinical samples.  In this chapter, I will discuss ways to 
address this limitation with the objective of utilization of the clinical samples with the 
microfluidic platform.  
Since some optical dyes are known to induce fluorescence in bacteria [1], I approached to 
circumvent this issue by utilizing optical dyes.  The goal for this study was to search and 
optimize a dye that fluoresces in live bacterial cells while they proliferate over an extended 
period (12 hours or more).  Long term experiments using this method are challenging since the 
dye amount per cell is halved in each cell division cycle.  This phenomenon makes the 
fluorescence intensity to drop exponentially and the approach particularly affects the cells with 
short doubling times.  Hence, an ideal optical dye will have several desirable traits including 
applicability in long term cell proliferation experiments, bright enough for counting bacterial 
cells over time, stable, and would have low toxicity to the cells or would not negatively affect the 
bacterial cells physiology.  The subsequent paragraphs will discuss several dyes that were tried 
with the AST techniques using the microfluidic platform.  
I first used the dye Alamar Blue that contains an active ingredient of resazurin, which is 
non-toxic, permeable, blue in color, and does not fluoresce.  Alamar blue is widely used in broth 
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dilution assays for cell viability in AST due to its colorimetric indicator and the dye does not 
affect cell physiology and growth [2-4].  When resazurin is reduced to resorufin, it induces a 
very bright red non-toxic fluorescence inside cells via cell metabolism (Fig. 6.1).  Here, the 
amount of resorufin produced is proportional to the number of living cells.   
 
Fig. 6.1. AlamarBlue indicator mechanism[5] 
 
Next, Cell TrackerTM Green BODIPY was tried that contains fluorescent probing that can 
pass freely through the cell membranes and get converted to impermeable reaction products [6, 
7].  Theoretically, the dye is transferred to several generations and not to adjacent population 
keeping the bacterial cells viable for up to 24 hours.   
STYO BC was also tried for AST because this dye is a mixture of several BC dyes 
specifically for bacterial staining [8-10].  The dye differs from Alamar Blue and BODIPY 
because it does not react with intracellular enzymes of the cells and does not remain the 
cytoplasm of the cells.  Specifically, the non-fluorescent dye binds to the nucleic acid and turns 
fluorescent upon entering the bacterial cells.  Hence, this dye is capable of staining both live and 
dead cells.   
Next, I tried Carboxyfluorescein Diacetate Succinimidyl Ester (CFDA-SE) since this 
particular due is one of the gold standard dyes used for live cell staining because of its stability 
and low toxicity[11-13].  This dye utilizes incorporates properties of AlamarBlue and BODIPY.  
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Specifically, initially the CFDA-SE is non-fluorescent and highly cell permeable.  However, 
upon entering the cell the dye is converted CFSE, which is fluorescent and has lower cell 
permeability.  The converted product (CFSE) binds to amine group within the cells and the 
combination is retained inside the cells for extended time periods.  The dye is considered a live 
staining dye since it can be digested only from intracellular esterase.  
CellVue was the last dye tried in the AST experiments.  This dye rapidly binds to the cell 
membrane and hence, has relatively low toxicity compared to previously described nucleic acid 
stains.  The bound dye molecules are stable unlike the CFDA-SE, and hence, eliminate the risk 
of dye leaking out of the cells.  However, the key limitation of dye concentration getting halved 
with each cell division exists.  
This chapter addresses several limitations of the genetically modified bacteria by utilizing 
optical dyes for its compatibility with TLFM.  Specifically five dyes are tested and optimized.  
Off the dyes tested, CellVue and CFDA-SE provide the most promising results for determination 
of MIC of antibiotics rapidly (2-4 hours) with non-genetically modified bacteria or “real 
bacteria”.  
6.2 Experimental 
6.2.1Alamar blue 
 Preparation of assay was straightforward using this dye.  After addition of the dye in the cell 
culture and after ~ 3 hour incubation time, the assay was ready for fluorescence reading.  
Specifically, cells at concentrations 1-5x107 CFU/mL were first added to the wells.  This was 
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followed by addition of 40 µL of 10x AlamarBlue to each well and absorption of light is 
measured at 570 nm over a time period of approximately 20 hours (Fig6. 2).  
 
Figure 6.2. AlamarBlue assay using a 96-well plate  
6.2.2 Cell trackerTM BODIPY 
The working concentration for the dye used was in the range 5-25 µM for fast dividing cells [6].  
The procedure to stain the cells is outlined in Fig. 6.3.  Briefly, the dye vial was first warmed up 
to room temperature and is dissolved in to DMSO to a final concentration of 10 mM.  Next, this 
stock diluted further to a working concentration of 0.5-25 µM in LB and the dye solution is 
warmed to a temperature of 37 °C.  Overnight cell culture of E. coli MG1655 was then collected, 
centrifuged and the supernatant was removed.  Dye solution was then added to the cells and the 
solution was incubated for 45 minutes as suggested in the dye protocol [6, 14].  The solution was 
again centrifuged and after removing the supernatant, an equal amount of LB was added, and this 
solution was incubated for 30 minutes.  These bacterial cells were then collected and flowed in 
the microfluidic device as discussed in previous chapters.  
126 
 
 
 
Figure 6.3. BODIPY staining process 
 
6.2.3 STYO BC green nucleic acid stain 
The staining procedure is outlined in Fig. 6.4.  Briefly, the dye is added to the overnight cell 
culture as above such that the final concentration of the dye is 40-50 µM.  The solution is 
vortexed and covered with aluminum foil to prevent exposure to light since the dye is extremely 
photosensitive.  These cells are then flowed in to the microfluidic device as discussed previously 
ensuring minimal exposure to light since the dye was known to photo bleach upon exposure to 
light.  
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Figure 6.4. SYTO BC staining process 
6.2.4 Carboxyfluorescein diacetate succinimidyl ester CFDA-SE 
E. coli cells were prepared as described previously.  The cell preparation steps are shown 
in Fig. 6.5.  Briefly, bacterial concentration ranging between 1-5x107 CFU/mL was washed with 
PBS/0.1 % BSA three times.  Next, 1 µL of 100 mM CFDA-SE is pipetted into the bacterial 
solution prepared in the previous step followed by rigorous vortex.  This bacteria-dye solution is 
incubated for 15 minutes followed by washing with LB and incubation of 30 minutes to ensure 
the dye molecules gets incorporated in to the bacterial cells.  This solution was washed again to 
remove unstable dye molecules that diffuse out and cause fluorescent background.  This solution 
can be stored overnight at 4ºC or flowed in to the microfluidic device immediately as discussed 
above.  
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Figure 6.5. CFDA-SE staining process 
6.2.5 CellVue (Jade) 
To stain E. coli cells using CellVue, first the cells were prepared such that the cell density was at 
2x107 CFU/mL.  Second, the cells were washed with PBS by centrifugation, and then PBS is 
removed.  1 mL of the diluent C (from the CellVue kit) was added to the cell pellet which was 
followed by addition of 4 µL of CellVue dye stock into 1 mL of diluent C and mixed without 
vortexing.  This solution was then incubated for 5 minutes and washed three times with LB until 
the cells were ready for AST experiment.  
6.3 Results and Discussion 
6.3.1 Alamar blue 
Alamar Blue was used first in bulk scale or using 96-well plates (for validation) (Fig. 6.6) and 
then on-chip.  I observed that, though AlamarBlue is an appropriate choice for absorbance 
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measurement, this dye did not work for the application on-chip.  The fluorescent resorufin was 
cell permeable, which leaks out and gave uniform fluorescence in chambers.  Due to this 
leakage, counting the cell numbers was not possible.  
 
Figure 6.6. Proof-of-principle platform validation using AlamarBlue in 96-well plates  
 
6.3.2 Cell trackerTM  BODIPY 
 Next, Cell TrackerTM Green BODIPY was tried since this dye is impermeable after 
formation of reaction products.  Here, a special mechanism is utilized to first transport dye into 
the cells. CellTracker BODIPY (8-Chloromethyl-4,4-Difluoro-1,3,5,7-Tetramethyl-4-Bora-
3a,4a-Diaza-S-Indacene) dye is cell permeable and upon entering the cells, it gets converted to 
cell-impermeant product using glutathione transferase.  Here too, each successive division of 
cells halves the fluorescence intensity compared to the previous generation.  However, since the 
dye can be digested only from intracellular enzymes, it makes BODIPY a live cell staining dye.  
Since the reaction products are cell impermeable, BODIPY dye can be retained within cell 
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membrane, which results in localized staining.  On one hand, BODIPY was successful in 
staining and counting the cells, and the stained cells are clearly visible under fluorescent 
microscope (Fig. 6.7).  On the other hand, only 30% of the cells were stained on-chip, even after 
several optimizations to the protocol.  
 
Figure 6.7. Proof-of-principle platform validation using Cell TrackerTM Green Bodipy 
(only a fraction of the cells get stained) 
6.3.3 STYO BC green nucleic acid stain  
Compared to BODIPY, although SYTO BC was able to stain up to 95-100% of cells and 
provided bright fluorescence initially, SYTO dyes photo-bleached rapidly.  In addition, I 
observed the SYTO dyes appeared to alter cell functions (due to changes in doubling times of 
bacteria) by binding to DNA and RNA of the cells[15].  Specifically, I observed that the cell 
growth rate is slowed down significantly due to apparent increases in doubling times (Fig. 6.7).  
Further, literature corroborates that DNA damage is not uncommon with these dyes because 
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excited products can react with DNA and cause mutations within the bacterial cells. Due to the 
above limitations, I did not try to further optimize this dye.  
 
Figure 6.8 Proof-of-principle platform validation using STYO BC on-chip (doubling times 
are drastically affected.  
6.3.4 Carboxyfluorescein diacetate succinimidyl ester CFDA-SE  
Even though the dye amount is halved with each division of cells from the previous time, 
this dye has been the most successful in my microfluidic AST.  I was able to determine precise 
MIC values in 2-4 hours using the dye for E. coli cells.  Fig. 6.9 shows MIC of ampicillin and 
tobramycin against E. coli cells using the dye.  It can be inferred that the MIC of ampicillin and 
tobramycin is ~ 2 µg/mL, which is comparable to the values found in literature and the 
conventional broth dilution methods [16]. 
 Since one of the key limitations of using this dye was the decrease in fluorescence after 
3-4 hours, I approached the limitations by mixing CFDA with medium prior to introduction in 
cells.  However, the dye cannot be mixed with medium containing amine because it gets 
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hydrolyzed, hence; LB was not a viable option.  In addition, CFSE gradually leaks out from the 
cells to the surrounding medium in the first 24 hours after cell lysis which makes the counting 
cell process tedious.  The issue of background fluorescence can be resolved by storing the 
stained cells in LB broth overnight to let majority of the unstable CFSE leak out overnight.  The 
cells are then washed and flowed the next day which provides with a much brighter fluorescence 
and low background.  Unfortunately, background increases with time but at a lower rate than 
previously.  Furthermore, I observed a fraction of cells turning non-motile after dye staining and 
consequently not responding to the antibiotic treatment, alluding that the dye was perhaps 
altering the cell physiology.  Another limitation of the dye is that the dye cannot be used to stain 
P. aeruginosa cells[12].  
 
Figure 6.9. Proof-of-principle platform validation using CFDA-SE on-chip using 
ampicillin and tobramycin against E. coli MG1655 cells.  
6.3.5 Cell Vue (Jade) 
As discussed previously, staining of the cells was successful with CellVue. The dye was the most 
effective at low concentrations (2 µM) (Fig. 6.10), after which the dye concentrations were 
perhaps toxic to the cells.  Higher concentrations of the dye led to lower cell viability but 
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brighter cells. With this dye as well, though MIC determination was possible, lowering of 
fluorescence after a few hours remained the key limitation that hindered long term AST studies 
for monomicrobial cultures.  
 
Figure 6.10 Proof-of-principle micrographs showing dye staining at three concentrations 
for the same cell density (MG1655 strain).  The dye staining is most effective at the 
lowest concentration.  
6.4 Conclusions 
In summary, CFDA-SE and CellVue were the most effective dyes for the staining of non-
genetically modified bacteria for AST.  I was able to determine the primary AST parameter 
(MIC); however, the one key physical limitation still remains is the loss of fluorescence over 
time.  This challenge further limits the ability of the technology to be used for long term studies. 
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Nevertheless, optical dyes mentioned here can be used in the determination of MICs of non-
genetically modified bacteria in a rapid and multiplexed format, an approach that is still far 
superior to conventional methods of AST (broth dilution and disc diffusion).  
In the future, several options exists for observing long term interaction of “real” bacteria 
and antibiotics including phase contrast microscopy where bacteria can be differentiated based 
on shapes and motility in polymicrobial infections.  In addition, more optical dyes can be tested 
and/designed where the key objective would be to ensure the fluorescence does not decrease over 
time such that long term antibiotic screening studies are possible.  
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Chapter 7 
Summary of accomplishments and future outlook 
7.1 Summary of accomplishments 
As much as 50% of the antibiotic prescriptions in the clinics are currently inaccurate [1], 
which is one of the primary reasons for the rise in antibiotic resistance [2-5].  Hence, 
development of new technologies for prescription of precise antibiotic dosing regimen is critical 
to address this issue.  Conventional technologies including broth dilution and disc diffusion are 
time consuming, require large sample volumes, have low detection sensitivity and low 
throughput, and are standardized for monomicrobial infections only [6-13].  In this respect, 
microfluidics is an attractive technology that can address the issues of these conventional 
methods for AST.  Microfluidic chips/reactors/platforms comprise a simple to complex network 
of channels, chambers, valves, pumps etc. and enable precise spatio-temporal control over the 
flow of reagents.  As a result, microfluidics has been explored for a wide range of applications, 
from chemical synthesis to fundamental biological studies [11-29].  With respect to performing 
AST, microfluidics offers several advantages compared to conventional techniques, including 
assay with low sample volumes (~ 1-10 µL), enhanced detection sensitivity (~ 1 cell), faster 
analysis (2-4 h), improved portability, and the ability to perform species-specific AST in 
polymicrobial infections.   
The primary objectives of my doctoral thesis focused on the goal of providing precise 
antibiotic susceptibility results using microfluidics: 
• Optimization of normally-closed (NC) valves for their incorporation into high 
throughput screening chips: NC valves have been used previously in different microfluidic 
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applications [30] but none of these studies specifically focused on the design rules to optimize 
the performance of NC valves, in particular with respect to minimizing their actuation 
pressures and improving their reliability.  I formulated a set of design rules for these 
microvalves so they can be utilized in high throughput biological screening applications, such 
as antibiotic screening and protein crystallization [8].  The design rules have enabled 
fabrication of valves with dimensions that can be easily achieved with standard soft 
lithography procedures.   
• Proof-of-concept antibiotic susceptibility testing: I have successfully designed and 
implemented a microfluidic platform for antibiotic susceptibility screening [8].  Using E. coli 
as a model organism, I demonstrated the utility of the platform to precisely and rapidly 
quantify microbial antibiograms.  I also showed the importance of rapid determination of 
pathogen antibiogram by demonstrating the rapid deterioration of antibiotic efficacy with 
amplification of microbial population.  Although I quantified antibacterial effects of 
antibiotics based on their effects on cell growth in 10 h., a preliminary idea of antibiotic 
susceptibilities was discernible in ≈ 4 h, which makes the platform ideally suited for rapid 
diagnosis and management of infections.  Furthermore, my results underscore the potential 
dangers of administering empirical therapies based on combinations of broad-spectrum 
antibiotics.  By accentuating several instances in which antibiotic combinations fare poorly, I 
expound the need to rigorously evaluate antibiotic cocktails prior to clinical administration. 
• Antibiotic susceptibility testing using clinically relevant pathogens such as P. aeruginosa 
and K. pneumoniae in monomicrobial and polymicrobial cultures: Several infections such 
as urinary tract infections (UTI) are polymicrobial; yet, most AST studies have focused on 
monomicrobial AST [31-33].  I performed AST on polymicrobial cultures involving E. coli, 
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P. aeruginosa, and K. pneumoniae.  Since these types of experiments are challenging to 
perform using conventional techniques for AST, the current practice often involves 
extrapolating monomicrobial AST results to determine treatment of polymicrobial infections.  
Such practices increase the risk of prescribing incorrect antibiotic dosing regimen, 
consequently antibiotic resistance, bacteria behaves differently in presence of other types of 
bacteria[31-33].  The approach reported in this thesis offers the potential to prescribe an 
appropriate antibiotic dosing regimen in a timely fashion based on bacteria-specific 
polymicrobial AST results.  In addition, the technique presents an opportunity to study 
dynamic bacterial interactions for extended periods of time.    
• Pharmacodynamics/pharmacokinetics (PK-PD) of antibiotics: PD modeling helps in 
determination of a precise MIC that can further be used to perform PK modeling for 
determining a precise in vivo antibiotic dosing regimen using experimental data from the 
microfluidic device.  I performed a proof-of-concept study to demonstrate PK-PD modeling 
from experimental data obtained from time-kill curves for monomicrobial and polymicrobial 
AST.  
• AST using non-genetically modified bacteria: Since the tools developed in the work utilize 
genetically modified bacteria, I attempted to address this issue by optimizing fluorescent dyes 
to be used with non-genetically modified bacteria.  Though determination of MIC is possible 
using optical dyes mentioned here, more work is needed to advance this part of the study for 
performing long-term cell studies with “real” clinical samples.  
7.2 Future directions 
 The discussed microfluidic platforms in this thesis for AST have primarily been used as a 
research tool to study the interaction of antibiotics and monomicrobial/polymicrobial bacteria.  
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Although these platforms have led to interesting microbiological insights, two key advances are 
required to translate the microfluidic technology to clinics.  First, since most of the microfluidic-
based AST studies have utilized genetically modified bacteria for assays, optimized microfluidic 
platforms need to be developed that utilize non-genetically modified bacteria, which is 
representative of the actual clinical samples.  Though this aspect was tested in chapter 6 of my 
thesis, more studies are needed to further advance the technology since the current optimization 
allows determination of MIC only and no long-term studies are possible due to loss of 
fluorescence overtime.  Second, since the current technology is dependent on ancillaries such as 
microscope for TLFM and the current set up requires trained personnel for performing AST, the 
technology needs to be further optimized for point-of-care applications.  Cell-phone based 
colorimetric detection could be an approach to realize the goal of a point-of-care technology.  
Finally, the current techniques for AST have been used for decades to treat microbial infections, 
and introduction of a new technology would require collaboration between scientists and 
clinicians to specifically perform comparative studies on AST and PK/PD modeling using 
conventional techniques and microfluidic platforms.  These types of collaborations will help in 
overcoming resistance faced by the clinicians in the healthcare for the adoption of the new 
technologies that will enable prescription of accurate antibiotic dosing regimen, which would 
ultimately help in addressing the global health issue of antibiotic resistance.  
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Appendix A 
A.1 Distribution of cells in the microfluidic device 
Distribution of cells was studied in the microfluidic device that helped in optimization of 
the device in polymicrobial studies.  The primary objective here was to model distribution of 
particles in the microfluidic device discussed in chapter 3 under conditions such as high and low 
density of beads and longer actuation of valves.  The key goal was the optimization of the 
platform based on the results obtained experimentally and using COMSOL modeling.  
Fluorescent beads of the same size as typical bacterial cells were used as model particles in the 
experiment.  Experiment was performed on 18 devices using micro fluorescence beads solution 
at three different concentrations. (C1: 500x106, C2: 50x106, and C3: 5x106 beads/mL).   
Theoretical values 
C1, C2, C3:  1500, 150, 15 beads/chamber   
500x106, 50x106, 5x106 beads/mL 
Experimental values (before actuation) 
C1, C2, C3:  1693, 170, 19 beads/chamber   
564x106, 57x106, 6x106 beads/mL 
Experimental values (after actuation) 
C1, C2, C3: 1264, 166, 22 beads/chamber   
421x106, 55x106, 7x106 beads/mL 
Note that standard deviation of errors in the bead counts increase as the beads solutions were 
diluted and beads distribution was more uniform (lower standard error) when fluid valves 
were closed. 
Standard deviation with fluid valves closed (C1, C2, and C3): 0.87%, 0.94%, 1.99% 
Standard deviation with fluid valves actuated (C1, C2, and C3): 5.14%, 8.87%, 34.70% 
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In order to analyze the beads distribution, number of beads within a column was normalized by 
minimum (# of beads in each chamber/minimum beads in that column). 
Beads distribution within a column was more uniform at higher concentration (lower normalized 
values) and fluid valves actuation had negligible effect on beads distribution within a column.  
With fluid valves closed, average highest (C1, C2, C3):   1.09, 1.22, 1.72 
With fluid valves actuated, average highest (C1, C2, C3):   1.08, 1.19, 1.71 
Standard errors of normalized values ( % compare to normalized values) increase as the beads 
solutions were diluted.  Fluid valves actuation had no effect on of normalized values. 
With fluid valves closed (C1, C2, C3):   0.91%, 2.46%, 6.98% 
With fluid valves actuated (C1, C2, C3):   0.93%, 1.68%, 5.85% 
Table A.1 : Distribution of beads with valves closed 
 Device#1 Device #2 Device #3 Average 
Dilute 10 folds (500x106 beads/mL) 
Average 1597.31 1575.33 1907.33 1693.33 
S.E. 9.68 12.44 15.71 14.66 (0.87%) 
Range 276 333 525  
Dilute 100 folds (50x106 beads/mL) 
Average 166.02 175.63 167.40 169.68 
S.E. 2.29 3.58 2.08 1.60 (0.94%) 
Range 64 110 64  
Dilute 1000 folds (5x106 beads/mL) 
Average 19.25 18.65 17.83 18.58 
S.E. 0.64 0.57 0.68 0.37 (1.99%) 
Range 24 17 21  
 
Normalization by minimum:  maximum beads in a column/minimum beads in the column 
 Device#1 Device #2 Device #3 Average 
Dilute 10 folds (500x106 beads/mL) 
Average 1.08 1.11 1.09 1.09 
S.E. 0.01 0.01 0.01 0.01 (0.91%) 
Dilute 100 folds (50x106 beads/mL) 
Average 1.20 1.25 1.20 1.22 
S.E. 0.03 0.04 0.03 0.03 (2.46%) 
Dilute 1000 folds (5x106 beads/mL) 
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Average 1.60 1.70 1.86 1.72 
S.E. 0.08 0.12 0.18 0.12 (6.98%) 
 
 
Table A.2 : Distribution of beads with valves open 
 Device#1 Device #2 Device #3 Average 
Dilute 10 folds (500x106 beads/mL) 
Average 1248.19 1262.83 1281.56 1264.19 
S.E. 59.40 52.32 77.50 64.97 (5.14%) 
Range 258 214 329 267 
Dilute 100 folds (50x106 beads/mL) 
Average 169.96 169.40 159.02 166.13 
S.E. 13.62 14.88 13.26 14.73 (8.87%) 
Range 56 65 56 59 
Dilute 1000 folds (5x106 beads/mL) 
Average 18.83 19.23 28.42 22.16 
S.E. 4.57 5.27 8.44 7.69 (34.70%) 
Range 20 24 48 31 
 
Normalization by minimum:  maximum beads in a column/minimum beads in the column 
 Device#1 Device #2 Device #3 Average 
Dilute 10 folds (500x106 beads/mL) 
Average 1.08 1.08 1.10 1.08 
S.E. 0.01 0.01 0.01 0.01 (0.93%) 
Dilute 100 folds (50x106 beads/mL) 
Average 1.19 1.21 1.18 1.19 
S.E. 0.02 0.02 0.02 0.02 (1.68%) 
Dilute 1000 folds (5x106 beads/mL) 
Average 1.70 1.67 1.75 1.71 
S.E. 0.09 0.09 0.13 0.10 (5.85%) 
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COMSOL modeling was performed to see the distribution of particles in the device (Fig A.1-
A.8).  Modeling results demonstrated accumulation of beads more likely on the ends and non-
uniform distribution of beads, perhaps due to inconsistent hydrodynamic resistance.  
 
 
 
 
Figure A.1.  Heat map with no normalization and cell culture diluted by 10 folds with LB 
 
146 
 
 
 
 
Figure A.2. Heat map with no normalization and cell culture diluted by 100 folds with LB 
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Figure A.3. Heat map with no normalization and cell culture diluted by 1000 folds with LB 
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Figure A.4. Heat map with normalization (max) and cell culture diluted by 10 folds with LB 
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Figure A.5. Heat map with normalization (max) and cell culture diluted by 100 folds with LB 
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Figure A.6. Heat map with normalization (max) and cell culture diluted by 10 folds with LB 
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Figure A.7. Heat map with normalization (min) and cell culture diluted by 10 folds with LB 
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Figure A.8. Heat map with normalization (min) and cell culture diluted by 100 folds with LB 
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Figure A.9. Heat map with normalization (min) and cell culture diluted by 1000 folds with LB 
I changed the dimensions of the mixing valves and determined growth rate  to see effect of valve 
dimensions on the physiology of the cells.  All chambers that initially had the same material 
(LB/cells) gave a similar growth curve.  Thus, width and height of mixing valve does not alter 
the growth rate (Fig. A.9). The following graphs show growth of cells in adjacent chambers.  
The graph on the left shows growth in the chamber where cells are added and the one on right 
show growth rate where medium (LB) is added. Fig. A.10 utilizes COMSOL modeling to show 
dimensions of the mixing valve that give the most efficient mixing. 
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 Figure A.10. Growth rate of bacteria in when different mixing valve dimensions are utilized.  
Negligible change in growth rate is seen for all cases.  
 
 
Figure A.11. Mixing is the most efficient (~ 1:1) with valve dimensions 300 x 350.  
  
-1
0
1
2
3
4
0 1 2 3 4 5 6 7 8 9 10
-1
0
1
2
3
4
5
6
7
0 1 2 3 4 5 6 7 8 9 10
155 
 
Appendix B 
B.1 MATLAB codes for image analysis 
MATLAB codes have been divided into three categories. First describes the codes used 
in chapter 3, second describes when 20x objective is utilized, and third category describes 
codes used in polymicrobial AST experiments in chapter 4.  
 
Sorting the images after acquisition [Chapter 3 - with 10x objective] 
function 10x_single_sort() 
clc % clear existing text on the screen 
disp('Image sorting - sort RAW IGB images into chambers.') 
path =  uigetdir('C:\Users\pkgroup\Desktop'); % show folder selection 
toolbox 
disp('Sorting....') 
global blank 
blank = 0; 
manage(path,path); % Use recursive function to sort all *.tif files 
into corresponding folders 
rmdir(fullfile(path,'sorted',num2str(blank,'%02d')),'s'); % remove 
blank background images after sorting 
disp('     Done!') 
end 
 
function manage(path,givenpath) 
global blank 
listing = dir(fullfile(path,'\')); % list all the files/folders inside 
the selected folder 
for i = 3:numel(listing) % work on each file/folder one by one 
 subpath = fullfile(path,listing(i).name); 
    [~, name, ext] = fileparts(listing(i).name); 
if isdir(subpath)==1 
 manage(subpath,givenpath); % if a folder is found inside a given 
folder, run function 'manage' with that folder 
elseif strcmpi(ext,'.tif') 
% create the chamber folders. Since one image contains two chambers 
(10x), a copy of an image set is created to make a folder for each 
chamber. 
foldername = sprintf('%02d',str2num(name(end-1:end))*2-1);    
foldernext = sprintf('%02d',str2num(name(end-1:end))*2); 
 if exist(fullfile(givenpath,'sorted',foldername),'dir')==0 
  mkdir(fullfile(givenpath,'sorted',foldername)); 
        mkdir(fullfile(givenpath,'sorted',foldernext)); 
             if blank<str2num(foldernext) 
                blank = str2num(foldernext); 
             end 
    end 
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copyfile(fullfile(subpath),fullfile(givenpath,'sorted',foldernext)); 
 movefile(fullfile(subpath),fullfile(givenpath,'sorted',foldername
)); % move the file to corresponding chamber folder 
end 
end 
end 
 
Cropping the images after sorting 
function 10x_single_crop() 
clc % clear the existing text on the screen 
disp('IGB cropping code - Please select experiment folder to 
proceed.') 
disp('The last chamber must be a blank') 
mainpath = uigetdir();% shows folder selection dialog box 
path1 = fullfile(mainpath,'sorted'); 
list = dir(path1); % make a list of folders inside 
% create 'stackimage' folder if not already exists 
if ~exist(fullfile(mainpath,'stackimage'), 'dir') 
     mkdir(fullfile(mainpath,'stackimage')); 
end 
 
disp('cropping, please wait...') 
 
% Gather all background reference images 
i=numel(list); 
if isdir(fullfile(path1,list(i).name))==1 
        subpath = fullfile(path1,list(i).name); 
        piclist = dir(subpath); % make a list of blank images at 
different time 
        blank = zeros(600,800,numel(piclist)-3,'uint8'); % create a 
variable for storing blank images 
        for j=3:1:numel(piclist 
            [~, ~, ext] = 
fileparts(fullfile(subpath,piclist(j).name)); 
            if strcmpi(ext,'.TIF')==1  
                blank(:,:,j-2) = 
imread(fullfile(subpath,piclist(j).name)); % store blank images for in 
variable ‘blank’ 
            end 
        end 
end 
 
% work on cropping folder by folder 
for i=3:1:(numel(list)-1) 
    if isdir(fullfile(path1,list(i).name))==1 
        subpath = fullfile(path1,list(i).name); 
        piclist = dir(subpath); % make a list of images in each chamber 
folder 
        allpic = zeros(600,800,numel(piclist)-3,'uint8'); % create a 
blank variable for storing chamber images 
157 
 
        for j=3:1:numel(piclist) 
            [~, name, ext] = 
fileparts(fullfile(subpath,piclist(j).name)); 
            if strcmpi(ext,'.TIF')==1 
                allname(j-2) = {name}; 
                allpic(:,:,j-2) = 
imread(fullfile(subpath,piclist(j).name)); %store images in the 
variable created 
            end 
        end 
    end 
% This code relies on user to indicate the chamber position. The 
following commands will allows the 'chamber shape' to be seen easily. 
I = sum(allpic,3); 
I = histeq(I/max(max(I))); 
s = warning('off', 'Images:initSize:adjustingMag'); 
imshow(I); % display stacked image on screen for cropping 
set(gcf,'NumberTitle','off'); 
set(gcf,'Name',strcat(list(i).name,'/',list(end-1).name)); 
warning(s); 
 
h = imrect(gca, [250 200 289 289]); % display cropping rectangle on the 
stack image 
setResizable(h,false); 
 
% record the stacked image  
ipath = fullfile(mainpath,'stackimage',strcat(list(i).name,'.jpg')); 
imwrite(I,ipath,'jpg'); 
 
%subtract each image with corresponding background reference, crop, 
and then save as *.jpg files 
pause 
position = getPosition(h); % get the cropping rectangle position 
for k=1:1:numel(blank(1,1,:)) 
allpic(:,:,k) = allpic(:,:,k)-blank(:,:,k); %subtract chamber images 
with blank reference images 
despath = fullfile(subpath,strcat(allname{k},'.jpg')); 
cropped = imcrop(allpic(:,:,k),position); % crop images in that chamber 
at the given rectangle position 
imwrite(cropped,despath,'jpg','Quality',100); %write jpg image in the 
same chamber folder 
end 
end 
close 
 
disp('Deleting *tiff files....') 
 
rmdir(fullfile(path1,list(numel(list)).name),'s'); % remove blank 
images 
recycle off; 
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manage(mainpath,mainpath); % delete every *tif files using recursive 
function 
recycle on; 
disp('     Done!') 
 
end 
 
function manage(path,givenpath) 
listing = dir(fullfile(path,'\')); 
for i = 3:numel(listing) 
 subpath = fullfile(path,listing(i).name); 
    [~, name, ext] = fileparts(listing(i).name); 
if isdir(subpath)==1 
 delete(fullfile(subpath,'*.tif')); 
 manage(subpath,givenpath); 
end 
end 
end 
 
Counting the cells 
function 10x_single_count() 
clc% clear existing images on the screen 
disp('Configuring necessary parameters...') 
warning off all; 
clear global variable 
clear java 
 
% Request for the threshold inputs for ‘Find Maxima’ algorithm 
threshold = str2double(input('Please enter the threshold: ','s')); 
 
% This code relies on ImageJ function (Requires ImageJ) 
javaaddpath('C:/Program Files (x86)/ImageJ/ij.jar'); 
javaaddpath('C:/Program Files/ImageJ/ij.jar'); 
import('ij.IJ.*'); % Import ImageJ functions 
import('ij.plugin.filter.*'); % Import more ImageJ functions 
% 'Find Maxima' function is avaiable only in version 1.46 or later 
if versionLessThan('1.46')==1 
    return 
end 
 
disp('Please locate the sorted, cropped experiment folder...') 
folder = uigetdir();% locate experiment folder 
path = fullfile(folder,'sorted'); 
 
listing = dir(path); % make a list of chamber folders inside channal 
folders 
disp('Counting cells in chamber number:  ') 
 
for a=3:(numel(listing)) % count cells folder by folder 
    filelist = dir(fullfile(path,listing(a).name,'*.jpg')); % make a 
list of chamber images inside each chamber folder 
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    fprintf(1,'\b\b%s',listing(a).name); 
    chambername(1,a-2) = str2num(listing(a).name); 
    chambername(2,a-2) = 1; 
    first = imread(fullfile(path,listing(a).name,filelist(1).name)); 
    overall = sum(sum(first)); % obtain intensity sum of the first 
image in that folder.   
% for each file, load image into Java variable, then use getMaxima 
function to achieve the cell count. 
    for b=1:numel(filelist) 
        imp = 
openImage(fullfile(path,listing(a).name,filelist(b).name)); 
        ip = imp.getProcessor();  
        mf = MaximumFinder; 
        maxima = mf.getMaxima(ip,threshold, 0); % call function Maximum 
Finder using the defined threshold 
        maximacount(b,a-2) = maxima.npoints; %get the cell count from 
ImageJ 
% alternative counting method: count by comparing intensity sum with 
the first image intensity sum. The cell count is then related to the 
first image cell count.       
        I = imread(fullfile(path,listing(a).name,filelist(b).name)); 
        intensity = sum(sum(I)); 
        intensitycount(b,a-2) = 
floor(intensity/overall*maximacount(1,a-2)); % record cell count by 
intensity (relative to the first image) in an array 
        rawintensity(b,a-2) = floor(intensity); % record raw intensity 
of each image in another array 
    end 
end 
fprintf('\n') 
disp('Done counting cells. ') 
 
% record the cell counts in Excel file. 
disp('Writing result in .xls file...') 
filename = 'Cell Count.xls';  
timepoints = numel(dir(fullfile(path,listing(3).name,'*.jpg')))-1; 
time = transpose(0:30:timepoints*30); 
 
A1 = sprintf('threshold = %d',threshold); 
 
xlswrite(fullfile(folder,filename), {A1;'Y/N = 1/0';'time(min)'}, 
3,'A1'); 
xlswrite(fullfile(folder,filename), chambername, 3,'B1'); 
xlswrite(fullfile(folder,filename), time, 3,'A4'); 
xlswrite(fullfile(folder,filename), rawintensity, 3,'B4'); 
 
xlswrite(fullfile(folder,filename), {A1;'Y/N = 1/0';'time(min)'}, 
2,'A1'); 
xlswrite(fullfile(folder,filename), chambername, 2,'B1'); 
xlswrite(fullfile(folder,filename), time, 2,'A4'); 
xlswrite(fullfile(folder,filename), intensitycount, 2,'B4'); 
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xlswrite(fullfile(folder,filename), {A1;'Y/N = 1/0';'time(min)'}, 
1,'A1'); 
xlswrite(fullfile(folder,filename), chambername, 1,'B1'); 
xlswrite(fullfile(folder,filename), time, 1,'A4'); 
xlswrite(fullfile(folder,filename), maximacount, 1,'B4'); 
 
e = actxserver ('Excel.Application'); % open Activex server 
ewb = e.Workbooks.Open(fullfile(folder,filename)); % open file (enter 
full path!) 
ewb.Worksheets.Item(1).Name = 'Local Maxima';% rename 1st sheet 
ewb.Worksheets.Item(2).Name = '# from Intensity'; 
ewb.Worksheets.Item(3).Name = 'Raw Intensity';  
ewb.Save % save to the same file 
ewb.Close(false) 
e.Quit 
 
fprintf('Output file: %s\n', filename) 
clear all 
clear global variable 
clear java 
disp('     Done!') 
warning on all; 
end 
 
MATLAB codes with 20x objective  
Sorting code 
function 20x_single_sort() 
clc % clear existing text on the screen 
disp('Image sorting - sort RAW IGB images into chambers.') 
path =  uigetdir('C:\Users\pkgroup\Desktop'); % show folder 
selection toolbox 
disp('Sorting....') 
manage(path,path); % Use recursive function to sort all *.tif 
files into corresponding folders 
disp('     Done!') 
end 
 
function manage(path,givenpath) 
listing = dir(fullfile(path,'\')); % list all the files/folders 
inside the selected folder 
for i = 3:numel(listing) 
 subpath = fullfile(path,listing(i).name);  
    [~, name, ext] = fileparts(listing(i).name); 
if isdir(subpath)==1  
 manage(subpath,givenpath); % if detect folder inside, run 
‘manage’ function on this folder again 
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elseif strcmpi(ext,'.tif') % if detect *.tif file, create 
chamber folder and move the file into corresponding chamber 
folder 
    foldername = sprintf('%02d',str2num(name(end-1:end))); 
 if exist(fullfile(givenpath,'sorted',foldername),'dir')==0  
  mkdir(fullfile(givenpath,'sorted',foldername)); 
    end 
 movefile(fullfile(subpath),fullfile(givenpath,'sorted',fold
ername));  
end 
end 
end 
 
Cropping the images  
function 20x_single_crop() 
clc % clear existing text on the screen 
disp('IGB cropping code - Please select experiment folder to 
proceed.') 
disp('The last chamber must be a blank') 
mainpath = uigetdir(); % show folder selection toolbox 
path1 = fullfile(mainpath,'sorted');% go to ‘sorted’ folder 
list = dir(path1);% list all chamber folders 
if ~exist(fullfile(mainpath,'stackimage'), 'dir') 
     mkdir(fullfile(mainpath,'stackimage'));% create 
‘stackimage’ folder 
end 
 
disp('cropping, please wait...') 
 
% start collecting noise images (last chamber) 
i=numel(list); 
if isdir(fullfile(path1,list(i).name))==1 
        subpath = fullfile(path1,list(i).name);% locate the last 
folder 
        piclist = dir(subpath);% list all files (images) in the 
last folder 
        blank = zeros(600,800,numel(piclist)-3,'uint8');% create 
a blank variable for blank background image storage. 
        for j=3:1:numel(piclist)%% from j=1 
            [~, ~, ext] = 
fileparts(fullfile(subpath,piclist(j).name)); 
            if strcmpi(ext,'.TIF')==1                
blank(:,:,j-2) = imread(fullfile(subpath,piclist(j).name)); % 
store blank images in ‘blank’ variable 
            end 
        end 
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else 
    disp('error: non folder is the last item in sorted folder') 
    return 
end 
 
% start collecting real images 
for i=3:1:(numel(list)-1) % work on each chamber folder one by 
one 
    if isdir(fullfile(path1,list(i).name))==1 
        subpath = fullfile(path1,list(i).name); 
        piclist = dir(subpath); 
        allpic = zeros(600,800,numel(piclist)-3,'uint8'        
for j=3:1:numel(piclist) 
            [~, name, ext] = 
fileparts(fullfile(subpath,piclist(j).name)); 
            if strcmpi(ext,'.TIF')==1 
                allname(j-2) = {name}; 
                allpic(:,:,j-2) = 
imread(fullfile(subpath,piclist(j).name)); % read images in that 
folder into ‘allpic’ variable 
            end 
        end 
    end 
% This code relies on user to indicate the chamber position. The 
following commands will allows the 'chamber shape' to be seen 
easily. 
I = sum(allpic,3); 
I = imadjust(histeq(I/max(max(I)))); 
s = warning('off', 'Images:initSize:adjustingMag'); 
imshow(I); % display an enhanced image of that chamber for 
cropping 
set(gcf,'NumberTitle','off'); 
set(gcf,'Name',strcat(list(i).name,'/',list(end-1).name)); 
warning(s); 
h = imrect(gca, [50 20 559 559]); % display a cropping rectangle 
setResizable(h,false); 
 
% record a stacked image  
ipath = 
fullfile(mainpath,'stackimage',strcat(list(i).name,'.jpg')); 
imwrite(I,ipath,'jpg'); 
 
%subtract each image with corresponding background reference, 
crop the green channel, and then save as *.jpg files 
pause 
position = getPosition(h); % get position from the cropping 
rectangle 
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for k=1:1:numel(blank(1,1,:)) 
allpic(:,:,k) = allpic(:,:,k)-blank(:,:,k); % subtract every 
images in that chamber with a blank image at the same time point 
despath = fullfile(subpath,strcat(allname{k},'.jpg')); 
cropped = imcrop(allpic(:,:,k),position); % crop images 
imwrite(cropped,despath,'jpg','Quality',100); % write cropped 
images in the same folder as the original images 
end 
 
end 
close 
 
% delete original *tiff files 
disp('Deleting *tiff files....') 
rmdir(fullfile(path1,list(numel(list)).name),'s'); 
recycle off; 
manage(mainpath,mainpath); % recursive function for deleting 
*.tiff files 
recycle on; 
disp('     Done!') 
 
end 
 
function manage(path,givenpath) 
listing = dir(fullfile(path,'\')); 
for i = 3:numel(listing) 
 subpath = fullfile(path,listing(i).name); 
    [~, name, ext] = fileparts(listing(i).name); 
if isdir(subpath)==1 
 delete(fullfile(subpath,'*.tif')); 
 manage(subpath,givenpath); 
end 
end 
end 
 
Counting the cells 
function 20x_single_count() 
clc  % clear existing text on the screen 
disp('Configuring necessary parameters...') 
warning off all; 
clear global variable 
clear java 
 
% Request for threshold input for ‘Find Maxima’ algorithm 
threshold = str2double(input('Please enter the threshold: 
','s')); 
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% This code relies on ImageJ function as it's core, thus ImageJ 
is needed 
javaaddpath('C:/Program Files (x86)/ImageJ/ij.jar'); 
javaaddpath('C:/Program Files/ImageJ/ij.jar'); 
import('ij.IJ.*'); % Import ImageJ functions 
import('ij.plugin.filter.*'); % Import more ImageJ functions 
if versionLessThan('1.46')==1 % 'Find Maxima' function is 
avaiable only in version 1.46 or later 
    return 
end 
 
% locate experiment folder and update the counting progress 
disp('Please locate the sorted, cropped experiment folder...') 
folder = uigetdir(); 
path = fullfile(folder,'sorted'); 
 
listing = dir(path); 
disp('Counting cells in chamber number:  ') 
 
for a=3:(numel(listing)) % count cells folder by folder 
    filelist = dir(fullfile(path,listing(a).name,'*.jpg')); 
    fprintf(1,'\b\b%s',listing(a).name); 
    chambername(1,a-2) = str2num(listing(a).name); 
    chambername(2,a-2) = 1; 
    first = 
imread(fullfile(path,listing(a).name,filelist(1).name)); 
    overall = sum(sum(first)); % obtain intensity sum of the 
first image in that folder. 
 
% for each file, load image into Java variable, then use 
getMaxima function to achieve the cell count. 
    for b=1:numel(filelist) 
        imp = 
openImage(fullfile(path,listing(a).name,filelist(b).name)); 
        ip = imp.getProcessor();  
        mf = MaximumFinder; 
        maxima = mf.getMaxima(ip,threshold, 0); % call function 
Maximum Finder using the defined threshold 
        maximacount(b,a-2) = maxima.npoints; %get the cell count 
from ImageJ 
% alternative counting method: count by comparing intensity sum 
with the first image intensity sum. The cell count is then 
related to the first image cell count. 
        I = 
imread(fullfile(path,listing(a).name,filelist(b).name)); 
        intensity = sum(sum(I)); 
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        intensitycount(b,a-2) = 
floor(intensity/overall*maximacount(1,a-2)); 
        rawintensity(b,a-2) = floor(intensity); 
    end 
end 
 
% record the counting result in Excel file. 
fprintf('\n') 
disp('Done counting cells. ') 
disp('Writing result in .xls file...') 
filename = 'Cell Count.xls';  
timepoints = numel(dir(fullfile(path,listing(3).name,'*.jpg')))-
1; 
time = transpose(0:30:timepoints*30); 
 
A1 = sprintf('threshold = %d',threshold); 
 
xlswrite(fullfile(folder,filename), {A1;'Y/N = 
1/0';'time(min)'}, 3,'A1'); 
xlswrite(fullfile(folder,filename), chambername, 3,'B1'); 
xlswrite(fullfile(folder,filename), time, 3,'A4'); 
xlswrite(fullfile(folder,filename), rawintensity, 3,'B4'); 
 
xlswrite(fullfile(folder,filename), {A1;'Y/N = 
1/0';'time(min)'}, 2,'A1'); 
xlswrite(fullfile(folder,filename), chambername, 2,'B1'); 
xlswrite(fullfile(folder,filename), time, 2,'A4'); 
xlswrite(fullfile(folder,filename), intensitycount, 2,'B4'); 
 
xlswrite(fullfile(folder,filename), {A1;'Y/N = 
1/0';'time(min)'}, 1,'A1'); 
xlswrite(fullfile(folder,filename), chambername, 1,'B1'); 
xlswrite(fullfile(folder,filename), time, 1,'A4'); 
xlswrite(fullfile(folder,filename), maximacount, 1,'B4'); 
 
e = actxserver ('Excel.Application'); % open Activex server 
ewb = e.Workbooks.Open(fullfile(folder,filename)); % open file 
ewb.Worksheets.Item(1).Name = 'Local Maxima';% rename 1st sheet 
ewb.Worksheets.Item(2).Name = '# from Intensity'; 
ewb.Worksheets.Item(3).Name = 'Raw Intensity';  
ewb.Save % save to the same file 
ewb.Close(false) 
e.Quit 
 
fprintf('Output file: %s\n', filename) 
 
clear all 
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clear global variable 
clear java 
disp('     Done!') 
warning on all; 
end 
 
The following codes are for polymicrobial AST (Chapter 4)  
Sorting the images 
function 20x_poly_sort() 
clc % clear existing text on the screen 
disp('Image sorting - sort RAW IGB images into chambers.') 
path =  uigetdir('C:\Users\pkgroup\Desktop'); % show a folder 
selection dialog box 
disp('Sorting....') 
manage(path,path); % recursive function, repeat function 
'manage' with everything inside the selected folder 
disp('     Done!') 
end 
 
function manage(path,givenpath) 
listing = dir(fullfile(path,'\')); % list all the files/folders 
inside the selected folder 
 
% create FITC and Texas Red folder if they are not already 
existed 
mkdir(fullfile(path,'FITC'));  
mkdir(fullfile(path,'Texas Red'));  
for i = 3:numel(listing) % work on each file/folder one by one 
subpath = fullfile(path,listing(i).name); 
    [~, name, ext] = fileparts(listing(i).name); 
if isdir(subpath)==1 
 manage(subpath,givenpath); % if a folder is found inside a 
given folder, run function 'manage' with that folder 
     
elseif ((strfind(name,'Texas Red')~=0)&(strcmpi(ext,'.tif')==1)) 
% if a tif file name includes 'Texas Red' 
    foldername = sprintf('%02d',str2num(name(end-1:end))); 
 if exist(fullfile(givenpath,'Texas 
Red',foldername),'dir')==0 % if the chamber folder is not 
already created 
  mkdir(fullfile(givenpath,'Texas Red',foldername)); % 
create the chamber folder 
    end 
       movefile(fullfile(subpath),fullfile(givenpath,'Texas 
Red',foldername)); % move the file to corresponding chamber 
folder 
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elseif ((strfind(name,'FITC')~=0)&(strcmpi(ext,'.tif')==1)) % if 
file name includes FITC 
    foldername = sprintf('%02d',str2num(name(end-1:end))); 
 if exist(fullfile(givenpath,'FITC',foldername),'dir')==0 % 
if the chamber folder is not already created 
  mkdir(fullfile(givenpath,'FITC',foldername)); % create 
the chamber folder 
    end 
       
movefile(fullfile(subpath),fullfile(givenpath,'FITC',foldername)
); % move the file to corresponding chamber folder 
end 
end 
end 
 
Cropping the images 
function 20x_poly_crop() 
clc % clear the existing text on the screen 
disp('IGB cropping code - Please select experiment folder to 
proceed.') 
mainpath = uigetdir(); % shows folder selection dialog box 
path1 = fullfile(mainpath,'FITC'); % define path1 as FITC folder 
path2 = fullfile(mainpath,'Texas Red'); % define path 2 as Texas 
Red folder 
 
list1 = dir(path1); % make a list of folders inside FITC 
list2 = dir(path2);% make a list of folders inside Texas Red 
if ~exist(fullfile(mainpath,'stackimage'), 'dir') % create 
'stackimage' folder if not already exists 
     mkdir(fullfile(mainpath,'stackimage')); 
end 
 
disp('cropping, please wait...') 
 
% Gather all background reference images 
i=numel(list1);% index the number of 'blank' folder 
% Get blank images for FITC 
if isdir(fullfile(path1,list1(i).name))==1 
        subpath = fullfile(path1,list1(i).name); 
        piclist = dir(subpath);% make a list of blank images at 
different time 
        blank1 = zeros(600,800,numel(piclist)-3,'uint8');% 
create an array for storing blank images 
        for j=3:1:numel(piclist) 
            [~, ~, ext] = 
fileparts(fullfile(subpath,piclist(j).name)); 
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            if strcmpi(ext,'.TIF')==1 
                blank1(:,:,j-2) = 
imread(fullfile(subpath,piclist(j).name)); % store blank images 
for FITC in variable ‘blank1’ 
            end 
        end 
end 
 
% Get blank images for Texas Red 
if isdir(fullfile(path2,list2(i).name))==1 
        subpath = fullfile(path2,list2(i).name); 
        piclist = dir(subpath); 
        blank2 = zeros(600,800,numel(piclist)-3,'uint8'); 
        for j=3:1:numel(piclist) 
            [~, ~, ext] = 
fileparts(fullfile(subpath,piclist(j).name)); 
            if strcmpi(ext,'.TIF')==1 
                blank2(:,:,j-2) = 
imread(fullfile(subpath,piclist(j).name));% store blank images 
for Texas Red in variable ‘blank2’ 
            end 
        end 
end 
 
% work on cropping folder by folder  
for i=3:1:(numel(list1)-1)  
    if isdir(fullfile(path1,list1(i).name))==1 
        subpath1 = fullfile(path1,list1(i).name); 
        piclist = dir(subpath1);% make a list of images in each 
chamber folder 
        allpic1 = zeros(600,800,numel(piclist)-3,'uint8'); % 
create a blank variable for storing chamber images 
        for j=3:1:numel(piclist) 
            [~, name, ext] = 
fileparts(fullfile(subpath1,piclist(j).name)); 
            if strcmpi(ext,'.TIF')==1 
                allname1(j-2) = {name}; 
                allpic1(:,:,j-2) = 
imread(fullfile(subpath1,piclist(j).name)); %store images in the 
variable created 
            end 
        end 
    end 
% repeat the image storing process with red channel folders     
    if isdir(fullfile(path2,list2(i).name))==1 
        subpath2 = fullfile(path2,list2(i).name); 
        piclist = dir(subpath2); 
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        allpic2 = zeros(600,800,numel(piclist)-3,'uint8'); 
        for j=3:1:numel(piclist) 
            [~, name, ext] = 
fileparts(fullfile(subpath2,piclist(j).name)); 
            if strcmpi(ext,'.TIF')==1 
                allname2(j-2) = {name}; 
                allpic2(:,:,j-2) = 
imread(fullfile(subpath2,piclist(j).name)); 
            end 
        end 
    end 
% This code relies on user to indicate the chamber position. The 
following commands will allows the 'chamber shape' to be seen 
easily. 
I = sum(allpic1,3)+sum(allpic2,3);  
I = imadjust(histeq(I/max(max(I))));  
s = warning('off', 'Images:initSize:adjustingMag'); 
imshow(I); % display stacked image on screen for cropping 
set(gcf,'NumberTitle','off'); 
set(gcf,'Name',strcat(list1(i).name,'/',list1(end-1).name)); 
warning(s); 
 
h = imrect(gca, [50 20 559 559]); % display cropping rectangle 
on the stack image 
setResizable(h,false); 
 
% record the stacked image  
ipath = 
fullfile(mainpath,'stackimage',strcat(list1(i).name,'.jpg')); 
imwrite(I,ipath,'jpg');  
 
%subtract each image with corresponding background reference, 
crop the green channel, and then save as *.jpg files 
pause 
position = getPosition(h); % get the cropping rectangle position  
for k=1:1:numel(blank1(1,1,:)) 
allpic1(:,:,k) = allpic1(:,:,k)-blank1(:,:,k); %subtract chamber 
images with blank reference images 
despath = fullfile(subpath1,strcat(allname1{k},'.jpg')); 
cropped = imcrop(allpic1(:,:,k),position); % crop images in that 
chamber at the given rectangle position 
imwrite(cropped,despath,'jpg','Quality',100); %write jpg image 
in the same chamber folder 
end 
 
% Repeat cropping with other channel (red) 
for k=1:1:numel(blank2(1,1,:)) 
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allpic2(:,:,k) = allpic2(:,:,k)-blank2(:,:,k); 
despath = fullfile(subpath2,strcat(allname2{k},'.jpg')); 
cropped = imcrop(allpic2(:,:,k),position); 
imwrite(cropped,despath,'jpg','Quality',100); 
end 
end 
close 
 
disp('Deleting *.tiff files....') 
rmdir(fullfile(path1,list1(numel(list1)).name),'s');% remove 
blank images in FITC 
rmdir(fullfile(path2,list2(numel(list2)).name),'s');% remove 
blank images in Texas Red 
recycle off; 
manage(mainpath,mainpath); % delete every *tif files 
recycle on; 
disp('     Done!') 
end 
 
function manage(path,givenpath) 
listing = dir(fullfile(path,'\')); 
for i = 3:numel(listing) 
 subpath = fullfile(path,listing(i).name); 
    [~, name, ext] = fileparts(listing(i).name); 
if isdir(subpath)==1 
 delete(fullfile(subpath,'*.tif')); 
 manage(subpath,givenpath); 
end 
end 
end 
 
Counting the cells 
function 20x_poly_count() 
clc % clear existing images on the screen 
disp('Configuring necessary parameters...') 
warning off all; 
clear global variable 
clear java 
 
% This code relies on ImageJ function as it's core, thus ImageJ 
is needed 
javaaddpath('C:/Program Files (x86)/ImageJ/ij.jar');% Locate 
ImageJ (default location for ImageJ in both 32 and 64 bit 
systems) 
javaaddpath('C:/Program Files/ImageJ/ij.jar'); 
import('ij.IJ.*');% Import ImageJ functions 
import('ij.plugin.filter.*');% Import more ImageJ functions 
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if versionLessThan('1.46')==1 % 'Find Maxima' function is 
avaiable only in version 1.46 or later 
    return 
end 
 
% Request for the threshold inputs for ‘Find Maxima’ algorithm 
th1 = str2double(input('Threshold for FITC: ','s')); 
th2 = str2double(input('Threshold for Texas Red: ','s')); 
 
disp('Please locate the sorted, cropped experiment folder...') 
folder = uigetdir();% locate experiment folder 
 
for i=1:1:2 
% display the thresholds assigned by user 
if i==1 
    celltype = 'FITC'; 
    disp('-----FITC-----') 
    threshold = th1; 
    fprintf('The sensitivity is %d \n',threshold); 
elseif i==2 
    celltype = 'Texas Red'; 
    disp('-----Texas Red-----') 
    threshold = th2; 
    fprintf('The sensitivity is %d \n',threshold); 
else 
    disp('Error!') 
end 
 
path = fullfile(folder,celltype); 
 
listing = dir(path);% make a list of chamber folders inside 
channal folders 
disp('Counting cells in chamber number:  ') 
 
for a=3:numel(listing) % count cells folder by folder 
    filelist = dir(fullfile(path,listing(a).name,'*.jpg'));% 
make a list of chamber images inside each chamber folder 
    fprintf(1,'\b\b%s',listing(a).name); %display progress 
during counting 
    chambername(1,a-2) = str2num(listing(a).name); 
    chambername(2,a-2) = 1; 
    first = 
imread(fullfile(path,listing(a).name,filelist(1).name)); 
    overall = sum(sum(first)); % obtain intensity sum of the 
first image in that folder.         
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% for each file, load image into Java variable, then use 
getMaxima function to achieve the cell count. 
    for b=1:numel(filelist) 
        imp = 
openImage(fullfile(path,listing(a).name,filelist(b).name)); 
        ip = imp.getProcessor();  
        mf = MaximumFinder; 
        maxima = mf.getMaxima(ip,threshold, 0);% call function 
Maximum Finder using the defined threshold 
        maximacount(b,a-2) = maxima.npoints;%get the cell count 
from ImageJ 
% alternative counting method: count by comparing intensity sum 
with the first image intensity sum. The cell count is then 
related to the first image cell count.         
I = imread(fullfile(path,listing(a).name,filelist(b).name)); 
        intensity = sum(sum(I)); 
        intensitycount(b,a-2) = 
floor(intensity/overall*maximacount(1,a-2));% record cell count 
by intensity (relative to the first image) in an array 
        rawintensity(b,a-2) = floor(intensity);% record raw 
intensity of each image in another array 
    end 
end 
fprintf('\n') 
 
disp('Done counting cells. ') 
disp('Writing result in .xls file...') 
 
% record the counting result in Excel file. 
filename = strcat('Cell Count_',celltype,'.xls');  
timepoints = numel(dir(fullfile(path,listing(3).name,'*.jpg')))-
1; 
time = transpose(0:30:timepoints*30); 
 
A1FTIC = sprintf('threshold = %d',threshold); 
 
xlswrite(fullfile(folder,filename), {A1FTIC;'Y/N = 
1/0';'time(min)'}, 3,'A1'); 
xlswrite(fullfile(folder,filename), chambername, 3,'B1'); 
xlswrite(fullfile(folder,filename), time, 3,'A4'); 
xlswrite(fullfile(folder,filename), rawintensity, 3,'B4'); 
 
xlswrite(fullfile(folder,filename), {A1FTIC;'Y/N = 
1/0';'time(min)'}, 2,'A1'); 
xlswrite(fullfile(folder,filename), chambername, 2,'B1'); 
xlswrite(fullfile(folder,filename), time, 2,'A4'); 
xlswrite(fullfile(folder,filename), intensitycount, 2,'B4'); 
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xlswrite(fullfile(folder,filename), {A1FTIC;'Y/N = 
1/0';'time(min)'}, 1,'A1'); 
xlswrite(fullfile(folder,filename), chambername, 1,'B1'); 
xlswrite(fullfile(folder,filename), time, 1,'A4'); 
xlswrite(fullfile(folder,filename), maximacount, 1,'B4'); 
 
e = actxserver ('Excel.Application'); % open Activex server 
ewb = e.Workbooks.Open(fullfile(folder,filename)); % open file 
(enter full path) 
ewb.Worksheets.Item(1).Name = 'Local Maxima';% rename 1st sheet 
ewb.Worksheets.Item(2).Name = '# from Intensity'; 
ewb.Worksheets.Item(3).Name = 'Raw Intensity';  
ewb.Save % save to the same file 
ewb.Close(false) 
e.Quit 
 
fprintf('Output file: %s\n', filename) 
 
end 
clear all 
clear global variable 
clear java 
disp('     Done!') 
warning on all; 
end 
 
